{"title":"Hematology oncology","description":null,"products":[{"product_id":"uscap-confronting-the-unfamiliar-and-unnerving-in-dermpath-practical-tips-to-curb-hair-pulling-and-nail-biting-at-the-microscope-2026","title":"USCAP Confronting the Unfamiliar and Unnerving in Dermpath Practical Tips to Curb Hair Pulling and Nail Biting at the Microscope 2026","description":"\u003cdiv class=\"prod-edition\"\u003e\r\n\u003cdiv class=\"field field--name-field-heading field--type-heading field--label-hidden field__item\"\u003e\r\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\r\n\u003ch1 data-section-id=\"1qvrnjo\" data-start=\"0\" data-end=\"136\"\u003eUSCAP Confronting the Unfamiliar and Unnerving in Dermpath: Practical Tips to Curb Hair Pulling and Nail Biting at the Microscope 2026\u003c\/h1\u003e\r\n\u003ch2 data-section-id=\"aqza83\" data-start=\"138\" data-end=\"257\"\u003eAdvanced Dermatopathology Update on Hair Disorders, Nail Pathology, Dermatologic Emergencies \u0026amp; Melanocytic Neoplasms\u003c\/h2\u003e\r\n\u003cp data-start=\"259\" data-end=\"588\"\u003eThe \u003cstrong data-start=\"263\" data-end=\"401\"\u003eUSCAP Confronting the Unfamiliar and Unnerving in Dermpath: Practical Tips to Curb Hair Pulling and Nail Biting at the Microscope 2026\u003c\/strong\u003e course is an advanced dermatopathology educational program designed to help pathologists confidently navigate some of the most challenging diagnostic areas encountered in daily practice.\u003c\/p\u003e\r\n\u003cp data-start=\"590\" data-end=\"1026\"\u003eDeveloped by leading experts in dermatopathology, this focused course provides practical, case-based instruction on the interpretation of alopecia biopsies, nail unit pathology, dermatologic emergencies, and complex melanocytic lesions. Through real-world examples, clinicopathologic correlation, and discussions of diagnostic pitfalls, participants gain valuable strategies for improving diagnostic accuracy and avoiding common errors.\u003c\/p\u003e\r\n\u003cp data-start=\"1028\" data-end=\"1248\"\u003eReleased on \u003cstrong data-start=\"1040\" data-end=\"1056\"\u003eMay 26, 2026\u003c\/strong\u003e, this program emphasizes practical decision-making, appropriate ancillary testing, and systematic approaches that can be immediately applied in both academic and community pathology practice.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"1250\" data-end=\"1253\"\u003e\r\n\r\n\u003ch2 data-section-id=\"1sp67mj\" data-start=\"1255\" data-end=\"1273\"\u003eCourse Overview\u003c\/h2\u003e\r\n\u003cp data-start=\"1275\" data-end=\"1590\"\u003eDermatopathology often presents diagnostic challenges that can be intimidating even for experienced pathologists. Hair disorders, nail diseases, urgent dermatologic conditions, and melanocytic neoplasms frequently require careful integration of clinical information, histopathologic findings, and ancillary studies.\u003c\/p\u003e\r\n\u003cp data-start=\"1592\" data-end=\"1777\"\u003eThis course provides a structured framework for approaching these difficult specimens while highlighting common diagnostic traps that may lead to misclassification or delayed diagnosis.\u003c\/p\u003e\r\n\u003cp data-start=\"1779\" data-end=\"1836\"\u003eParticipants will learn practical methods for evaluating:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"1838\" data-end=\"2059\"\u003e\r\n \t\u003cli data-section-id=\"snqze6\" data-start=\"1838\" data-end=\"1867\"\u003eAlopecia and hair disorders\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"k6xztn\" data-start=\"1868\" data-end=\"1889\"\u003eNail unit pathology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1hu7j7x\" data-start=\"1890\" data-end=\"1916\"\u003eDermatologic emergencies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"yktsxo\" data-start=\"1917\" data-end=\"1940\"\u003eMelanocytic neoplasms\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1nd3qr9\" data-start=\"1941\" data-end=\"1969\"\u003eInflammatory skin diseases\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"13jhtqu\" data-start=\"1970\" data-end=\"2000\"\u003eAncillary diagnostic testing\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1n8uj5d\" data-start=\"2001\" data-end=\"2032\"\u003eClinicopathologic correlation\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1hcs978\" data-start=\"2033\" data-end=\"2059\"\u003eHistopathologic pitfalls\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2061\" data-end=\"2197\"\u003eThe curriculum combines foundational knowledge with advanced diagnostic insights to improve confidence and efficiency at the microscope.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"2199\" data-end=\"2202\"\u003e\r\n\r\n\u003ch2 data-section-id=\"1scsphp\" data-start=\"2204\" data-end=\"2226\"\u003eLearning Objectives\u003c\/h2\u003e\r\n\u003cp data-start=\"2228\" data-end=\"2291\"\u003eUpon completion of this activity, participants will be able to:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"2293\" data-end=\"2918\"\u003e\r\n \t\u003cli data-section-id=\"11r5wmq\" data-start=\"2293\" data-end=\"2357\"\u003eDevelop a systematic diagnostic approach to alopecia biopsies.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1a8vnfm\" data-start=\"2358\" data-end=\"2437\"\u003eRecognize inflammatory and neoplastic disorders affecting the nail apparatus.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"gjxao5\" data-start=\"2438\" data-end=\"2533\"\u003eIntegrate clinical and histopathologic findings when evaluating urgent dermatologic biopsies.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"15hexx0\" data-start=\"2534\" data-end=\"2611\"\u003eApply current classification principles to challenging melanocytic lesions.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"j1hi35\" data-start=\"2612\" data-end=\"2690\"\u003eUtilize ancillary studies appropriately in difficult dermatopathology cases.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"f9y2rh\" data-start=\"2691\" data-end=\"2758\"\u003eIdentify common diagnostic pitfalls and strategies to avoid them.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"n4v59c\" data-start=\"2759\" data-end=\"2837\"\u003eImprove clinicopathologic correlation in complex dermatopathology specimens.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"14xiil9\" data-start=\"2838\" data-end=\"2918\"\u003eEnhance diagnostic accuracy in routine and referral dermatopathology practice.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"2920\" data-end=\"2923\"\u003e\r\n\r\n\u003ch2 data-section-id=\"1ti0lfk\" data-start=\"2925\" data-end=\"2947\"\u003eCore Topics Covered\u003c\/h2\u003e\r\n\u003ch3 data-section-id=\"1i3e0j6\" data-start=\"2949\" data-end=\"2988\"\u003eHair Disorders \u0026amp; Alopecia Pathology\u003c\/h3\u003e\r\n\u003cp data-start=\"2990\" data-end=\"3063\"\u003eA major focus of the course is the evaluation of hair and scalp biopsies.\u003c\/p\u003e\r\n\u003cp data-start=\"3065\" data-end=\"3080\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"3082\" data-end=\"3275\"\u003e\r\n \t\u003cli data-section-id=\"1x5a7cw\" data-start=\"3082\" data-end=\"3114\"\u003eAlopecia biopsy interpretation\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"39683p\" data-start=\"3115\" data-end=\"3134\"\u003eScarring alopecia\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"muht3b\" data-start=\"3135\" data-end=\"3158\"\u003eNon-scarring alopecia\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"uqfzlq\" data-start=\"3159\" data-end=\"3181\"\u003eFollicular pathology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"13gv7aw\" data-start=\"3182\" data-end=\"3208\"\u003eHair cycle abnormalities\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1bmgzlw\" data-start=\"3209\" data-end=\"3238\"\u003eInflammatory hair disorders\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1bwqfkk\" data-start=\"3239\" data-end=\"3275\"\u003eDiagnostic algorithms for alopecia\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3277\" data-end=\"3429\"\u003eFaculty present practical approaches to differentiating common and uncommon causes of hair loss using histopathologic features and clinical correlation.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"3431\" data-end=\"3434\"\u003e\r\n\r\n\u003ch3 data-section-id=\"1avr6ut\" data-start=\"3436\" data-end=\"3459\"\u003eNail Unit Pathology\u003c\/h3\u003e\r\n\u003cp data-start=\"3461\" data-end=\"3530\"\u003eParticipants review diseases affecting the nail apparatus, including:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"3532\" data-end=\"3691\"\u003e\r\n \t\u003cli data-section-id=\"1q9prz4\" data-start=\"3532\" data-end=\"3545\"\u003eNail tumors\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"f49qu4\" data-start=\"3546\" data-end=\"3575\"\u003eInflammatory nail disorders\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1j8j13a\" data-start=\"3576\" data-end=\"3599\"\u003eNail matrix pathology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1r7qy80\" data-start=\"3600\" data-end=\"3618\"\u003eNail bed lesions\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1tz8rk2\" data-start=\"3619\" data-end=\"3637\"\u003eNail dystrophies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1afavqm\" data-start=\"3638\" data-end=\"3662\"\u003ePigmented nail lesions\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"k9uuie\" data-start=\"3663\" data-end=\"3691\"\u003eNeoplastic nail conditions\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3693\" data-end=\"3816\"\u003eSpecial attention is given to recognizing uncommon presentations and avoiding diagnostic pitfalls unique to nail specimens.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"3818\" data-end=\"3821\"\u003e\r\n\r\n\u003ch3 data-section-id=\"fmmxfn\" data-start=\"3823\" data-end=\"3851\"\u003eDermatologic Emergencies\u003c\/h3\u003e\r\n\u003cp data-start=\"3853\" data-end=\"3944\"\u003eThe course addresses urgent dermatologic conditions requiring rapid and accurate diagnosis.\u003c\/p\u003e\r\n\u003cp data-start=\"3946\" data-end=\"3961\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"3963\" data-end=\"4154\"\u003e\r\n \t\u003cli data-section-id=\"is8zxu\" data-start=\"3963\" data-end=\"3994\"\u003eAcute inflammatory dermatoses\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1itwlmn\" data-start=\"3995\" data-end=\"4036\"\u003eLife-threatening dermatologic disorders\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"99a5z8\" data-start=\"4037\" data-end=\"4060\"\u003eSevere drug reactions\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1q0sfeu\" data-start=\"4061\" data-end=\"4086\"\u003eEmergency skin biopsies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"ppkkxj\" data-start=\"4087\" data-end=\"4118\"\u003eClinicopathologic integration\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1uzv94n\" data-start=\"4119\" data-end=\"4154\"\u003eDifferential diagnosis strategies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4156\" data-end=\"4276\"\u003eFaculty discuss how pathologists can provide timely and clinically meaningful interpretations in high-acuity situations.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"4278\" data-end=\"4281\"\u003e\r\n\r\n\u003ch3 data-section-id=\"nmvd9u\" data-start=\"4283\" data-end=\"4308\"\u003eMelanocytic Neoplasms\u003c\/h3\u003e\r\n\u003cp data-start=\"4310\" data-end=\"4400\"\u003eOne of the most challenging areas in dermatopathology involves melanocytic proliferations.\u003c\/p\u003e\r\n\u003cp data-start=\"4402\" data-end=\"4421\"\u003eKey topics include:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"4423\" data-end=\"4612\"\u003e\r\n \t\u003cli data-section-id=\"3dlwc2\" data-start=\"4423\" data-end=\"4453\"\u003eAtypical melanocytic lesions\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"ndkv2a\" data-start=\"4454\" data-end=\"4471\"\u003eDysplastic nevi\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1e2v1z7\" data-start=\"4472\" data-end=\"4492\"\u003eMelanoma diagnosis\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"296f9k\" data-start=\"4493\" data-end=\"4524\"\u003eBorderline melanocytic tumors\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"e88xj2\" data-start=\"4525\" data-end=\"4556\"\u003eHistologic mimics of melanoma\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"vc2twu\" data-start=\"4557\" data-end=\"4584\"\u003eClassification challenges\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"v3xm97\" data-start=\"4585\" data-end=\"4612\"\u003ePrognostic considerations\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4614\" data-end=\"4713\"\u003eThe course emphasizes practical diagnostic frameworks for evaluating difficult melanocytic lesions.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"4715\" data-end=\"4718\"\u003e\r\n\r\n\u003ch3 data-section-id=\"w5yczc\" data-start=\"4720\" data-end=\"4752\"\u003eAncillary Diagnostic Testing\u003c\/h3\u003e\r\n\u003cp data-start=\"4754\" data-end=\"4820\"\u003eParticipants learn appropriate use of ancillary studies including:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"4822\" data-end=\"4936\"\u003e\r\n \t\u003cli data-section-id=\"1sd9e56\" data-start=\"4822\" data-end=\"4844\"\u003eImmunohistochemistry\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1a5bs4c\" data-start=\"4845\" data-end=\"4864\"\u003eMolecular testing\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"sclc57\" data-start=\"4865\" data-end=\"4881\"\u003eSpecial stains\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"nhu5qy\" data-start=\"4882\" data-end=\"4905\"\u003eDiagnostic biomarkers\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"z6weab\" data-start=\"4906\" data-end=\"4936\"\u003eGenomic testing applications\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4938\" data-end=\"5044\"\u003eFaculty discuss how ancillary testing can improve diagnostic confidence and accuracy in challenging cases.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"5046\" data-end=\"5049\"\u003e\r\n\r\n\u003ch3 data-section-id=\"1mwe58f\" data-start=\"5051\" data-end=\"5084\"\u003eClinicopathologic Correlation\u003c\/h3\u003e\r\n\u003cp data-start=\"5086\" data-end=\"5127\"\u003eStrong emphasis is placed on integrating:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"5129\" data-end=\"5250\"\u003e\r\n \t\u003cli data-section-id=\"16d4mn9\" data-start=\"5129\" data-end=\"5147\"\u003eClinical history\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"9t5jb4\" data-start=\"5148\" data-end=\"5179\"\u003ePhysical examination findings\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"8hgs34\" data-start=\"5180\" data-end=\"5205\"\u003eDermoscopic information\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"vtrn4a\" data-start=\"5206\" data-end=\"5232\"\u003eHistopathologic features\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"17doo4b\" data-start=\"5233\" data-end=\"5250\"\u003eLaboratory data\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5252\" data-end=\"5343\"\u003eThis multidisciplinary approach helps optimize diagnostic precision and patient management.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"5345\" data-end=\"5348\"\u003e\r\n\r\n\u003ch3 data-section-id=\"59kwug\" data-start=\"5350\" data-end=\"5391\"\u003eDiagnostic Pitfalls \u0026amp; Near-Miss Cases\u003c\/h3\u003e\r\n\u003cp data-start=\"5393\" data-end=\"5441\"\u003eA unique feature of the course is the review of:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"5443\" data-end=\"5586\"\u003e\r\n \t\u003cli data-section-id=\"xwydt\" data-start=\"5443\" data-end=\"5473\"\u003eReal-world diagnostic errors\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1xvqi5a\" data-start=\"5474\" data-end=\"5491\"\u003eNear-miss cases\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"12i3qrb\" data-start=\"5492\" data-end=\"5522\"\u003eCommon interpretive mistakes\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"14ajz88\" data-start=\"5523\" data-end=\"5548\"\u003eMimickers of malignancy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"48cutv\" data-start=\"5549\" data-end=\"5586\"\u003eChallenging inflammatory conditions\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5588\" data-end=\"5700\"\u003eFaculty provide practical lessons learned from difficult cases and discuss strategies to avoid similar pitfalls.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"5702\" data-end=\"5705\"\u003e\r\n\r\n\u003ch2 data-section-id=\"1cq7b5x\" data-start=\"5707\" data-end=\"5730\"\u003eEducational Features\u003c\/h2\u003e\r\n\u003cp data-start=\"5732\" data-end=\"5769\"\u003e✔ Advanced Dermatopathology Education\u003c\/p\u003e\r\n\u003cp data-start=\"5771\" data-end=\"5792\"\u003e✔ Case-Based Learning\u003c\/p\u003e\r\n\u003cp data-start=\"5794\" data-end=\"5824\"\u003e✔ Hair \u0026amp; Nail Pathology Review\u003c\/p\u003e\r\n\u003cp data-start=\"5826\" data-end=\"5861\"\u003e✔ Melanocytic Lesion Classification\u003c\/p\u003e\r\n\u003cp data-start=\"5863\" data-end=\"5897\"\u003e✔ Dermatologic Emergency Diagnosis\u003c\/p\u003e\r\n\u003cp data-start=\"5899\" data-end=\"5929\"\u003e✔ Ancillary Testing Strategies\u003c\/p\u003e\r\n\u003cp data-start=\"5931\" data-end=\"5962\"\u003e✔ Clinicopathologic Correlation\u003c\/p\u003e\r\n\u003cp data-start=\"5964\" data-end=\"5993\"\u003e✔ Practical Diagnostic Pearls\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"5995\" data-end=\"5998\"\u003e\r\n\r\n\u003ch2 data-section-id=\"1m9xcqo\" data-start=\"6000\" data-end=\"6018\"\u003eTarget Audience\u003c\/h2\u003e\r\n\u003cp data-start=\"6020\" data-end=\"6045\"\u003eThis course is ideal for:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"6047\" data-end=\"6249\"\u003e\r\n \t\u003cli data-section-id=\"biiv77\" data-start=\"6047\" data-end=\"6061\"\u003ePathologists\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"3z1mqf\" data-start=\"6062\" data-end=\"6083\"\u003eDermatopathologists\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1bg468m\" data-start=\"6084\" data-end=\"6107\"\u003eAcademic Pathologists\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"ezbu8w\" data-start=\"6108\" data-end=\"6132\"\u003eCommunity Pathologists\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"3nl10y\" data-start=\"6133\" data-end=\"6154\"\u003ePathology Residents\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"10yt9zz\" data-start=\"6155\" data-end=\"6174\"\u003ePathology Fellows\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1591kc0\" data-start=\"6175\" data-end=\"6207\"\u003eDermatology-Pathology Trainees\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"hlopgl\" data-start=\"6208\" data-end=\"6249\"\u003ePhysicians Interested in Skin Pathology\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"6251\" data-end=\"6254\"\u003e\r\n\r\n\u003ch2 data-section-id=\"8w266h\" data-start=\"6256\" data-end=\"6285\"\u003eWhy This Course Stands Out\u003c\/h2\u003e\r\n\u003cp data-start=\"6287\" data-end=\"6345\"\u003e✔ Focuses on notoriously difficult dermatopathology topics\u003c\/p\u003e\r\n\u003cp data-start=\"6347\" data-end=\"6397\"\u003e✔ Practical microscope-based diagnostic strategies\u003c\/p\u003e\r\n\u003cp data-start=\"6399\" data-end=\"6433\"\u003e✔ Extensive case-based instruction\u003c\/p\u003e\r\n\u003cp data-start=\"6435\" data-end=\"6479\"\u003e✔ Real-world examples of diagnostic pitfalls\u003c\/p\u003e\r\n\u003cp data-start=\"6481\" data-end=\"6531\"\u003e✔ Strong emphasis on clinicopathologic correlation\u003c\/p\u003e\r\n\u003cp data-start=\"6533\" data-end=\"6588\"\u003e✔ Expert faculty from leading dermatopathology programs\u003c\/p\u003e\r\n\u003cp data-start=\"6590\" data-end=\"6642\"\u003e✔ Applicable to both academic and community practice\u003c\/p\u003e\r\n\u003cp data-start=\"6644\" data-end=\"6703\"\u003e✔ Improves confidence in challenging dermatopathology cases\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"6705\" data-end=\"6708\"\u003e\r\n\r\n\u003ch2 data-section-id=\"1ilfxpc\" data-start=\"6710\" data-end=\"6741\"\u003eClinical \u0026amp; Educational Value\u003c\/h2\u003e\r\n\u003cp data-start=\"6743\" data-end=\"7211\"\u003eThe \u003cstrong data-start=\"6747\" data-end=\"6814\"\u003eUSCAP Confronting the Unfamiliar and Unnerving in Dermpath 2026\u003c\/strong\u003e course delivers a practical and highly focused review of some of the most challenging areas in dermatopathology. Through expert-led case discussions, systematic diagnostic approaches, and real-world examples of common pitfalls, participants gain the knowledge and confidence needed to accurately diagnose complex hair disorders, nail diseases, dermatologic emergencies, and melanocytic neoplasms.\u003c\/p\u003e\r\n\u003cp data-start=\"7213\" data-end=\"7395\"\u003eThis program serves as an excellent educational resource for pathologists seeking to strengthen their dermatopathology expertise and improve diagnostic accuracy in everyday practice.\u003c\/p\u003e\r\n\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDiagnostic Approach to Alopecia – Eleanor Knopp, MD Section: 1 Presentation 1 Document\u003c\/li\u003e\r\n \t\u003cli\u003eIntroduction to Nail Pathology – Beth S. Ruben, MD Section: 1 Presentation 1 Document\u003c\/li\u003e\r\n \t\u003cli\u003eNail Pathology – Beth S. Ruben, MD Section: 2 Presentations 3 Documents\u003c\/li\u003e\r\n \t\u003cli\u003eDermatologic Emergencies – May P. Chan, MD Section: 2 Presentations 3 Documents\u003c\/li\u003e\r\n \t\u003cli\u003eAlopecia Pathology – Eleanor Knopp, MD Section: 2 Presentations 3 Documents\u003c\/li\u003e\r\n \t\u003cli\u003eMelanocytic Neoplasms and Medicolegal Cases – Steven R. Tahan, MD Section: 2 Presentations 3 Documents\u003c\/li\u003e\r\n \t\u003cli\u003eFREE SECTION: Panel Discussion and Q\u0026amp;A\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663481655625,"sku":"MED-AMB09400","price":130.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/USCAP-Confronting-the-Unfamiliar-and-Unnerving-in-Dermpath-Practical-Tips-to-Curb-Hair-Pulling-and-Nail-Biting-at-the-Microscope-2026.jpg?v=1781875427"},{"product_id":"asco-sep-qbank-2022","title":"ASCO SEP Qbank 2022","description":"\u003cdiv id=\"bookDescription_feature_div\" class=\"celwidget\" data-feature-name=\"bookDescription\" data-csa-c-type=\"widget\" data-csa-c-content-id=\"bookDescription\" data-csa-c-slot-id=\"bookDescription_feature_div\" data-csa-c-asin=\"\" data-csa-c-is-in-initial-active-row=\"false\" data-csa-c-id=\"sp3pi4-mkskqy-y4o8kl-7jkh2a\" data-cel-widget=\"bookDescription_feature_div\"\u003e\r\n\u003cdiv class=\"a-expander-collapsed-height a-row a-expander-container a-spacing-base a-expander-partial-collapse-container\" data-a-expander-name=\"book_description_expander\" data-a-expander-collapsed-height=\"140\"\u003e\r\n\u003cdiv class=\"a-expander-content a-expander-partial-collapse-content\" aria-expanded=\"false\"\u003e\r\n\u003cdiv id=\"toc-header\" class=\"toc-header bottomShadow topPadding\"\u003e\r\n\u003cdiv class=\"mura-body\"\u003e\r\n\u003cdiv class=\"mura-region mura-region-loose\"\u003e\r\n\u003cdiv class=\"mura-region-local\"\u003e\r\n\u003cdiv class=\"prod-format\"\u003e\r\n\u003ch2\u003eASCO SEP Qbank 2022\u003c\/h2\u003e\r\nAssess your knowledge in all areas of oncology and address any learning gaps with the family of ASCO Education assessment tools.\r\n\r\n\u003cstrong\u003eASCO Question Bank is\u003c\/strong\u003e A bank of questions from which users select parameters to generate personalized quizzes for customized learning needs.\r\n\r\n\u003chr\u003e\r\n\r\n\u003cstrong\u003eDetails :\u003c\/strong\u003e Full 2022 Qbank as PDF Files – Subjectwise\r\n\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663481688393,"sku":"MED-AMB00081","price":40.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/ASCO-SEP-Qbank-2022_b2f832fa-efee-4cdb-a8a8-edc89c9995cd.jpg?v=1781875427"},{"product_id":"comprehensive-review-of-urology-2021","title":"Comprehensive Review of Urology 2021‍","description":"\u003ch1 data-section-id=\"gf3lf1\" data-start=\"0\" data-end=\"40\"\u003eComprehensive Review of Urology 2021\u003c\/h1\u003e\r\n\u003cp data-start=\"41\" data-end=\"144\"\u003eAdvanced CME Update in Adult \u0026amp; Pediatric Urology, Oncology, Reconstruction \u0026amp; Minimally Invasive Surgery\u003c\/p\u003e\r\n\u003cp data-start=\"146\" data-end=\"686\"\u003eThe \u003cem data-start=\"150\" data-end=\"188\"\u003eComprehensive Review of Urology 2021\u003c\/em\u003e delivers an extensive, guideline-driven review of modern urologic practice across adult and pediatric urology, urologic oncology, reconstructive surgery, urinary disorders, minimally invasive procedures, and advanced imaging. Developed as a high-yield continuing medical education program, the course is designed to help clinicians strengthen both board-level knowledge and real-world clinical decision-making across the full spectrum of contemporary urology.\u003c\/p\u003e\r\n\u003cp data-start=\"688\" data-end=\"1015\"\u003eLed by internationally recognized faculty and chaired by renowned urologist \u003cstrong data-start=\"764\" data-end=\"785\"\u003eAria F. Olumi, MD\u003c\/strong\u003e, the program combines evidence-based recommendations, practical surgical principles, imaging interpretation, pathology review, and multidisciplinary management strategies relevant to both academic and community urologic practice.\u003c\/p\u003e\r\n\u003cp data-start=\"1017\" data-end=\"1079\"\u003eThe course emphasizes clinically applicable updates involving:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"1080\" data-end=\"1462\"\u003e\r\n \t\u003cli data-section-id=\"13mlpl2\" data-start=\"1080\" data-end=\"1123\"\u003eProstate cancer diagnosis and treatment\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"17bbtc4\" data-start=\"1124\" data-end=\"1164\"\u003eKidney and bladder cancer management\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"spm0hn\" data-start=\"1165\" data-end=\"1208\"\u003eUrologic imaging and MRI interpretation\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1m89kpr\" data-start=\"1209\" data-end=\"1251\"\u003eMinimally invasive and robotic surgery\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1xh1z1b\" data-start=\"1252\" data-end=\"1295\"\u003eMale infertility and sexual dysfunction\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"n9ff9s\" data-start=\"1296\" data-end=\"1329\"\u003eFemale pelvic floor disorders\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"hw64h4\" data-start=\"1330\" data-end=\"1351\"\u003ePediatric urology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"14fb59s\" data-start=\"1352\" data-end=\"1389\"\u003eTrauma and reconstructive urology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"148okyi\" data-start=\"1390\" data-end=\"1418\"\u003eUrinary tract infections\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"ppghzb\" data-start=\"1419\" data-end=\"1436\"\u003eStone disease\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"ruzcbc\" data-start=\"1437\" data-end=\"1462\"\u003eGender-affirming care\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2 data-section-id=\"12eh7qp\" data-start=\"1464\" data-end=\"1507\"\u003eA Comprehensive Modern Review of Urology\u003c\/h2\u003e\r\n\u003cp data-start=\"1509\" data-end=\"1582\"\u003eUrology has evolved dramatically over the past decade due to advances in:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"1583\" data-end=\"1808\"\u003e\r\n \t\u003cli data-section-id=\"1er0kvl\" data-start=\"1583\" data-end=\"1606\"\u003eMultiparametric MRI\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"16rchej\" data-start=\"1607\" data-end=\"1626\"\u003eRobotic surgery\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1a0drke\" data-start=\"1627\" data-end=\"1649\"\u003ePrecision oncology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"hpm9md\" data-start=\"1650\" data-end=\"1682\"\u003eBiomarker-driven diagnostics\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"10l608h\" data-start=\"1683\" data-end=\"1719\"\u003eMinimally invasive interventions\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"11pm712\" data-start=\"1720\" data-end=\"1737\"\u003eImmunotherapy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"dx0tm4\" data-start=\"1738\" data-end=\"1772\"\u003eGender-affirming surgical care\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1y8oiqj\" data-start=\"1773\" data-end=\"1808\"\u003ePediatric transitional medicine\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"1810\" data-end=\"1942\"\u003eAt the same time, practicing urologists increasingly manage highly complex patients requiring multidisciplinary coordination across:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"1943\" data-end=\"2063\"\u003e\r\n \t\u003cli data-section-id=\"9obxko\" data-start=\"1943\" data-end=\"1955\"\u003eOncology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"2eswzo\" data-start=\"1956\" data-end=\"1969\"\u003eRadiology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1mgr4c7\" data-start=\"1970\" data-end=\"1983\"\u003ePathology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"3f0d8b\" data-start=\"1984\" data-end=\"1998\"\u003eNephrology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"r5dfpp\" data-start=\"1999\" data-end=\"2025\"\u003eReconstructive surgery\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1nvgbsc\" data-start=\"2026\" data-end=\"2043\"\u003eEndocrinology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"o732zt\" data-start=\"2044\" data-end=\"2063\"\u003ePelvic medicine\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2065\" data-end=\"2232\"\u003eThis CME program provides a broad but clinically focused review intended to consolidate core knowledge while integrating evolving evidence and contemporary guidelines.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"i2r1et\" data-start=\"2234\" data-end=\"2285\"\u003eProstate Cancer: Imaging, Diagnosis \u0026amp; Management\u003c\/h2\u003e\r\n\u003cp data-start=\"2287\" data-end=\"2363\"\u003eA major strength of the course is its extensive coverage of prostate cancer.\u003c\/p\u003e\r\n\u003cp data-start=\"2365\" data-end=\"2386\"\u003eThe lectures examine:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"2387\" data-end=\"2573\"\u003e\r\n \t\u003cli data-section-id=\"11armz9\" data-start=\"2387\" data-end=\"2413\"\u003eMRI of prostate cancer\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1m91lhf\" data-start=\"2414\" data-end=\"2437\"\u003eActive surveillance\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"11ghnlp\" data-start=\"2438\" data-end=\"2452\"\u003eBiomarkers\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"lecmlr\" data-start=\"2453\" data-end=\"2476\"\u003eSurgical management\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1vifjm0\" data-start=\"2477\" data-end=\"2498\"\u003eRadiation therapy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"116djht\" data-start=\"2499\" data-end=\"2544\"\u003eSystemic treatment for metastatic disease\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"9f16fg\" data-start=\"2545\" data-end=\"2573\"\u003eFocal therapy approaches\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2575\" data-end=\"2655\"\u003eThe MRI-focused sessions review how multiparametric MRI increasingly influences:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"2656\" data-end=\"2772\"\u003e\r\n \t\u003cli data-section-id=\"73i0op\" data-start=\"2656\" data-end=\"2680\"\u003eScreening strategies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"icow3d\" data-start=\"2681\" data-end=\"2704\"\u003eLesion localization\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1wnn8qv\" data-start=\"2705\" data-end=\"2725\"\u003eBiopsy targeting\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"d1ddlf\" data-start=\"2726\" data-end=\"2749\"\u003eRisk stratification\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"fnzvsh\" data-start=\"2750\" data-end=\"2772\"\u003eTreatment planning\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2774\" data-end=\"2867\"\u003eThe course also discusses how modern management increasingly balances oncologic control with:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"2868\" data-end=\"2969\"\u003e\r\n \t\u003cli data-section-id=\"1gqik96\" data-start=\"2868\" data-end=\"2887\"\u003eQuality of life\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"183jgxq\" data-start=\"2888\" data-end=\"2911\"\u003eFunctional outcomes\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1gf4w68\" data-start=\"2912\" data-end=\"2941\"\u003ePatient-reported outcomes\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1814uhn\" data-start=\"2942\" data-end=\"2969\"\u003eOvertreatment reduction\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2 data-section-id=\"3wpt0k\" data-start=\"2971\" data-end=\"3011\"\u003eKidney Cancer \u0026amp; Renal Mass Management\u003c\/h2\u003e\r\n\u003cp data-start=\"3013\" data-end=\"3048\"\u003eThe renal oncology sections review:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"3049\" data-end=\"3208\"\u003e\r\n \t\u003cli data-section-id=\"77x2nq\" data-start=\"3049\" data-end=\"3089\"\u003eActive surveillance for renal masses\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1ryobuc\" data-start=\"3090\" data-end=\"3110\"\u003eOpen nephrectomy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1u1pjis\" data-start=\"3111\" data-end=\"3147\"\u003eLaparoscopic and robotic surgery\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1vykslp\" data-start=\"3148\" data-end=\"3170\"\u003eAblative therapies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"m7m5v\" data-start=\"3171\" data-end=\"3208\"\u003eSystemic therapy for advanced RCC\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3210\" data-end=\"3377\"\u003eMinimally invasive renal surgery has transformed kidney cancer management by reducing morbidity while preserving oncologic efficacy in appropriately selected patients.\u003c\/p\u003e\r\n\u003cp data-start=\"3379\" data-end=\"3473\"\u003eThe course emphasizes patient selection, tumor staging, and individualized treatment planning.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"phr9aa\" data-start=\"3475\" data-end=\"3513\"\u003eBladder Cancer \u0026amp; Multimodal Therapy\u003c\/h2\u003e\r\n\u003cp data-start=\"3515\" data-end=\"3554\"\u003eThe bladder cancer curriculum includes:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"3555\" data-end=\"3755\"\u003e\r\n \t\u003cli data-section-id=\"17gdo3c\" data-start=\"3555\" data-end=\"3601\"\u003eNon-muscle invasive bladder cancer (NMIBC)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1fh5acs\" data-start=\"3602\" data-end=\"3626\"\u003eIntravesical therapy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1e0ih31\" data-start=\"3627\" data-end=\"3661\"\u003eMuscle-invasive bladder cancer\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"kv1sni\" data-start=\"3662\" data-end=\"3701\"\u003eTrimodality bladder-sparing therapy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1sifhfu\" data-start=\"3702\" data-end=\"3733\"\u003eSystemic treatment advances\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"gp63at\" data-start=\"3734\" data-end=\"3755\"\u003eUrinary diversion\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3757\" data-end=\"3866\"\u003eOne recurring theme throughout the lectures is the increasing complexity of bladder cancer management due to:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"3867\" data-end=\"3997\"\u003e\r\n \t\u003cli data-section-id=\"1y1yyfc\" data-start=\"3867\" data-end=\"3896\"\u003eImmunotherapy integration\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"2pqvwo\" data-start=\"3897\" data-end=\"3930\"\u003eOrgan preservation strategies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"3dbg36\" data-start=\"3931\" data-end=\"3966\"\u003eRisk-adapted treatment pathways\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"8724d9\" data-start=\"3967\" data-end=\"3997\"\u003eMolecular characterization\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2 data-section-id=\"1gfewig\" data-start=\"3999\" data-end=\"4030\"\u003eUrologic Imaging \u0026amp; Pathology\u003c\/h2\u003e\r\n\u003cp data-start=\"4032\" data-end=\"4180\"\u003eThe imaging and pathology sections are particularly valuable because modern urology increasingly depends on close radiologic-pathologic correlation.\u003c\/p\u003e\r\n\u003cp data-start=\"4182\" data-end=\"4197\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"4198\" data-end=\"4430\"\u003e\r\n \t\u003cli data-section-id=\"11armz9\" data-start=\"4198\" data-end=\"4224\"\u003eMRI of prostate cancer\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1lz7oqu\" data-start=\"4225\" data-end=\"4266\"\u003eRadiologic evaluation of renal masses\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"ah4fgc\" data-start=\"4267\" data-end=\"4311\"\u003eImaging assessment of metastatic disease\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1s76ab1\" data-start=\"4312\" data-end=\"4334\"\u003eProstate pathology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"rojvf6\" data-start=\"4335\" data-end=\"4361\"\u003eKidney tumor pathology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1eo2brj\" data-start=\"4362\" data-end=\"4383\"\u003eBladder pathology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1xam9uu\" data-start=\"4384\" data-end=\"4405\"\u003eAdrenal pathology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"17innpd\" data-start=\"4406\" data-end=\"4430\"\u003eTesticular pathology\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4432\" data-end=\"4548\"\u003eThe pathology lectures reinforce clinically meaningful interpretation relevant to surgical and oncologic management.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"5qyt4u\" data-start=\"4550\" data-end=\"4580\"\u003eStone Disease \u0026amp; Obstruction\u003c\/h2\u003e\r\n\u003cp data-start=\"4582\" data-end=\"4618\"\u003eThe nephrolithiasis sessions review:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"4619\" data-end=\"4742\"\u003e\r\n \t\u003cli data-section-id=\"zyvkk3\" data-start=\"4619\" data-end=\"4647\"\u003eMedical stone management\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"z0s4jf\" data-start=\"4648\" data-end=\"4676\"\u003eSurgical stone treatment\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1cezuw2\" data-start=\"4677\" data-end=\"4712\"\u003eUpper urinary tract obstruction\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"m7jdnv\" data-start=\"4713\" data-end=\"4742\"\u003eEndourologic intervention\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4744\" data-end=\"4890\"\u003eStone disease remains one of the most common reasons for urgent urologic evaluation, and the course emphasizes individualized management based on:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"4891\" data-end=\"4975\"\u003e\r\n \t\u003cli data-section-id=\"urac1t\" data-start=\"4891\" data-end=\"4907\"\u003eStone burden\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"c41iog\" data-start=\"4908\" data-end=\"4923\"\u003eComposition\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1vhh45l\" data-start=\"4924\" data-end=\"4935\"\u003eAnatomy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"bm4vbu\" data-start=\"4936\" data-end=\"4956\"\u003eSymptom severity\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"2qpro0\" data-start=\"4957\" data-end=\"4975\"\u003eInfection risk\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2 data-section-id=\"1xkjbto\" data-start=\"4977\" data-end=\"5024\"\u003eFemale Pelvic Medicine \u0026amp; Voiding Dysfunction\u003c\/h2\u003e\r\n\u003cp data-start=\"5026\" data-end=\"5070\"\u003eThe course provides substantial coverage of:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"5071\" data-end=\"5212\"\u003e\r\n \t\u003cli data-section-id=\"18pz1yx\" data-start=\"5071\" data-end=\"5095\"\u003eUrinary incontinence\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1jpjknm\" data-start=\"5096\" data-end=\"5118\"\u003eOveractive bladder\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1jfk50e\" data-start=\"5119\" data-end=\"5144\"\u003ePelvic organ prolapse\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1b19g12\" data-start=\"5145\" data-end=\"5160\"\u003eUrodynamics\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"7jsxcu\" data-start=\"5161\" data-end=\"5192\"\u003eStress incontinence surgery\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"7nnq6q\" data-start=\"5193\" data-end=\"5212\"\u003eUrinary fistula\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5214\" data-end=\"5312\"\u003eThe lectures highlight how pelvic floor disorders frequently require nuanced management combining:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"5313\" data-end=\"5417\"\u003e\r\n \t\u003cli data-section-id=\"ftqc2c\" data-start=\"5313\" data-end=\"5337\"\u003eConservative therapy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1px2dpl\" data-start=\"5338\" data-end=\"5365\"\u003ePharmacologic treatment\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1gtxut5\" data-start=\"5366\" data-end=\"5391\"\u003eSurgical intervention\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"glhsh\" data-start=\"5392\" data-end=\"5417\"\u003eFunctional assessment\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2 data-section-id=\"1fwycm7\" data-start=\"5419\" data-end=\"5463\"\u003eMale Sexual Health \u0026amp; Reproductive Urology\u003c\/h2\u003e\r\n\u003cp data-start=\"5465\" data-end=\"5499\"\u003eThe andrology curriculum includes:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"5500\" data-end=\"5632\"\u003e\r\n \t\u003cli data-section-id=\"1ffrptt\" data-start=\"5500\" data-end=\"5524\"\u003eErectile dysfunction\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"qzqx5a\" data-start=\"5525\" data-end=\"5545\"\u003eMale infertility\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"15r5ftj\" data-start=\"5546\" data-end=\"5566\"\u003ePeyronie disease\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1f7xi2t\" data-start=\"5567\" data-end=\"5579\"\u003ePriapism\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1gm9yh5\" data-start=\"5580\" data-end=\"5603\"\u003eChronic pelvic pain\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"12ilv5c\" data-start=\"5604\" data-end=\"5632\"\u003eGender-affirming surgery\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5634\" data-end=\"5798\"\u003eThe course approaches these conditions from both physiologic and psychosocial perspectives, reflecting the increasingly multidisciplinary nature of sexual medicine.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"1tfosly\" data-start=\"5800\" data-end=\"5838\"\u003eTransgender \u0026amp; Gender-Affirming Care\u003c\/h2\u003e\r\n\u003cp data-start=\"5840\" data-end=\"5908\"\u003eOne particularly modern component of the course is its inclusion of:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"5909\" data-end=\"6037\"\u003e\r\n \t\u003cli data-section-id=\"147oqg4\" data-start=\"5909\" data-end=\"5935\"\u003eTransgender healthcare\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"12ilv5c\" data-start=\"5936\" data-end=\"5964\"\u003eGender-affirming surgery\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"cz50lg\" data-start=\"5965\" data-end=\"5998\"\u003eOffice-based transgender care\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"vy377\" data-start=\"5999\" data-end=\"6037\"\u003eSurgical reconstruction principles\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"6039\" data-end=\"6156\"\u003eAs access to gender-affirming care expands, urologists increasingly participate in multidisciplinary treatment teams.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"11pq6l0\" data-start=\"6158\" data-end=\"6198\"\u003ePediatric Urology \u0026amp; Transitional Care\u003c\/h2\u003e\r\n\u003cp data-start=\"6200\" data-end=\"6238\"\u003eThe pediatric urology section reviews:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"6239\" data-end=\"6441\"\u003e\r\n \t\u003cli data-section-id=\"1od1hkf\" data-start=\"6239\" data-end=\"6267\"\u003eAntenatal hydronephrosis\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1t6ncoh\" data-start=\"6268\" data-end=\"6293\"\u003eVesicoureteral reflux\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"phd5y3\" data-start=\"6294\" data-end=\"6309\"\u003eHypospadias\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"15e9421\" data-start=\"6310\" data-end=\"6339\"\u003ePosterior urethral valves\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"6u4vgj\" data-start=\"6340\" data-end=\"6360\"\u003ePediatric trauma\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"kfsgfp\" data-start=\"6361\" data-end=\"6383\"\u003eNeurogenic bladder\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"qgz1hb\" data-start=\"6384\" data-end=\"6416\"\u003eDisorders of sex development\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1qnjqwv\" data-start=\"6417\" data-end=\"6441\"\u003eTransitional urology\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"6443\" data-end=\"6569\"\u003eThe lectures emphasize long-term continuity of care, particularly for congenital urologic conditions extending into adulthood.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"1qaver4\" data-start=\"6571\" data-end=\"6605\"\u003eTrauma \u0026amp; Reconstructive Urology\u003c\/h2\u003e\r\n\u003cp data-start=\"6607\" data-end=\"6638\"\u003eThe trauma curriculum examines:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"6639\" data-end=\"6750\"\u003e\r\n \t\u003cli data-section-id=\"ddyo76\" data-start=\"6639\" data-end=\"6655\"\u003eRenal trauma\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1oh4647\" data-start=\"6656\" data-end=\"6675\"\u003eUrethral trauma\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"159mzca\" data-start=\"6676\" data-end=\"6694\"\u003eGenital trauma\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1rmtspe\" data-start=\"6695\" data-end=\"6726\"\u003eBladder and prostate injury\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"s7bqgj\" data-start=\"6727\" data-end=\"6750\"\u003eUrethral strictures\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"6752\" data-end=\"6883\"\u003eThe course reviews acute management principles alongside reconstructive considerations important for long-term functional outcomes.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"135fhb9\" data-start=\"6885\" data-end=\"6929\"\u003eOffice-Based \u0026amp; Minimally Invasive Urology\u003c\/h2\u003e\r\n\u003cp data-start=\"6931\" data-end=\"6960\"\u003eAdditional sessions focus on:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"6961\" data-end=\"7099\"\u003e\r\n \t\u003cli data-section-id=\"5n0qbg\" data-start=\"6961\" data-end=\"6995\"\u003eUltrasound in urology practice\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"ukdhab\" data-start=\"6996\" data-end=\"7017\"\u003eEnergy modalities\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"193f3my\" data-start=\"7018\" data-end=\"7035\"\u003eLaser physics\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1frrw5r\" data-start=\"7036\" data-end=\"7068\"\u003eRobotic surgery fundamentals\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"ix0ool\" data-start=\"7069\" data-end=\"7099\"\u003eElectrosurgical techniques\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"7101\" data-end=\"7189\"\u003eThese practical lectures are especially relevant for procedural urologists and trainees.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"1hqt8b\" data-start=\"7191\" data-end=\"7208\"\u003eTopics Covered\u003c\/h2\u003e\r\n\u003cul data-start=\"7209\" data-end=\"7652\"\u003e\r\n \t\u003cli data-section-id=\"ouawp3\" data-start=\"7209\" data-end=\"7250\"\u003eProstate cancer imaging and treatment\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"11armz9\" data-start=\"7251\" data-end=\"7277\"\u003eMRI of prostate cancer\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1oi2wl3\" data-start=\"7278\" data-end=\"7306\"\u003eKidney cancer management\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"n04aq5\" data-start=\"7307\" data-end=\"7335\"\u003eBladder cancer therapies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1hl8zq6\" data-start=\"7336\" data-end=\"7357\"\u003eUrologic oncology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"148okyi\" data-start=\"7358\" data-end=\"7386\"\u003eUrinary tract infections\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"ppghzb\" data-start=\"7387\" data-end=\"7404\"\u003eStone disease\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"10e4lak\" data-start=\"7405\" data-end=\"7450\"\u003eMale infertility and erectile dysfunction\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"ruzcbc\" data-start=\"7451\" data-end=\"7476\"\u003eGender-affirming care\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"hw64h4\" data-start=\"7477\" data-end=\"7498\"\u003ePediatric urology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1jfk50e\" data-start=\"7499\" data-end=\"7524\"\u003ePelvic organ prolapse\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1jpjknm\" data-start=\"7525\" data-end=\"7547\"\u003eOveractive bladder\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1m1e3as\" data-start=\"7548\" data-end=\"7584\"\u003eRobotic and laparoscopic surgery\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"vtarr9\" data-start=\"7585\" data-end=\"7617\"\u003eGU trauma and reconstruction\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"13y4orc\" data-start=\"7618\" data-end=\"7652\"\u003eUrologic pathology and imaging\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2 data-section-id=\"1uqeci3\" data-start=\"7654\" data-end=\"7681\"\u003eFinal Expert Perspective\u003c\/h2\u003e\r\n\u003cp data-start=\"7683\" data-end=\"8117\"\u003eModern urology now encompasses a highly diverse and technologically advanced field spanning oncology, reconstruction, minimally invasive surgery, pelvic medicine, pediatric disorders, imaging, genomics, and gender-affirming care. Clinicians are increasingly expected to integrate evidence-based guidelines, advanced imaging interpretation, surgical innovation, and multidisciplinary management into highly individualized patient care.\u003c\/p\u003e\r\n\u003cp data-start=\"8119\" data-end=\"8670\"\u003eThe \u003cem data-start=\"8123\" data-end=\"8161\"\u003eComprehensive Review of Urology 2021\u003c\/em\u003e provides a broad yet clinically practical update across virtually every major area of contemporary urology through expert-led lectures focused on diagnosis, surgical management, imaging, pathology, and evolving therapeutic strategies. For urologists, fellows, residents, advanced practice providers, and clinicians involved in urologic care, the course offers a valuable and comprehensive educational resource for both board preparation and real-world clinical practice.\u003c\/p\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663481721161,"sku":"MED-AMB02928","price":10.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Capture-1.png?v=1781875428"},{"product_id":"uscap-challenges-in-hematopathology-2022","title":"USCAP Challenges in Hematopathology 2022","description":"\u003cspan style=\"font-size: 14.4px;\"\u003eUSCAP Challenges in Hematopathology 2022 Distinguishing between reactive and neoplastic proliferations in blood, bone marrow, lymph nodes, spleen and extra-nodal hematopoietic tissues, as well as accurately classifying neoplasms once they are identified, are essential for appropriate patient care. Pathologists struggle with differentiating reactive from neoplastic conditions in these organs, as well as in properly classifying hematopoietic neoplasms once they are diagnosed.\u003c\/span\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u003cspan style=\"font-size: 14.4px;\"\u003e This highly respected expert faculty will provide a unique mentoring experience and will cover diagnostic criteria for new entities in the 2016 WHO Classification of Hematopoietic and Lymphoid Neoplasms and provide useful morphologic clues and ancillary techniques to help you distinguish neoplastic and reactive conditions.\u003c\/span\u003e\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n \r\n\u003cdiv class=\"single-main-content\"\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch3\u003e\u003cstrong\u003eTarget Audience\u003c\/strong\u003e\u003c\/h3\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp style=\"padding-left: 40px;\"\u003ePracticing academic and community pathologists, and pathologists-in-training\u003c\/p\u003e\r\n\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch3\u003e\u003cstrong\u003eLearning Objectives\u003c\/strong\u003e\u003c\/h3\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nUpon completion of this educational activity, learners will be able to:\r\n\u003cul\u003e\r\n \t\u003cli\u003eBecome familiar with new and rare disease entities involving blood and hematopoietic tissues\u003c\/li\u003e\r\n \t\u003cli\u003eUnderstand the changes caused by reactive and specific infectious agents in hematopoietic tissues\u003c\/li\u003e\r\n \t\u003cli\u003eUnderstand the spectrum of Hodgkin lymphoma and its mimics\u003c\/li\u003e\r\n \t\u003cli\u003eIncorporate the clues and ancillary techniques to differentiate neoplastic from reactive proliferations in blood, bone marrow, lymph nodes, spleen and extranodal hematopoietic tissues\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eProgram : \u003c\/strong\u003e\r\n\r\nItems Included in the Purchase of this Course\r\n\u003cul\u003e\r\n \t\u003cli\u003eBenign and Neoplastic Disorders Initially Encountered on Blood Smears – M. Kathryn Foucar, MD\u003c\/li\u003e\r\n \t\u003cli\u003eMyeloid and Lymphoid Neoplasms and Lookalikes in Bone Marrow – M. Kathryn Foucar, MD\u003c\/li\u003e\r\n \t\u003cli\u003eClassic Hodgkin Lymphoma and Nodular Lymphocyte Predominant Hodgkin Lymphoma and Challenges with Diagnosis and Overlapping Entities – Rebecca L. King, MD\u003c\/li\u003e\r\n \t\u003cli\u003eChallenges With EBV-Related B Cell Lineage Lymphomas\/Lymphoproliferations and Their Classification – Rebecca L. King, MD\u003c\/li\u003e\r\n \t\u003cli\u003eSplenic Tumors and Tumor-Like Proliferations – Daniel A. Arber, MD\u003c\/li\u003e\r\n \t\u003cli\u003eMixed Bag of Hematologic Neoplasms (Examples of New and Novel Entities) – Daniel A. Arber, MD\u003c\/li\u003e\r\n \t\u003cli\u003eSubtle Reactive and Infectious Lymphoid Proliferations – Girish Venkataraman, MD, MBBS Add to Cart\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnosing Castleman and Castleman-Like Lymphoid Proliferations – Girish Venkataraman, MD, MBBS\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eOriginal release date: \u003cspan style=\"color: #ff0000;\"\u003eMay 24, 2022\u003c\/span\u003e\u003c\/strong\u003e\r\n\r\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663481753929,"sku":"MED-AMB06854","price":75.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/USCAP-Challenges-in-Hematopathology-2022.jpg?v=1781875428"},{"product_id":"uscap-2022-modern-approaches-to-classification-of-hematolymphoid-neoplasms-2022","title":"USCAP 2022 Modern Approaches to Classification of Hematolymphoid Neoplasms 2022","description":"\u003cdiv class=\"product-gallery large-6 col\"\u003e\r\n\u003cdiv class=\"product-images relative mb-half has-hover woocommerce-product-gallery woocommerce-product-gallery--with-images woocommerce-product-gallery--columns-4 images\" data-columns=\"4\"\u003e\r\n\u003ch1\u003eUSCAP 2022 Modern Approaches to Classification of Hematolymphoid Neoplasms 2022\u003c\/h1\u003e\r\n\u003cul\u003e\r\n \t\u003cli class=\"image-tools absolute bottom left z-3\"\u003e\u003cstrong\u003eInclude:8 videos + 8 pdfs, size: 16 GB\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv id=\"tab-description\" class=\"woocommerce-Tabs-panel woocommerce-Tabs-panel--description panel entry-content active\" role=\"tabpanel\" aria-labelledby=\"tab-title-description\"\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eTarget Audience: training and practicing pathologists\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMyelodysplastic Syndrome and Its Differential Diagnosis – Kaaren K. Reichard, MD\r\nSection: 1 Presentation 1 Document 1 Certificate 1 Survey\u003c\/li\u003e\r\n \t\u003cli\u003eMyeloproliferative Neoplasms and Progression in Myeloid Neoplasms – Kaaren K. Reichard, MD\r\nSection: 1 Presentation 1 Document 1 Certificate 1 Survey\u003c\/li\u003e\r\n \t\u003cli\u003eCutaneous Lymphomas and Atypical Cutaneous Lymphoid Proliferations – Elaine S. Jaffe, MD\r\nSection: 1 Presentation 1 Document 1 Certificate 1 Survey\u003c\/li\u003e\r\n \t\u003cli\u003eVery Abnormal Lymph Nodes – Elaine S. Jaffe, MD\r\nSection: 1 Presentation 1 Document 1 Certificate 1 Survey\u003c\/li\u003e\r\n \t\u003cli\u003eUncommon Patterns of Common Lymphomas – Yuri Fedoriw, MD\r\nSection: 1 Presentation 1 Document 1 Certificate 1 Survey\u003c\/li\u003e\r\n \t\u003cli\u003eWhen the Malignant Cells are in the Minority (Hodgkin and Hodgkin Mimics) – Yuri Fedoriw, MD\r\nSection: 1 Presentation 1 Document 1 Certificate 1 Survey\u003c\/li\u003e\r\n \t\u003cli\u003ePrognostic and Predictive Biomarkers – Olga K. Weinberg, MD\r\nSection: 1 Presentation 1 Document 1 Certificate 1 Survey\u003c\/li\u003e\r\n \t\u003cli\u003eCirculating Neoplasms – Olga K. Weinberg, MD\r\nSection: 1 Presentation 1 Document 1 Certificate 1 Survey\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663481819465,"sku":"MED-AMB06768","price":80.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/USCAP-2022-Modern-Approaches-to-Classification-of-Hematolymphoid-Neoplasms-2022.jpg?v=1781875428"},{"product_id":"mena-conference-9th-emirates-oncology-conference-2021","title":"MENA Conference 9th Emirates Oncology Conference 2021","description":"\u003ch1\u003e\u003cstrong\u003eMENA Conference 9th Emirates Oncology Conference 2021\u003c\/strong\u003e\u003c\/h1\u003e\r\nMENA Conference 9th Emirates Oncology Conference 2021On behalf of Tawam Hospital, it is with pride and pleasure that we cordially invite you to the “9th Emirates Oncology Conference” with the theme “Modern comprehensive cancer care in the era of the pandemic” that is to be held as virtual on November 12-13 \u0026amp; 19-20, 2021.\r\n\r\n\u003cspan style=\"color: #1b1919; font-size: 24px;\"\u003eDescription\u003c\/span\u003e\r\n\r\n\u003cstrong\u003eInclude: 41 videos + 3 pdfs, size: 30.1 GB\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eTarget Audience: cancer researchers, oncologists, radiation oncologists, surgeons, radiologists, pathologists\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eSample video: \u003cspan style=\"color: #3366ff;\"\u003e\u003ca style=\"color: #3366ff;\" href=\"https:\/\/medustudent.com\/contact_us\/\"\u003econtact me\u003c\/a\u003e\u003c\/span\u003e for sample video\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eInformation:\u003c\/strong\u003e\r\n\r\nOn behalf of Tawam Hospital, it is with pride and pleasure that we cordially invite you to the “9th Emirates Oncology Conference” with the theme “Modern comprehensive cancer care in the era of the pandemic” that is to be held as virtual on November 12-13 \u0026amp; 19-20, 2021.\r\n\r\nThrough a culmination of collective efforts, an outstanding four-day program is designed to deliver a high-level scientific content with several key note lectures, parallel symposia, oral and poster presentations that revolve on the innovation in cancer treatment and care. The\r\n\r\nsessions provide major updates and state-of-the art presentations that has been fostered through a collaboration among experts in oncology and advanced cancer care. The conference is hosting hundreds of oncology experts from around the world to provide a unique platform to expedite the knowledge transfer emulating both academic and applied cancer care to combat a complex disease – cancer.\r\n\r\nThe conference is one of the largest health-related conferences in the region with more than 2000 expected delegates attending from around the Middle East and GCC region. The conference not only brings together international and local expertise to cancer care and management, but also offers to the companies the opportunity to showcase their products and services to the largest gathering of healthcare professionals from the region. We are confident that the 9th Emirates Oncology Conference will serve as a place of learning where we can all share the latest models, approaches, and research representing for all participants a treasured personal and professional experience. On behalf of the conference committee board and members, we look forward to your participation and trust this will be a unique educational experience.\r\n\r\n\u003cstrong\u003eDATE \u0026amp; TIME: \u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFriday 12th \u0026amp; Saturday 13th November 2021\u003c\/li\u003e\r\n \t\u003cli\u003eFriday 19th \u0026amp; Saturday 20th November 2021\u003c\/li\u003e\r\n \t\u003cli\u003eFrom 15:00 to 21:00\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eCONFERENCE HIGHLIGHTS: \u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003ePrecision Immunotherapy for Head and Neck Cancer\u003c\/li\u003e\r\n \t\u003cli\u003ePursuing Cancer Care Quality\u003c\/li\u003e\r\n \t\u003cli\u003eHeavy Particle Radiotherapy for Cancer Treatment\u003c\/li\u003e\r\n \t\u003cli\u003eInternational application of Quality Oncology Practice Initiative (iQOPI)\u003c\/li\u003e\r\n \t\u003cli\u003eGenetics of Unknown Significance in Breast Cancer\u003c\/li\u003e\r\n \t\u003cli\u003eAxillary Node Management in Breast Cancer after Neoadjuvant Chemotherapy\u003c\/li\u003e\r\n \t\u003cli\u003eSurgical Perspective on Hepatic Colorectal Metastases\u003c\/li\u003e\r\n \t\u003cli\u003eHyper thermic Intraperitoneal Chemotherapy in GI Malignancies\u003c\/li\u003e\r\n \t\u003cli\u003eThe TEAM Approach to Palliative Care\u003c\/li\u003e\r\n \t\u003cli\u003eCare after Allogeneic Hematopoietic Cell Transplant in Children\u003c\/li\u003e\r\n \t\u003cli\u003eThe Quality Cancer Care Through CCPC Certification\u003c\/li\u003e\r\n \t\u003cli\u003eFocus on Survivorship in Cancer Survivor\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eTARGET AUDIENCE: \u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eCancer Researchers\u003c\/li\u003e\r\n \t\u003cli\u003eOncologists\u003c\/li\u003e\r\n \t\u003cli\u003eRadiation Oncologists\u003c\/li\u003e\r\n \t\u003cli\u003eSurgeons, Radiologists\u003c\/li\u003e\r\n \t\u003cli\u003ePathologists\u003c\/li\u003e\r\n \t\u003cli\u003eNurses\u003c\/li\u003e\r\n \t\u003cli\u003ePhysicians\u003c\/li\u003e\r\n \t\u003cli\u003eMedical Students\u003c\/li\u003e\r\n \t\u003cli\u003eNurses\u003c\/li\u003e\r\n \t\u003cli\u003ePharmacists\u003c\/li\u003e\r\n \t\u003cli\u003eAllied Health Professionals\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eTopics:\u003c\/strong\u003e\r\n\r\n*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the Detail section below\r\n\u003cul\u003e\r\n \t\u003cli\u003e9th-Emirates-Oncology-Conference-Brochure2_pdf_06Oct2021155204.pdf\u003c\/li\u003e\r\n \t\u003cli\u003eAgenda_12-13_Nov_-_EOC2021_pdf_07Oct2021154400.pdf\u003c\/li\u003e\r\n \t\u003cli\u003eAgenda_19-20_Nov_-_EOC2021_pdf_07Oct2021154426.pdf\u003c\/li\u003e\r\n \t\u003cli\u003eDay 1 Breast Session 1.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 1 Breast Session 2.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 1 Opening.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 1 Pediatric Session 1.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 1 Pediatric Session 2.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 1 Plenary Session.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 1 Roche Symposium.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 2 Bristol-Myers Squibb Symposium.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 2 Gynecology Session 1.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 2 Gynecology Session 2.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 2 Nursing Session 1.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 2 Nursing Session 2.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 2 Palliative Care Session 1.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 2 Palliative Care Session 2.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 2 Radiation Session 1.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 2 Radiation Session 2.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 2 Radiation Session 3.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 2 Surgical Workshop.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 3 3rd Women Surgeons of the Gulf Meeting.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 3 Adult Haematology Session 1.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 3 Adult Haematology Session 2.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 3 GI Session 1.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 3 GI Session 2 C.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 3 GI Session 2.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 3 GI Session 3.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 3 Lilly Symposium.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 3 MSD Symposium.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 3 Opening and Plenary Session.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 4 Astellas Symposium.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 4 AstraZeneca Symposium 1.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 4 AstraZeneca Symposium 2.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 4 CLosing Remarks.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 4 CNS Session 1.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 4 CNS Session 2.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 4 GU Session 1 Prostate.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 4 GU Session 2.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 4 Lung Session 1.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 4 Lung Session 2.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 4 Nursing 2 Session 1.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 4 Nursing 2 Session 2.mp4\u003c\/li\u003e\r\n \t\u003cli\u003eDay 4 Oral Presentation.mp4\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nDetails:\r\n\r\n\u003cimg class=\"alignnone size-large wp-image-5713\" src=\"https:\/\/coursemedicalshop.com\/wp-content\/uploads\/2023\/12\/bandicam-2023-12-05-21-15-34-970-1024x746.jpg\" alt=\"\" width=\"1024\" height=\"746\"\u003e \u003cimg class=\"alignnone size-large wp-image-5714\" src=\"https:\/\/coursemedicalshop.com\/wp-content\/uploads\/2023\/12\/bandicam-2023-12-05-21-15-37-830-1024x746.jpg\" alt=\"\" width=\"1024\" height=\"746\"\u003e \u003cimg class=\"alignnone size-large wp-image-5715\" src=\"https:\/\/coursemedicalshop.com\/wp-content\/uploads\/2023\/12\/bandicam-2023-12-05-21-15-40-741-1024x746.jpg\" alt=\"\" width=\"1024\" height=\"746\"\u003e \u003cimg class=\"alignnone size-large wp-image-5716\" src=\"https:\/\/coursemedicalshop.com\/wp-content\/uploads\/2023\/12\/bandicam-2023-12-05-21-15-44-576-1024x746.jpg\" alt=\"\" width=\"1024\" height=\"746\"\u003e \u003cimg class=\"alignnone size-large wp-image-5717\" src=\"https:\/\/coursemedicalshop.com\/wp-content\/uploads\/2023\/12\/bandicam-2023-12-05-21-15-47-839-1024x746.jpg\" alt=\"\" width=\"1024\" height=\"746\"\u003e \u003cimg class=\"alignnone size-large wp-image-5718\" src=\"https:\/\/coursemedicalshop.com\/wp-content\/uploads\/2023\/12\/bandicam-2023-12-05-21-15-56-978-1024x746.jpg\" alt=\"\" width=\"1024\" height=\"746\"\u003e \u003cimg class=\"alignnone size-large wp-image-5719\" src=\"https:\/\/coursemedicalshop.com\/wp-content\/uploads\/2023\/12\/bandicam-2023-12-05-21-16-10-342-1024x746.jpg\" alt=\"\" width=\"1024\" height=\"746\"\u003e \u003cimg class=\"alignnone size-large wp-image-5720\" src=\"https:\/\/coursemedicalshop.com\/wp-content\/uploads\/2023\/12\/bandicam-2023-12-05-21-16-13-478-1024x746.jpg\" alt=\"\" width=\"1024\" height=\"746\"\u003e \u003cimg class=\"alignnone size-large wp-image-5721\" src=\"https:\/\/coursemedicalshop.com\/wp-content\/uploads\/2023\/12\/bandicam-2023-12-05-21-16-16-558-1024x746.jpg\" alt=\"\" width=\"1024\" height=\"746\"\u003e \u003cimg class=\"alignnone size-large wp-image-5722\" src=\"https:\/\/coursemedicalshop.com\/wp-content\/uploads\/2023\/12\/bandicam-2023-12-05-21-16-18-733-1024x746.jpg\" alt=\"\" width=\"1024\" height=\"746\"\u003e \u003cimg class=\"alignnone size-large wp-image-5723\" src=\"https:\/\/coursemedicalshop.com\/wp-content\/uploads\/2023\/12\/bandicam-2023-12-05-21-16-39-871-1024x746.jpg\" alt=\"\" width=\"1024\" height=\"746\"\u003e \u003cimg class=\"alignnone size-large wp-image-5724\" src=\"https:\/\/coursemedicalshop.com\/wp-content\/uploads\/2023\/12\/bandicam-2023-12-05-21-16-47-386-1024x746.jpg\" alt=\"\" width=\"1024\" height=\"746\"\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663481852233,"sku":"MED-AMB06775","price":10.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/MENA-Conference-9th-Emirates-Oncology-Conference-2021.jpg?v=1781875429"},{"product_id":"american-society-of-clinical-oncology-annual-meeting-2025","title":"American Society of Clinical Oncology Annual Meeting 2025","description":"\u003cdiv class=\"prod-edition\"\u003e\r\n\u003cdiv class=\"field field--name-field-heading field--type-heading field--label-hidden field__item\"\u003e\r\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\r\n\u003cdiv class=\"elementor-element elementor-element-bbb44b8 elementor-widget elementor-widget-heading\" data-id=\"bbb44b8\" data-element_type=\"widget\" data-widget_type=\"heading.default\"\u003e\r\n\u003cdiv class=\"bundle--paragraph_component paragraph paragraph--type--paragraph-component paragraph--view-mode--default\"\u003e\r\n\u003cdiv class=\"row\"\u003e\r\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\r\n\u003cdiv class=\"outer-wrapper\"\u003e\u003csection id=\"main-container\" class=\"main-container\" role=\"main\"\u003e\u003csection class=\"course\" data-id=\"108054\" data-role=\"course\"\u003e\u003csection class=\"product\"\u003e\u003csection class=\"content-item-container-section\"\u003e\u003csection class=\"content\"\u003e\r\n\u003cdiv class=\"description\"\u003e\r\n\u003cdiv id=\"course-item-description-wrapper\"\u003e\r\n\u003ch3\u003eAmerican Society of Clinical Oncology Annual Meeting 2025\u003c\/h3\u003e\r\n\u003cstrong\u003e Target Audience: oncologists, hematologists, pathologists, radiologists, surgical, and radiation oncologists\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003e Information:\u003c\/strong\u003e\r\n\r\nThe \u003cstrong\u003e2025 American Society of Clinical Oncology (ASCO) Annual Meeting\u003c\/strong\u003e took place from \u003cstrong\u003eMay 30 to June 3\u003c\/strong\u003e in \u003cstrong\u003eChicago, Illinois\u003c\/strong\u003e, under the theme \u003cem\u003e“Driving Knowledge to Action: Building a Better Future”\u003c\/em\u003e.\r\n\r\nHere are some key highlights:\r\n\u003cul\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOver 5,400 presentations\u003c\/strong\u003e covered cutting-edge research, clinical trials, and treatment innovations across a wide range of cancers.\u003c\/li\u003e\r\n \t\u003cli class=\"ps-2\"\u003e\n\u003cstrong\u003eBreast, lung, ovarian, and colorectal cancers\u003c\/strong\u003e were among the most featured tumor types.\u003c\/li\u003e\r\n \t\u003cli class=\"ps-2\"\u003e\n\u003cstrong\u003eAstraZeneca and Daiichi Sankyo\u003c\/strong\u003e presented promising results from the DESTINY-Breast09 study, suggesting a potential new standard of care for HER2-positive metastatic breast cancer.\u003c\/li\u003e\r\n \t\u003cli class=\"ps-2\"\u003e\n\u003cstrong\u003eGilead and Merck \u0026amp; Co\u003c\/strong\u003e made headlines with their TROP-2–targeted therapy Trodelvy combined with Keytruda, showing strong results in triple-negative breast cancer.\u003c\/li\u003e\r\n \t\u003cli class=\"ps-2\"\u003e\n\u003cstrong\u003eAmgen’s Imdelltra\u003c\/strong\u003e showed significant benefit in small cell lung cancer, a notoriously tough-to-treat disease.\u003c\/li\u003e\r\n \t\u003cli class=\"ps-2\"\u003eIn ovarian cancer, the \u003cstrong\u003eROSELLA trial\u003c\/strong\u003e and \u003cstrong\u003eOVATION-2 study\u003c\/strong\u003e offered encouraging data for patients with resistant or advanced disease\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe \u003cstrong\u003etarget audience\u003c\/strong\u003e for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is impressively broad, reflecting the multidisciplinary nature of cancer care. It includes:\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u003cstrong\u003eMedical, surgical, and radiation oncologists\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003eHematologists, pathologists, and radiologists\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003ePrimary care physicians and internal medicine specialists\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003eGynecologic, thoracic, colorectal, and urologic surgeons\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003ePulmonologists, dermatologists, and oral surgeons\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003eOncology nurse practitioners, nurses, and physician assistants\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003eResidents, fellows, and medical students\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eAllied health professionals\u003c\/strong\u003e involved in oncology care and research\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe meeting is designed to foster collaboration across specialties, highlight the latest in clinical and translational research, and support continuing education for professionals at all stages of their careers\r\n\r\n \r\n\r\n\u003cstrong\u003eTopics:\u003c\/strong\u003e\r\n\r\n*Note: \u003cstrong\u003e\u003ca href=\"https:\/\/cdn.bfldr.com\/KOIHB2Q3\/as\/x4kfgjgg9s7745gv3x3t9mj3\/AM25-Sessions-At-A-Glance\"\u003eAgenda\u003c\/a\u003e\u003c\/strong\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/section\u003e\u003c\/section\u003e\u003c\/section\u003e\u003c\/section\u003e\u003c\/section\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663482081609,"sku":"MED-AMB06443","price":90.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/American-Society-of-Clinical-Oncology-Annual-Meeting-2025.png?v=1781875429"},{"product_id":"geriatric-oncology-for-the-advanced-practice-provider-impacting-care-across-the-globe-2023","title":"Geriatric Oncology for the Advanced Practice Provider: Impacting Care Across the Globe 2023","description":"\u003cdiv id=\"tab-description\" class=\"woocommerce-Tabs-panel woocommerce-Tabs-panel--description panel entry-content wc-tab\" role=\"tabpanel\" aria-labelledby=\"tab-title-description\"\u003e\r\n\r\nGeriatric Oncology for the Advanced Practice Provider: Impacting Care Across the Globe 2023 Aging is a risk factor for the development of cancer.\u003cstrong\u003e \u003c\/strong\u003eAs the United States population ages, \u003cstrong\u003ethe need for clinicians skilled in the care of older adults with cancer will increase\u003c\/strong\u003e. Research however suggests that \u003cstrong\u003ecommon geriatric syndromes and many psychosocial needs of older adult oncology patients are often unintentionally overlooked or under-addressed\u003c\/strong\u003e.\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u003cstrong\u003e+ Include: 19 videos + 17 pdfs, size: 1.51 GB\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003e+ Target Audience: physicians (residents, fellows, and attending physicians), respiratory therapists, physical therapists, occupational therapists, social workers, case managers, and other healthcare professionals in medicine and surgery who provide care for the older adult\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003e+ Information:\u003c\/strong\u003e\r\n\u003cdiv class=\"form-group\"\u003e\r\n\u003cdiv class=\"form-control-plaintext\"\u003e\r\n\u003cdiv class=\"form-group\"\u003e\r\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eDate \u0026amp; Location\u003c\/strong\u003e\u003c\/div\u003e\r\nTuesday, April 18, 2023, 8:00 AM – 5:00 PM, Online, New York, NY\r\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eSpecialties\u003c\/strong\u003e\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv\u003e\n\u003cem\u003eSpecialties\u003c\/em\u003e – Allergy and Immunology, Anesthesiology, Bone Marrow Transplant, Breast Medical Oncology, Breast Surgery, Cardiology, Cardiothoracic Surgery, Colorectal Surgery, Critical Care, Dentistry, Dermatology, Emergency Medicine, Endocrinology, Diabetes and Metabolism, ENT, Gastroenterology, Gastrointestinal Oncology, General Surgery, Genitourinary Oncology, Geriatric Medicine, Gynecologic Oncology, Head and Neck Oncology, Head and Neck Surgery, Hematology, Hepatology, Hospice and Palliative Medicine, Infectious Diseases, Integrative Medicine, Internal Medicine, Interventional Radiology, Leukemia, Lymphoma, Nephrology, Neurology, Neuro-Oncology, Neurosurgery, Oncology and Hematology, Ophthalmology, Oral and Maxillofacial Surgery, Orthopedic Surgery, Otolaryngology, Physical Medicine and Rehabilitation, Plastic Surgery, Preventive and Occupational Medicine, Psychiatry, Pulmonary Medicine, Pulmonology, Radiation Oncology, Rheumatology, Sleep Medicine, Surgical Oncology, Thoracic Medical Oncology, Thoracic Surgery, Urology, Vascular Surgery\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eOverview\u003c\/strong\u003e\u003c\/div\u003e\r\nAging is a risk factor for the development of cancer.\u003cstrong\u003e \u003c\/strong\u003eAs the United States population ages, \u003cstrong\u003ethe need for clinicians skilled in the care of older adults with cancer will increase\u003c\/strong\u003e. Research however suggests that \u003cstrong\u003ecommon geriatric syndromes and many psychosocial needs of older adult oncology patients are often unintentionally overlooked or under-addressed\u003c\/strong\u003e.\r\n\r\nThis one-day evidence-based virtual program is designed to \u003cstrong\u003eoptimize the care of older adult oncology patients\u003c\/strong\u003e by advancing the knowledge and expertise of advanced practice providers. A \u003cstrong\u003egeneral overview of key geriatric oncology topics\u003c\/strong\u003e will be provided including: the use of the comprehensive geriatric assessment; communication strategies in the assessment of older adults; and assessment of fitness versus frailty, resilience, and risk stratification prior to cancer-directed therapies.\r\n\r\nAdditionally, the assessment, diagnosis, and treatment of \u003cstrong\u003ecognitive impairment\u003c\/strong\u003e will be addressed, including the role of neuropsychiatric testing, cognitive rehabilitation, and psychopharmacology interventions. Participants will be introduced to \u003cstrong\u003egeriatric collaborative programs\u003c\/strong\u003e in the context of breast medicine and bone marrow transplantation, and the \u003cstrong\u003eintersection of geriatric medicine and palliative care\u003c\/strong\u003e will be discussed. Comprehensive geriatric care will be highlighted in \u003cstrong\u003eacademic, community-based, and international settings\u003c\/strong\u003e. Content proficiency will be assessed with pre and post-conference evaluations.\r\n\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cstrong\u003eWho Should Attend\u003c\/strong\u003e\r\n\r\nThis program is designed for advanced practice providers, registered nurses, CRNAs, physicians (residents, fellows, and attending physicians), respiratory therapists, physical therapists, occupational therapists, social workers, case managers, and other healthcare professionals in medicine and surgery who provide care for the older adult.\r\n\r\nWe are pleased to offer \u003cstrong\u003ecomplimentary registration\u003c\/strong\u003e for \u003cstrong\u003enursing students\u003c\/strong\u003e in addition to registrants \u003cstrong\u003eresiding in low and lower-middle income countries \u003c\/strong\u003eto attend this program.\r\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eObjectives\u003c\/strong\u003e\u003c\/div\u003e\r\n\u003col\u003e\r\n \t\u003cli\u003eDefine the concepts of frailty and resilience in the older adult\u003c\/li\u003e\r\n \t\u003cli\u003eDemonstrate understanding in the comprehensive management (identification, diagnosis, and treatment) of cognitive dysfunction in the older adult with cancer\u003c\/li\u003e\r\n \t\u003cli\u003eUtilize effective communication strategies in the assessment of older adult patients\u003c\/li\u003e\r\n \t\u003cli\u003eRecognize the value of collaborative care in the care of older adults\u003c\/li\u003e\r\n \t\u003cli\u003eGain perspective from local and international standpoints on geriatric oncology care\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\r\n\u003cp style=\"padding-left: 40px;\"\u003eAdvancing Geriatric Oncology Knowledge for the APP Q\u0026amp;A.mp4\r\nApplication of Geriatrics Principles of Care in Transplantation and Cellular Therapy.mp4\r\nApplication of Geriatrics Principles of Care in Transplantation and Cellular Therapy.pdf\r\nCase Study- Collaborative Care.mp4\r\nCase Study- Collaborative Care.pdf\r\nCognition and the Older Adult Q\u0026amp;A.mp4\r\nFitness vs. Frailty- Why Chronological Age is Old.mp4\r\nFitness vs. Frailty- Why Chronological Age is Old.pdf\r\nGeriatric Assessment for the Advanced Practice Provider.mp4\r\nGeriatric Assessment for the Advanced Practice Provider.pdf\r\nGeriatric Assessment- Overview of the Evidence.pdf\r\nGeriatric Oncology – Advancing Collaborative Care Q\u0026amp;A.mp4\r\nGeriatric Oncology in an Academic Institution- Cancer and Aging Clinic.mp4\r\nGeriatric Oncology in an Academic Institution- Cancer and Aging Clinic.pdf\r\nGeriatric Oncology_A Global Perspective Q\u0026amp;A.mp4\r\nGeriOncAPP_2023_Brochure.pdf\r\nGlobal Geriatric Care- A Singapore Experience.mp4\r\nGlobal Geriatric Care- A Singapore Experience.pdf\r\nInternational Society of Geriatric Oncology- Bringing the World together to Improve the Care of Older Adults with Cancer.mp4\r\nInternational Society of Geriatric Oncology- Bringing the World together to Improve the Care of Older Adults with Cancer.pdf\r\nNeuropsychological Evaluation and Cognitive Assessment of Older Adults.mp4\r\nNeuropsychological Evaluation and Cognitive Assessment of Older Adults.pdf\r\nOccupational Therapy’s Role in Cognitive Rehabilitation.mp4\r\nOccupational Therapy’s Role in Cognitive Rehabilitation.pdf\r\nPrimum Non Nocere- The Art of Geriatric Psychopharmacology.mp4\r\nPrimum Non Nocere- The Art of Geriatric Psychopharmacology.pdf\r\nRisk Stratification of the Older Adult Prior to Cancer Directed Therapy.mp4\r\nRisk Stratification of the Older Adult Prior to Cancer Directed Therapy.pdf\r\nThe 3 D’s- Delirium, Dementia, and Depression in the Older Adult.mp4\r\nThe 3 D’s- Delirium, Dementia, and Depression in the Older Adult.pdf\r\nThe Intersection of Geriatrics and Palliative Care.mp4\r\nThe Intersection of Geriatrics and Palliative Care.pdf\r\nTreating Breast Cancer in Older Adults- Special Considerations to Maximize Benefit and Minimize Toxicity.mp4\r\nTreating Breast Cancer in Older Adults- Special Considerations to Maximize Benefit and Minimize Toxicity.pdf\r\n“It Can Be Done” Geriatric Oncology Assessment in a Community Cancer Center- The Hartford Experience.mp4\r\n“It Can Be Done” Geriatric Oncology Assessment in a Community Cancer Center- The Hartford Experience.pdf\u003c\/p\u003e\r\n\r\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663482114377,"sku":"MED-AMB06672","price":40.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Memorial-Sloan-Kettering-Cancer-Center-Geriatric-Oncology-for-the-Advanced.jpg?v=1781875429"},{"product_id":"alliance-for-regenerative-medicine-cell-gene-meeting-on-the-med-2025","title":"Alliance for Regenerative Medicine CELL \u0026 GENE Meeting On The Med 2025","description":"\u003ch2\u003eAlliance for Regenerative Medicine CELL \u0026amp; GENE Meeting On The Med 2025\u003c\/h2\u003e\r\n\u003cstrong\u003e+ Include: 5 videos + 1 pdf, size: 76.68 GB\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003e+ Target Audience: researchers, biotech entrepreneurs\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003e+ Information:\u003c\/strong\u003e\r\n\u003cp data-start=\"311\" data-end=\"767\"\u003eThe \u003cem data-start=\"337\" data-end=\"405\"\u003eCell \u0026amp; Gene Meeting on the Mediterranean (Meeting on the Med) 2025\u003c\/em\u003e, organized by the Alliance for Regenerative Medicine, is Europe’s foremost conference for advanced therapy stakeholders. This hybrid event brings together leading companies, investors, regulators, and researchers in the cell and gene therapy sector to explore commercialization, manufacturing, regulatory frameworks, and financing of next-generation treatments.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"769\" data-end=\"772\"\u003e\r\n\u003cp data-start=\"774\" data-end=\"799\"\u003e\u003cstrong data-start=\"774\" data-end=\"797\"\u003eWhat You Will Learn\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"800\" data-end=\"1358\"\u003e\r\n \t\u003cli data-start=\"800\" data-end=\"955\"\u003e\r\n\u003cp data-start=\"802\" data-end=\"955\"\u003eKey challenges and opportunities in bringing cell and gene therapies to market—including regulatory strategies, market access, and clinical development\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli data-start=\"956\" data-end=\"1078\"\u003e\r\n\u003cp data-start=\"958\" data-end=\"1078\"\u003eBest practices in manufacturing scale-up, quality assurance, and supply chain logistics specific to advanced therapies\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli data-start=\"1079\" data-end=\"1216\"\u003e\r\n\u003cp data-start=\"1081\" data-end=\"1216\"\u003eFinancial and investment insights tailored to advanced biotechnology companies navigating fundraising and public-private partnerships\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli data-start=\"1217\" data-end=\"1358\"\u003e\r\n\u003cp data-start=\"1219\" data-end=\"1358\"\u003eFirsthand lessons from company presentations, industry panels, and thought-leader insights across different stages of the therapy lifecycle\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"1360\" data-end=\"1363\"\u003e\r\n\u003cp data-start=\"1365\" data-end=\"1384\"\u003e\u003cstrong data-start=\"1365\" data-end=\"1382\"\u003eEvent Details\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"1385\" data-end=\"1954\"\u003e\r\n \t\u003cli data-start=\"1385\" data-end=\"1449\"\u003e\r\n\u003cp data-start=\"1387\" data-end=\"1449\"\u003e\u003cstrong data-start=\"1387\" data-end=\"1397\"\u003eEvent:\u003c\/strong\u003e ARM Cell \u0026amp; Gene Meeting on the Mediterranean 2025\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli data-start=\"1450\" data-end=\"1541\"\u003e\r\n\u003cp data-start=\"1452\" data-end=\"1541\"\u003e\u003cstrong data-start=\"1452\" data-end=\"1462\"\u003eDates:\u003c\/strong\u003e April 15–17, 2025 (in-person); April 21–22, 2025 (virtual partnering access)\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli data-start=\"1542\" data-end=\"1587\"\u003e\r\n\u003cp data-start=\"1544\" data-end=\"1587\"\u003e\u003cstrong data-start=\"1544\" data-end=\"1557\"\u003eLocation:\u003c\/strong\u003e Rome Cavalieri, Rome, Italy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli data-start=\"1588\" data-end=\"1722\"\u003e\r\n\u003cp data-start=\"1590\" data-end=\"1722\"\u003e\u003cstrong data-start=\"1590\" data-end=\"1601\"\u003eFormat:\u003c\/strong\u003e Hybrid delivery combining live in-person sessions, one-on-one partnering, interactive workshops, and virtual streaming\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli data-start=\"1723\" data-end=\"1954\"\u003e\r\n\u003cp data-start=\"1725\" data-end=\"1742\"\u003e\u003cstrong data-start=\"1725\" data-end=\"1740\"\u003eHighlights:\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"1745\" data-end=\"1954\"\u003e\r\n \t\u003cli data-start=\"1745\" data-end=\"1780\"\u003e\r\n\u003cp data-start=\"1747\" data-end=\"1780\"\u003eOver 50 corporate presentations\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli data-start=\"1783\" data-end=\"1849\"\u003e\r\n\u003cp data-start=\"1785\" data-end=\"1849\"\u003eExtensive partnering opportunities (1000+ one-on-one meetings)\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli data-start=\"1852\" data-end=\"1892\"\u003e\r\n\u003cp data-start=\"1854\" data-end=\"1892\"\u003eExpert-led panels and fireside chats\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli data-start=\"1895\" data-end=\"1954\"\u003e\r\n\u003cp data-start=\"1897\" data-end=\"1954\"\u003eNetworking receptions and collaborative industry sessions\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"1956\" data-end=\"1959\"\u003e\r\n\u003cp data-start=\"1961\" data-end=\"2247\"\u003e\u003cstrong data-start=\"1961\" data-end=\"1982\"\u003eWho Should Attend\u003c\/strong\u003e\u003cbr data-start=\"1982\" data-end=\"1985\"\u003eExecutives, researchers, biotech entrepreneurs, investors, regulators, manufacturing experts, and patient advocates engaged in the cell and gene therapy ecosystem—especially those seeking to accelerate commercialization and global adoption of advanced therapies.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"2249\" data-end=\"2252\"\u003e\r\n\u003cp data-start=\"2254\" data-end=\"2614\"\u003e\u003cstrong data-start=\"2254\" data-end=\"2268\"\u003eWhy Attend\u003c\/strong\u003e\u003cbr data-start=\"2268\" data-end=\"2271\"\u003eThis event unites the most relevant commercial, scientific, and regulatory perspectives in one of biotechnology’s fastest-moving fields. Participants gain invaluable connections, practical insight into industry challenges, and a strategic edge in positioning their innovations for global impact—all within an immersive, hybrid learning format.\u003c\/p\u003e\r\n \r\n\r\n\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\r\n\r\n*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the Detail section below\r\n\r\nApirl 15 Salone dei Cavalieri, Section 2.mp4\r\nApirl 15 Salone dei Cavalieri, Section 3\u0026amp;4.mp4\r\nApirl 16 Salone dei Cavalieri, Section 2.mp4\r\nApirl 16 Salone dei Cavalieri, Section 3\u0026amp;4.mp4\r\nApirl 17 Salone dei Cavalieri, Section 3\u0026amp;4.mp4\r\nCGMED-Event-Program-2025-Digital-Final-2.pdf","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663482147145,"sku":"MED-AMB06399","price":65.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Alliance-for-Regenerative-Medicine-CELL-GENE-Meeting-On-The-Med-2025.webp?v=1781875429"},{"product_id":"cedars-sinai-research-updates-in-lymphoma-2025","title":"Cedars Sinai Research Updates in Lymphoma 2025","description":"\u003ch3\u003eCedars Sinai Research Updates in Lymphoma 2025\u003c\/h3\u003e\r\n\u003cstrong\u003eInclude: 4 videos + 22 pdfs, size: 6.5 GB\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eTarget Audience: hematologists, oncologists, pathologists\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eInformation:\u003c\/strong\u003e\r\n\u003cdiv class=\"activitysectionbold\"\u003e\r\n\r\nDate \u0026amp; Location Saturday, October 18, 2025, 7:30 AM – Sunday, October 19, 2025, 3:00 PM PT, Cedars-Sinai Pavilion Education Center, Los Angeles, CA\r\n\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eTarget Audience\u003c\/strong\u003e\u003c\/div\u003e\r\n\u003cdiv\u003e\n\u003cem\u003eSpecialties\u003c\/em\u003e – Hematology, Imaging, Internal Medicine, Oncology, Pathology \u0026amp; Laboratory Medicine, Radiation Oncology, Radiology, Surgery\u003c\/div\u003e\r\n\u003cdiv\u003e\n\u003cem\u003eProfessions\u003c\/em\u003e – Nurse, Nurse (Advanced Practice NP CRNA CNM CNS), Other (non-physician), Physician, Physician Assistant, Researcher (non-physician), Researcher (physician)\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eOverview\u003c\/strong\u003e\u003c\/div\u003e\r\nThis conference will provide a chance for Southern California lymphoma specialists and national experts to gather and discuss updates and advancements in lymphoma treatment and research. The clinical updates sessions will highlight newly approved therapies and those in the pipeline. Case based, “How I Treat” sessions will address questions of sequencing therapies and patients selection. The scientific sessions will present high impact basic science with high translational relevance, such as new biomarkers, therapeutic targets and novel cellular therapies.\r\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eObjectives\u003c\/strong\u003e\u003c\/div\u003e\r\n\u003col\u003e\r\n \t\u003cli\u003eRecognize the utility of molecular testing in the classification and treatment of lymphoma\u003c\/li\u003e\r\n \t\u003cli\u003eIdentify current evidence based treatments for Hodgkin lymphoma, diffuse large B cell lymphoma, and peripheral T cell lymphoma\u003c\/li\u003e\r\n \t\u003cli\u003eDescribe new treatments under development including bi specific antibodies and CART therapies\u003c\/li\u003e\r\n \t\u003cli\u003eCollaborate as an interprofessional healthcare team to evaluate the role of molecular testing in lymphoma classification, apply evidence based treatments for various lymphoma subtypes, and discuss emerging therapies such as bispecific antibodies and CAR T cell therapies to optimize patient care through shared knowledge and coordinated decision making\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n \r\n\r\n\u003cstrong\u003e Topics:\u003c\/strong\u003e\r\n\u003cdiv class=\"6u 12u(small)\"\u003e\r\n\u003ch3 class=\"boxAgendaTitle\"\u003eSaturday, October 18, 2025\u003c\/h3\u003e\r\n\u003cdiv class=\"boxAgendaTitle agendaBlue\"\u003e\r\n\u003cdiv\u003eSession 1: Hot Topics in Clinical Lymphoma – Part I\u003c\/div\u003e\r\nSession Chair: TBD\r\n\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eFrontline Therapy for Advanced Hodgkin Lymphoma: ECHELON-1, SWOG S1826, and GHSG HD21 (BrECADD) Updates\u003c\/strong\u003e\r\n8:10AM – 8:35AM\r\nJoe Schroers-Martin, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eNovel Approaches in First-Line DLBCL: Beyond R-CHOP POLARIX, Zilovertamab Vedotin + R-CHP Updates\u003c\/strong\u003e\r\n8:35AM – 9:00AM\r\nMatthew G. Mei, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eDual Targeting CART for Lymphoma\u003c\/strong\u003e\r\n9:00AM – 9:25AM\r\nAkil Merchant, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eBreak and Exhibits\u003c\/strong\u003e\r\n9:25AM – 10:10AM\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgendaTitle agendaBlue\"\u003e\r\n\u003cdiv\u003eSession 2: Hot Topics in Clinical Lymphoma – Part II\u003c\/div\u003e\r\nSession Chair: Justin Darrah\r\n\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eT-Cell Lymphoma\u003c\/strong\u003e\r\n10:10AM – 10:35AM\r\nWen-Kai Weng, MD, PhD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eRole of Radiation Therapy in Lymphoma\u003c\/strong\u003e\r\n10:35AM – 11:00AM\r\nParag Sanghvi, MD\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgendaTitle agendaBlue\"\u003e\r\n\u003cdiv\u003eLightning Round\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eLightning Round: Open Clinical Trials for Lymphoma in LA area (90 sec per trial)\u003c\/strong\u003e\r\n11:00AM – 11:30AM\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgendaTitle agendaBlue\"\u003e\r\n\u003cdiv\u003eLunch and Networking\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eLunch and Exhibits\u003c\/strong\u003e\r\n11:30AM – 12:15PM\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgendaTitle agendaBlue\"\u003e\r\n\u003cdiv\u003eSession 3: Keynote \u0026amp; Basic Science Insights\u003c\/div\u003e\r\nSession Chair: Akil Merchant, MD\r\n\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eKEYNOTE ADDRESS: Spatial Profiling in Lymphoma Transformers: More than Meets the Eye\u003c\/strong\u003e\r\n12:15PM – 1:00PM\r\nMina Xu, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eMicroenvironment in Non-Hodgkin Lymphoma\u003c\/strong\u003e\r\n1:00PM – 1:20PM\r\nAnthony R Colombo, PhD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eHidden Opponents: The DLBCL Microenvironment\u003c\/strong\u003e\r\n1:20PM – 1:40PM\r\nDavid Russler-Germain, MD, PhD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eMetabolic Profiling and Modulation of the Lymphoma Microenvironment\u003c\/strong\u003e\r\n1:40PM – 2:00PM\r\nAkil Merchant, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eBreak and Exhibits\u003c\/strong\u003e\r\n2:00PM – 2:20PM\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgendaTitle agendaBlue\"\u003e\r\n\u003cdiv\u003eSession 4: Next Generation Diagnostics and Biomarkers\u003c\/div\u003e\r\nSession Chair: Joseph C. Lownik, MD\r\n\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eLymphoma Biomarker Development: Lessons Learned from Gene Expression Profiling\u003c\/strong\u003e\r\n2:20PM – 2:50PM\r\nLisa M Rimsza, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eDeveloping an Automated Multiplex IF for Diagnostic\/Biomarker Use in Lymphoma\u003c\/strong\u003e\r\n2:50PM – 3:10PM\r\nJoseph C. Lownik, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eRole of ct DNA in Lymphoma\u003c\/strong\u003e\r\n3:10PM – 3:30PM\r\nBrian Sworder, MD, PhD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eAssessments and Therapies for Older Patients with Aggressive Lymphomas\u003c\/strong\u003e\r\n3:30PM – 3:50PM\r\nElizabeth Brem, MD\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eMolecular Determinants of Sensitivity to Polatuzumab-Vedotin in DLBCL\u003c\/strong\u003e\r\n3:50PM – 4:10PM\r\nSean R Corcoran , MD, PhD\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eAdjourn\u003c\/strong\u003e\r\n4:10PM – 4:15PM\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgendaTitle agendaBlue\"\u003e\r\n\u003cdiv\u003eNetworking Reception\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eNetworking Reception\u003c\/strong\u003e\r\n4:15PM – 5:30PM\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"6u 12u(small)\"\u003e\r\n\u003ch3 class=\"boxAgendaTitle\"\u003eSunday, October 19, 2025\u003c\/h3\u003e\r\n\u003cdiv class=\"boxAgendaTitle agendaBlue\"\u003e\r\n\u003cdiv\u003eSession 1: CAR-T Cell Therapy: Managing Complex Toxicities\u003c\/div\u003e\r\nSession Chair: Hitomi Hosoya, MD, PhD\r\n\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eMechanisms of Neurotoxicity with IEC and Bispecific Therapies\u003c\/strong\u003e\r\n8:00AM – 8:20AM\r\nJuliane Gust, MD, PhD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eIEC-HS: Diagnosis (ASTCT Criteria), Pathophysiology, and Management\u003c\/strong\u003e\r\n8:20AM – 8:40AM\r\nHrishikesh Srinagesh, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eProphylactic Strategies for CAR-T Toxicities: Role of Early Steroids, Anakinra, and Other Novel Approaches\u003c\/strong\u003e\r\n8:40AM – 9:00AM\r\nCaspian Oliai, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eSecondary and T-cell Malignancies after CAR T-cell Therapy\u003c\/strong\u003e\r\n9:00AM – 9:20AM\r\nHitomi Hosoya, MD, PhD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eBreak and Exhibits\u003c\/strong\u003e\r\n9:20AM – 9:35AM\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgendaTitle agendaBlue\"\u003e\r\n\u003cdiv\u003eSession 2: Clinical Debate–What is the Optimal Bridging Strategy for CAR-T Therapy\u003c\/div\u003e\r\nSession Chair: Justin Darrah, MD\r\n\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eIntro: Why bridging?\u003c\/strong\u003e\r\n9:35AM – 9:40AM\r\nJustin Darrah, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eRole of Bispecifics as Bridging\u003c\/strong\u003e\r\n9:40AM – 9:50AM\r\nJustin Darrah, MD\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eRadiation as Bridging\u003c\/strong\u003e\r\n9:50AM – 10:00AM\r\nParag Sanghvi, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eOptimal Chemotherapy for Bridging\u003c\/strong\u003e\r\n10:00AM – 10:10AM\r\nDavid R. Oveisi, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eDebate and Discussion\u003c\/strong\u003e\r\n10:10AM – 10:35AM\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eBREAK\/EXHIBITS\u003c\/strong\u003e\r\n10:35AM – 11:05AM\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgendaTitle agendaBlue\"\u003e\r\n\u003cdiv\u003eSession 3: Next Generation Cellular Therapies for Lymphoma and Beyond (Non Accredited)\u003c\/div\u003e\r\nSession Chair: Yvonne Chen, PhD\r\n\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eNovel CART for Solid Tumors\u003c\/strong\u003e\r\n11:05AM – 11:25AM\r\nYvonne Chen, PhD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eInnovations in TIL Therapy\u003c\/strong\u003e\r\n11:25AM – 11:50AM\r\nGiri Ramsingh , MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eMacrophage Based Therapies\u003c\/strong\u003e\r\n11:50AM – 12:10PM\r\nAnn Liu, Other\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eEngineered Protein Circuits for Cancer Therapy\u003c\/strong\u003e\r\n12:10PM – 12:30PM\r\nMichael B. Elowitz, PhD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eClosing and Lunch\u003c\/strong\u003e\r\n12:30PM – 12:35PM\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663482179913,"sku":"MED-AMB06342","price":40.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Cedars-Sinai-Research-Updates-in-Lymphoma-2025.jpg?v=1781875430"},{"product_id":"oregon-health-amp-science-7th-annual-ms-and-cns-neuroimmunology-symposium-2024","title":"Oregon Health \u0026amp; Science 7th Annual MS and CNS Neuroimmunology Symposium 2024","description":"\u003cdiv class=\"prod-edition\"\u003e\r\n\u003cdiv class=\"field field--name-field-heading field--type-heading field--label-hidden field__item\"\u003e\r\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\r\n\u003cdiv class=\"elementor-element elementor-element-bbb44b8 elementor-widget elementor-widget-heading\" data-id=\"bbb44b8\" data-element_type=\"widget\" data-widget_type=\"heading.default\"\u003e\r\n\u003cdiv class=\"bundle--paragraph_component paragraph paragraph--type--paragraph-component paragraph--view-mode--default\"\u003e\r\n\u003cdiv class=\"row\"\u003e\r\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\r\n\u003ch3\u003eOregon Health \u0026amp; Science 7th Annual MS and CNS Neuroimmunology Symposium 2024\u003c\/h3\u003e\r\n\u003cstrong\u003e Include: 5 videos + 5 audios + 5 file sub vtt + 1 pdf, size: 2.15 GB\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eTarget Audience: g\u003c\/strong\u003e\u003cb data-path-to-node=\"10,0,0\" data-index-in-node=\"0\"\u003eeneral neurologists, n\u003c\/b\u003e\u003cb data-path-to-node=\"10,1,0\" data-index-in-node=\"0\"\u003eeuro-oncologists\u003c\/b\u003e\r\n\r\n\u003cstrong\u003eInformation:\u003c\/strong\u003e\r\n\u003cp data-path-to-node=\"2\"\u003eThe \u003cb data-path-to-node=\"2\" data-index-in-node=\"4\"\u003e7th Annual MS and CNS Neuroimmunology Symposium\u003c\/b\u003e was a specialized one-day event organized by \u003cb data-path-to-node=\"2\" data-index-in-node=\"101\"\u003eOregon Health \u0026amp; Science University (OHSU)\u003c\/b\u003e and the VA Portland Health Care System.\u003c\/p\u003e\r\n\u003cp data-path-to-node=\"3\"\u003eHeld in \u003cb data-path-to-node=\"3\" data-index-in-node=\"8\"\u003eSeptember 2024\u003c\/b\u003e, this symposium was designed to update clinicians on the rapidly evolving landscape of white matter disorders. The 2024 curriculum was particularly notable for moving beyond standard Multiple Sclerosis (MS) care to address “mimics” like gliomas and the cutting-edge frontier of \u003cb data-path-to-node=\"3\" data-index-in-node=\"301\"\u003ecell-based therapies\u003c\/b\u003e (stem cell and CAR-T approaches) for CNS autoimmunity.\u003c\/p\u003e\r\n\r\n\u003ch3 data-path-to-node=\"4\"\u003e\u003cb data-path-to-node=\"4\" data-index-in-node=\"0\"\u003e What You Will Learn\u003c\/b\u003e\u003c\/h3\u003e\r\n\u003cp data-path-to-node=\"5\"\u003eThe 2024 agenda focused on distinguishing MS from other pathologies and managing complex symptoms. Key learning outcomes included:\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"6\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"6,0,0\"\u003e\u003cb data-path-to-node=\"6,0,0\" data-index-in-node=\"0\"\u003eThe “Molecular” Diagnosis:\u003c\/b\u003e How genetic testing is reshaping our understanding of white matter disorders, moving from phenotypic description to molecular classification.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"6,1,0\"\u003e\u003cb data-path-to-node=\"6,1,0\" data-index-in-node=\"0\"\u003eRed Flags for Mimics:\u003c\/b\u003e Recognizing \u003cb data-path-to-node=\"6,1,0\" data-index-in-node=\"34\"\u003eDiffuse Midline Glioma\u003c\/b\u003e, a serious malignancy that can masquerade as inflammatory myelopathy (spinal cord inflammation), avoiding catastrophic delays in diagnosis.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"6,2,0\"\u003e\u003cb data-path-to-node=\"6,2,0\" data-index-in-node=\"0\"\u003eCell-Based Therapies:\u003c\/b\u003e A deep dive into the future of \u003cb data-path-to-node=\"6,2,0\" data-index-in-node=\"53\"\u003eAutologous Hematopoietic Stem Cell Transplantation (aHSCT)\u003c\/b\u003e and emerging mesenchymal stem cell trials for progressive MS.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"6,3,0\"\u003e\u003cb data-path-to-node=\"6,3,0\" data-index-in-node=\"0\"\u003eBiomarker Integration:\u003c\/b\u003e Practical case studies on using \u003cb data-path-to-node=\"6,3,0\" data-index-in-node=\"55\"\u003eSerum Neurofilament Light Chain (sNfL)\u003c\/b\u003e and other fluid biomarkers to track disease activity and treatment response in real-time.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"6,4,0\"\u003e\u003cb data-path-to-node=\"6,4,0\" data-index-in-node=\"0\"\u003ePain Management:\u003c\/b\u003e Evidence-based interventional and pharmacological strategies for the chronic, often refractory neuropathic pain seen in neuroimmunological disorders.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3 data-path-to-node=\"7\"\u003e\u003cb data-path-to-node=\"7\" data-index-in-node=\"0\"\u003e Event Details\u003c\/b\u003e\u003c\/h3\u003e\r\n\u003cul data-path-to-node=\"8\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,0,0\"\u003e\u003cb data-path-to-node=\"8,0,0\" data-index-in-node=\"0\"\u003eEvent:\u003c\/b\u003e 7th Annual MS and CNS Neuroimmunology Symposium\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,1,0\"\u003e\u003cb data-path-to-node=\"8,1,0\" data-index-in-node=\"0\"\u003eDate:\u003c\/b\u003e September 14, 2024 (Saturday)\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,2,0\"\u003e\u003cb data-path-to-node=\"8,2,0\" data-index-in-node=\"0\"\u003eLocation:\u003c\/b\u003e Oregon Health \u0026amp; Science University, Portland, Oregon (Hybrid Format)\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,3,0\"\u003e\u003cb data-path-to-node=\"8,3,0\" data-index-in-node=\"0\"\u003eCourse Director:\u003c\/b\u003e Vijayshree Yadav, MD, MCR, FANA, FAAN\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3 data-path-to-node=\"9\"\u003e\u003cb data-path-to-node=\"9\" data-index-in-node=\"0\"\u003e Who Should Attend\u003c\/b\u003e\u003c\/h3\u003e\r\n\u003cul data-path-to-node=\"10\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"10,0,0\"\u003e\u003cb data-path-to-node=\"10,0,0\" data-index-in-node=\"0\"\u003eGeneral Neurologists:\u003c\/b\u003e Who need to distinguish between “typical” MS and complex genetic or neoplastic mimics.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"10,1,0\"\u003e\u003cb data-path-to-node=\"10,1,0\" data-index-in-node=\"0\"\u003eNeuro-Oncologists:\u003c\/b\u003e Interested in the intersection of inflammatory and neoplastic CNS disease.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"10,2,0\"\u003e\u003cb data-path-to-node=\"10,2,0\" data-index-in-node=\"0\"\u003ePhysiatrists (PM\u0026amp;R) \u0026amp; Pain Specialists:\u003c\/b\u003e Managing the long-term functional deficits of CNS autoimmunity.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"10,3,0\"\u003e\u003cb data-path-to-node=\"10,3,0\" data-index-in-node=\"0\"\u003eAllied Health Professionals:\u003c\/b\u003e Nurses and PAs who manage the day-to-day monitoring of patients on high-efficacy immunotherapies.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3 data-path-to-node=\"11\"\u003e\u003cb data-path-to-node=\"11\" data-index-in-node=\"0\"\u003e Why It Matters\u003c\/b\u003e\u003c\/h3\u003e\r\n\u003cul data-path-to-node=\"12\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"12,0,0\"\u003e\u003cb data-path-to-node=\"12,0,0\" data-index-in-node=\"0\"\u003eFaculty Expertise:\u003c\/b\u003e The event featured \u003cb data-path-to-node=\"12,0,0\" data-index-in-node=\"38\"\u003eDr. Jeffrey Cohen\u003c\/b\u003e from the \u003cb data-path-to-node=\"12,0,0\" data-index-in-node=\"65\"\u003eCleveland Clinic Mellen Center\u003c\/b\u003e, a global authority on experimental therapeutics, who provided the keynote on “Emerging Cell-Based Therapies.”\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"12,1,0\"\u003e\u003cb data-path-to-node=\"12,1,0\" data-index-in-node=\"0\"\u003eDiagnostic Precision:\u003c\/b\u003e The session on “Molecular Landscape of White Matter Disorders” (Dr. Wojciech Wiszniewski) addressed a critical gap in adult neurology: identifying undiagnosed leukodystrophies that persist into adulthood.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"12,2,0\"\u003e\u003cb data-path-to-node=\"12,2,0\" data-index-in-node=\"0\"\u003eVA Collaboration:\u003c\/b\u003e The course highlighted the strong partnership between OHSU and the \u003cb data-path-to-node=\"12,2,0\" data-index-in-node=\"85\"\u003eVA MS Center of Excellence\u003c\/b\u003e, offering unique insights into the care of veterans with neuroimmunological conditions.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3 data-path-to-node=\"13\"\u003e\u003cb data-path-to-node=\"13\" data-index-in-node=\"0\"\u003e Topics\u003c\/b\u003e\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e01 Molecular landscape of white matter disorders\u003c\/li\u003e\r\n \t\u003cli\u003e02 Diffuse midline glioma A serious and under-recognized mimic of inflammatory myelopathy\u003c\/li\u003e\r\n \t\u003cli\u003e03 Emerging cell-based therapies in MS\u003c\/li\u003e\r\n \t\u003cli\u003e04 Biomarkers in MS A case-based presentation\u003c\/li\u003e\r\n \t\u003cli\u003e05 Pain management for chronic and complex disorders\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663482212681,"sku":"MED-AMB06340","price":20.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Oregon-Health-Science.jpg?v=1781875429"},{"product_id":"uchicago-medicine-22nd-annual-international-ultmann-chicago-lymphoma-symposium-2025","title":"UChicago Medicine 22nd Annual International Ultmann Chicago Lymphoma Symposium 2025","description":"\u003ch1 class=\"product_title entry-title\"\u003eUChicago Medicine 22nd Annual International Ultmann Chicago Lymphoma Symposium 2025\u003c\/h1\u003e\r\n\u003cstrong\u003e+ Include: 27 Videos (.mp4) + 27 Audios (.mp3) + 27 Subtitles (.vtt) + 26 PDFs, size: 9.29 GB\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003e+ Target Audience: practicing oncologists, hematologists\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003e+ Information:\u003c\/strong\u003e\r\n\u003ch2 data-path-to-node=\"0\"\u003e1. Overview\u003c\/h2\u003e\r\n\u003cp data-path-to-node=\"1\"\u003eThe UChicago Medicine 22nd Annual International Ultmann Chicago Lymphoma Symposium 2025 provides an in-depth review of the latest clinical advancements in lymphoma diagnosis and management. The course explores novel targeted therapies, cellular treatments like CAR T-cells and bispecifics, genomic testing, and multidisciplinary strategies for managing complex and relapsed lymphoma cases.\u003c\/p\u003e\r\n\u003cp data-path-to-node=\"1\"\u003e\u003cb data-path-to-node=\"1\" data-index-in-node=\"390\"\u003eCourse Date:\u003c\/b\u003e 04\/04\/2025\u003c\/p\u003e\r\n\r\n\u003cdiv\u003e\r\n\r\nThe 22nd International Ultmann Chicago Lymphoma Symposium (IUCLS) is a continuation of an annual conference dedicated solely to the science and clinical care of lymphoma. It has been organized to honor the achievements of Dr. John Ultmann, a pioneer in the treatment of lymphoma, who devoted his life to the understanding of this disease. He was particularly known for his work on the staging of Hodgkin lymphoma and the utility of staging as a guide for treatment.\r\n\r\nThe goal of this educational activity is to facilitate a forum for physicians, nurses, researchers, and other healthcare professionals to discuss biologic, diagnostic, and therapeutic aspects of Hodgkin and non-Hodgkin lymphoma.\r\n\r\nThis event gives opportunities for providers to explore vital information on clinical updates and research in order to ensure they are using the latest treatment options in their practice.\r\n\r\n\u003c\/div\u003e\r\n\u003ch2 data-path-to-node=\"2\"\u003e2. Learning Objectives\u003c\/h2\u003e\r\n\u003cul data-path-to-node=\"3\"\u003e\r\n \t\u003cli\u003eAt the conclusion of this educational activity, participants will be able to:\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003cdiv\u003eAssess clinical trial results of approved and investigational treatment strategies being studied in patients with indolent and aggressive subtypes of B-cell and T-cell non-Hodgkin lymphoma\u003c\/div\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cdiv\u003eCompare and contrast the selection and sequencing of therapeutic approaches for the care of patients with newly diagnosed and relapsed\/refractory Hodgkin lymphoma\u003c\/div\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cdiv\u003eEvaluate the various patient and disease-related factors that may impact therapeutic decisions for patients with newly diagnosed and previously treated CLL\/SLL\u003c\/div\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cdiv\u003eReview approaches to the care of patients with rarer hematologic malignancies, including CNS lymphoma and Waldenstrom macroglobulinemia\u003c\/div\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cdiv\u003eIdentify and nurture strategies to enhance communication and collaboration with the entire multidisciplinary healthcare team during the continuum of care of patients with lymphoma\u003c\/div\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2 data-path-to-node=\"4\"\u003e3. Target Audience\u003c\/h2\u003e\r\nBest for hematologists and oncologists who want updates on cellular therapies, genomic testing, and clinical management of complex lymphomas.\r\n\r\nThe target audience for this symposium is practicing oncologists, hematologists, advanced nurse practitioners, physician assistants, residents, fellows, nurses, pharmacists, and the other health professionals interested in the treatment and diagnosis of lymphoma.\r\n\u003ch2 data-path-to-node=\"6\"\u003e4. Topics\u003c\/h2\u003e\r\n\u003cul data-path-to-node=\"8\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,0,0\"\u003e01 Nivo-AVD for Advanced Stage Hodgkin Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,1,0\"\u003e02 Bv-AVD for Advanced Stage Hodgkin Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,2,0\"\u003e03 Contributions of the European Regimens to the Management of cHL\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,3,0\"\u003e04 The Impact of 1L Therapy Selection on Subsequent HL Treatment Approaches\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,4,0\"\u003e05 Prioritizing Clinical Research in Oncology Clinical Practice\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,5,0\"\u003e06 Comparison of CAR T-Cell Therapies in RR Follicular Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,6,0\"\u003e07 Comparison of Bispecific Therapies in RR Follicular Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,7,0\"\u003e08 Non-T-Cell Engaging Treatment Options in RR Follicular Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,8,0\"\u003e09 How I Approach Treatment-Naive CLL SLL\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,9,0\"\u003e10 Challenges in Treating Patients with TP53-Mutated MCL\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,10,0\"\u003e11 Role of Transplant and Cellular Therapy in RR MCL\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,11,0\"\u003e12 Globalizing Lymphoma Research – Challenges and Opportunities\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,12,0\"\u003e13 Current Role of BTK Inhibitors in Frontline MCL\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,13,0\"\u003e14 Overview of Treatment Options and Key Trials for CNS Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,14,0\"\u003e15 A Ticking Time B-Cell Lymphoma – A Case on High-Risk DLBCL for CNS Relapse\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,15,0\"\u003e16 Challenging Case Discussion – Newly Diagnosed Low-Grade FL Transformed Into Double-hit DLBCL With Secondary CNS Lymph…\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,16,0\"\u003e17 Frontline Treatment Options in Newly Diagnosed DLBCL\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,17,0\"\u003e18 RR DLBCL – The Role of CAR T-Cells vs. Bispecifics in First Relapse\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,18,0\"\u003e19 FrailOlder Patients With DLBCL – A Persistent Challenge\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,19,0\"\u003e20 Baseline Genomic Testing in Lymphoma – Are We There Yet\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,20,0\"\u003e21 Next Generation Hematopathology and the Standard of Care in Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,21,0\"\u003e22 Mediastinal Gray Zone Lymphoma Case-Based Panel Discussion – Diagnostic Criteria \u0026amp; Management Approach\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,22,0\"\u003e23 Novel Therapies for Lymphoma – Focus on CELMoDs and BTK Degraders\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,23,0\"\u003e24 Novel T-Cell Engaging Therapy Approaches – How Close are They to Prime Time\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,24,0\"\u003e25 Improving HRQoL for Patients With Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,25,0\"\u003e26 Nursing Perspective on Managing Neurotoxicity – What Tools Do We Have\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,26,0\"\u003e27 Incorporating Patient-Reported Outcomes in Clinical Trials\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663482474825,"sku":"MED-AMB06154","price":20.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/UChicago-Medicine-22nd-Annual-International-Ultmann-Chicago-Lymphoma-Symposium-2025.jpg?v=1781875430"},{"product_id":"association-for-the-advancement-of-blood-biotherapies-annual-meeting-on-demand-2025","title":"Association for the Advancement of Blood \u0026 Biotherapies Annual Meeting On-Demand 2025","description":"\u003ch3\u003eAssociation for the Advancement of Blood \u0026amp; Biotherapies Annual Meeting On-Demand 2025\u003c\/h3\u003e\r\n+ Include: 112 videos + 112 audios + 112 file sub vtt + 112 pdfs, size: 90.42 GB\r\n\r\n+ Target Audience: hematologists, transfusion medicine specialists, and blood bank professionals\r\n\r\n+ Information:\r\n\u003ch3\u003e1. Overview\u003c\/h3\u003e\r\nThe Association for the Advancement of Blood \u0026amp; Biotherapies (AABB) Annual Meeting On-Demand 2025 provides a comprehensive review of the latest advancements in transfusion medicine and biotherapies. The course covers critical updates on blood banking, cellular therapies, patient blood management, and evolving regulatory standards to enhance clinical practices and patient safety.\r\n\r\nCourse Date: 2025\r\n\u003ch3\u003e2. Learning Objectives\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eEvaluate the latest advancements in transfusion medicine and patient blood management strategies.\u003c\/li\u003e\r\n \t\u003cli\u003eImplement updated protocols for blood banking, donor screening, and pathogen reduction.\u003c\/li\u003e\r\n \t\u003cli\u003eAnalyze emerging trends and clinical applications in cellular therapies and biotherapies.\u003c\/li\u003e\r\n \t\u003cli\u003eAssess regulatory changes and quality assurance standards impacting blood and biotherapy facilities.\u003c\/li\u003e\r\n \t\u003cli\u003eDevelop strategies to manage blood shortages and optimize inventory during public health emergencies.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003e3. Target Audience\u003c\/h3\u003e\r\nBest for hematologists, transfusion medicine specialists, and blood bank professionals who want updates on biotherapies and blood management.\r\n\u003ch3\u003e4. Topics\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e2025 Ask the FDA and CMS_CLIA (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eA Tale of Twice-Annual Verification_ Why Two Matter, and Who’s Looking_ (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eAABB_ASHI Symposium_ Exploring Transplant Uncertainties_Conundrums in ABO (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eAABB_THOR Joint Session_ Some New Looks at Old Dogma, New Studies, and New Blood Products (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eAABB’s Updated Platelet and Red Blood Cell Transfusion Guidelines (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eAdvances in Labeling_ Practical Applications of 2-D Data Matrix Symbols with ISBT 128 (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eAdvancing Cord Blood Utilization_ Building Pathways for Innovation and Clinical Adoption (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eAllogeneic Transplant, Gene Therapy, or the Evolving Drug Landscape in Sickle Cell Disease_ Helping Patients Choose Between O..\u003c\/li\u003e\r\n \t\u003cli\u003eAlpha-Gal Syndrome_ Can Tick Bites Lead to Life-Threatening Allergic Transfusion Reactions_ (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eAM25-MN-07-O_ Cell Therapy Lab Jeopardy! (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eAsk the Standards (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eAssessor Townhall Assessment Readiness-Get Ready and Stay Ready\u003c\/li\u003e\r\n \t\u003cli\u003eBasic Blood Biology and Mechanisms of Immunity in Transfusion Medicine and Biotherapies (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eBlood Bank IT_ Compliance and Data Management Concepts (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eBlood Conservation in the OR_ How to Create a Comprehensive Pediatric Patient Blood Management Program (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eBlood Products as Pharmaceuticals_ Should that be our Goalÿ(Tibor Greenwalt Memorial Award and Lectureship) (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eBPDR Demystified_ A Practical Guide to Reporting and Preventing Errors (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eBuilding a Translational Arm to Your Cellular Therapy Laboratory (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eBuilding Trust-Based Teams_ A Strategic Imperative for Leaders (Enduring)\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eCABP Exam Prep (Enduring)\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eCBC_ A New Era for Cord Blood – The National Cord Blood Network (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eCBC_ Defining Novel Growth Opportunities for the Cord Blood Field_ Lessons Learned \u0026amp; Pathways Forward (Enduring) [CABP CE ELI..\u003c\/li\u003e\r\n \t\u003cli\u003eCBC_ Emerging Issues in Cord Blood Therapeutics and Gene Therapies (President’s Session) (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eCBC_ Evidence Based Communication in Cord Blood Donation and Banking (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eCBC_ Exploring the Unique Biology of Cord Blood and Birthing Tissues (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eCBC_ How does Cord Blood Facilitate Tissue Repair and Regeneration_ (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eCBC_ Innovative Approaches in Cord Blood Transplantation_ Clinical Outcomes and New Strategies (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eCBC_ Lightning Talks – The Future of Cord Blood_ Bold Visions \u0026amp; Innovations (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eCBC_ Opportunities \u0026amp; Challenges the Field of Cord Blood and Birthing Tissues (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eCBC_ State of the Science Symposium – Striking a New Cord in the Evolution of Stem Cell Transplant (Enduring) [CABP CE ELIGIB..\u003c\/li\u003e\r\n \t\u003cli\u003eCBC_ The New Frontiers of MSC’s in Regenerative Medicine (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eChoose Your Own Adventure_ Spooky Serology, Mysterious Molecular, and Eerie Incompatibility (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eClosing the Divide_ Pathways to Engaging Underrepresented Communities in Blood Donation (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eCold Truths_ The Potential Hidden Impact of “Clinically Insignificant” Antibodies in Hypothermic Cardiac Surgery (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eComputer Systems Under Attack_ Cybersecurity Best Practices and Lessons Learned (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eCOVID-19 Convalescent Plasma in the Immunocompromised Patient (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eCreating Effective Donor Recruitment Videos Through the Use of Co-Design with Community Partners (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eCrossmatch Incompatible Transfusions_ How Collaboration Between Transfusion Services and Immunohematology Reference Laborator..\u003c\/li\u003e\r\n \t\u003cli\u003eDonating for the Future_ Bridging Generations and Communities for a Stronger Blood Supply (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eEnhancing Perioperative Autologous Transfusion_ Bridging the Gap Between Standards and Practice (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eEnsuring Ethical and Regulatory Compliance in Donor Collections for Advanced Therapies (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eEnsuring Safe and Effective Distribution of Advanced Therapies_ Unique Perspectives from Pharmacy and Cell Therapy Labs (Endu..\u003c\/li\u003e\r\n \t\u003cli\u003eEthical Dilemmas in Compensating Blood Donors_ Navigating Global Health Perspectives (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eEvolving Immunologic Concepts – From Basic Mechanisms to Translation (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eExpanding Access, Ensuring Safety_ Best Practices in Out-of-Hospital Transfusion (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eExpanding CGT Access_ The Role of Blood Centers in Last-Mile Delivery (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eFcRN Inhibitors – a New Era for Transfusion Medicine_ (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eFrom Blueprint to Benchmark_ A Journey Through AABB Standards Development and Accreditation (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eFrom Fellow to Faculty_ Practical Insights for Trainees and Early Career Physicians (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eGenerations Apart and Together_ Navigating Today’s Culture to Build a Sustainable Workforce for Your Transfusion Service (End..\u003c\/li\u003e\r\n \t\u003cli\u003eHow New Red Cell Antigens Are Identified, Classified, Added to a Blood Group System or Creating a New Blood Group System, The..\u003c\/li\u003e\r\n \t\u003cli\u003eI Want It That Way Ethical Dilemmas in Pediatric Transfusion Medicine (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eImplementation of Lab Automation_ Best Practices and Benefits (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eImproving Recognition and Reporting of Transfusion Reactions_ Data-Driven Insights and Quality Improvement Strategies (Enduri..\u003c\/li\u003e\r\n \t\u003cli\u003eInclusive Blood Donation Strategies for 2SLGBTQIA+ Communities_ Rebuilding Trust and “Adding Your Sparkle to the Blood Supply..\u003c\/li\u003e\r\n \t\u003cli\u003eInteractive Panel and Audience Discussion_ Navigating Clinical, Professional, and Ethical `Sticky Wickets’ in Leukapheresis f..\u003c\/li\u003e\r\n \t\u003cli\u003eIRL Accreditation_ Case Studies and Helpful Hints for Better Conformance (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eIron Matters_ Regulating the Metal That Makes Blood Red (Landsteiner-Alter Award and Lectureship) (Enduring)\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eLord of the Antibodies (Enduring)\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMaximum Surgical Blood Order Schedule (MSBOS)_ Return on Investment, Implementation, and AI (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eNovel Insights into Iron Toxicities in Hematologic Diseases and Related Pharmacological and GeneÿTherapy Approaches (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eNovel Tools and Platform Designs in Biotherapies (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eOptimization of Postpartum Hemorrhage Management in the Academic and Community Setting (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eOral Abstract Session – Advances in Cord Blood Therapy (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eOral Abstract Session – Application of Novel Technology in Transfusion Medicine (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eOral Abstract Session – Hematology \u0026amp; Coagulation (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eOral Abstract Session – Infectious Diseases \u0026amp; Transfusion Medicine (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eOral Abstract Session – Insight into Whole Blood and Hemorrhage Management (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eOral Abstract Session – Lessons From the Immunohematology Lab (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eOral Abstract Session – New Insights into Components, Storage, and Patient Outcomes (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eOral Abstract Session – New Insights to Patient Blood Management (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eOral Abstract Session – New Variants in Kid \u0026amp; ABO (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eOral Abstract Session – Non-Infectious Hazards of Blood Transfusion (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eOral Abstract Session – Novel RHCE Variants (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eOral Abstract Session – Novel RHD Variants and Approaches to Overcoming Them (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eOral Abstract Session – Pediatric Transfusion Practice (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eOral Abstract Session – Therapeutic and Donor Apheresis and Blood Donation Infectious Disease (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eOral Abstract Spotlight Session – Biotherapies \u0026amp; Cell Transplantation (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eOral Abstract Spotlight Session – Cutting Edge Insights into Blood Donations and Allocations (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eOral Abstract Spotlight Session – Discoveries in the Science of Immunohematology (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003ePlanning for Disease X_ To Ensure a Safe and Sufficient Blood Supply During the Next Emerging Pathogen Event (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003ePlasma Failure in Multiple Organ Dysfunction Syndrome (MODS) (Enduring)\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003ePlenary Abstract (Enduring)\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003ePrehospital Transfusion Workshop_ Building Effective EMS Programs (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eQuality Agreements in Cell Therapy_ Building Successful Partnerships (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eReducing O Negative RBC Overutilization in Pediatric Transfusion Medicine_ Overcoming Challenges (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eResearch and Progress (RAPS)_ Organoids in Research and Biotherapies_ Promise, Progress, and Challenges (Enduring) [CABP CE E..\u003c\/li\u003e\r\n \t\u003cli\u003eResearch and Progress (RAPS)_ Whole Blood in Modern Transfusion Practice – A Debate on Evidence and Application (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eRevolutionizing Donor Selection_ Integrating AI, Omics Data, and Large-Scale Cohorts for Improved Cell Therapy Outcomes (Endu..\u003c\/li\u003e\r\n \t\u003cli\u003eSafety, Standards, and Sanity_ Navigating Compliance in Emergent Blood Product Release (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eSaving Infant Lives Through Public-Private Partnership_ The Development of an FDA-Approved Therapy for Infant Botulism (Endur..\u003c\/li\u003e\r\n \t\u003cli\u003eShould We Bring ABO Genotyping to Our Institution_ Things to Know About Taking the Leap (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eTest Your Blood Bank Knowledge 2025 – Are You up for a Challenge_ (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eThe Monocyte Monolayer Assay in Transfusion Medicine_ Historical Insights and Clinical Applications (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eThe Peer-Review Publication Process – How to Dip Your Toe in the Author and Reviewer Waters (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eThe Specialization of Hospital Transfusion Committees_ Pragmatic Approaches to Increasing Interest and Effectiveness (Endurin..\u003c\/li\u003e\r\n \t\u003cli\u003eThe Top Nonconformances Stratified by Facility Size and Location. Where Do You Fit_ (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eThe Transformative Power of Artificial Intelligence and Machine Learning_ From Blood Collectors to the Transfusion Service, a..\u003c\/li\u003e\r\n \t\u003cli\u003eThink Like a Detective_ Investigating Quality Issues with Root Cause Analysis (RCA) Tools (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eTransfusing Safely and Wisely_ Much Progress ButÿStill Need to Do Better (Emily Cooley Memorial Award and Lectureship) (Endur..\u003c\/li\u003e\r\n \t\u003cli\u003eTransfusion Medicine and Blood Bank Practice Guidelines for Von Willebrand Disease in Pregnancy (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eTransfusion Medicine Education for Physicians_ Ready-to-Use, Customizable, and Innovative Teaching Tools (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eTransfusion Medicine, Hemostasis, Apheresis, and Cellular Therapy Review Session for Trainees (Enduring) [CABP CE ELIGIBLE]\u003c\/li\u003e\r\n \t\u003cli\u003eUncovering New Blood Groups_ Impacts in Transfusion and Beyond (Sally Frank Award and Lectureship) (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eUnderstanding Generative AI_ A Friendly Introduction for Medical Professionals (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eUnexplained Reactivity in Red Cell Antibody Identification_ A Way Through (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eUnlocking the Power of Extracellular Vesicles_ From Intercellular Communication to Therapeutic Innovation (Enduring) [CABP CE..\u003c\/li\u003e\r\n \t\u003cli\u003eUpdate on the Use of Cryopreserved Platelets in Acute Surgical Settings (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eVeterinary Transfusion Medicine_ An Overview of Blood Banking for Our Furry Friends (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eWhat’s New in Transfusion Therapy for Sickle Cell Disease (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eWhen the Refrigerator Is Bare – Innovations from the Blood DESERT Coalition (Enduring)\u003c\/li\u003e\r\n \t\u003cli\u003eWhy, When and How Should You Use Electronic Batch Records (EBRs) in the Cell and Gene Therapy Manufacturing Process (Enduring..\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663482507593,"sku":"MED-AMB06132","price":70.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Association-for-the-Advancement-of-Blood-Biotherapies-Annual-Meeting-On-Demand-2025_bc41df17-305f-457a-9a4f-1906db733168.jpg?v=1781875430"},{"product_id":"liquid-biopsy-in-cancer-management-integrating-diagnostics-and-clinical-applications-true-pdf-from-publisher","title":"Liquid biopsy in Cancer Management: Integrating Diagnostics and Clinical Applications (True PDF from Publisher)","description":"\u003cdiv\u003e\r\n\u003cdiv class=\"prod-edition\"\u003e\r\n\r\nBy Shvetank Bhatt PhD., Kuttiappan Anitha PhD., Santenna Chenchula PhD., Neeraj Mishra PhD\r\nLiquid biopsy in Cancer Management: Integrating Diagnostics and Clinical Applications provides a comprehensive overview of liquid biopsy, covering its fundamental principles, technological advancements, clinical applications, and future prospects. In 16 chapters, the book focuses both on the practical implications of liquid biopsy in cancer management, and on its role in early detection, treatment monitoring, and personalized therapy. It emphasizes the integration of liquid biopsy into both diagnostic practices and therapeutic strategies, highlighting its potential to transform cancer care. The book discusses the latest research findings and explores future directions in liquid biopsy research, providing readers with a forward-looking view of the field.It includes case studies and examples to illustrate the clinical utility of liquid biopsy and enhance understanding of its applications. Overall, the book aims to be a comprehensive and authoritative resource on the subject, providing readers with a thorough understanding of the current state and future directions of liquid biopsy in cancer management.\r\n\u003cul class=\"a-unordered-list a-vertical\"\u003e\r\n \t\u003cli\u003eEmpowers clinicians to deliver more personalized and effective cancer care by highlighting the role of liquid biopsy in guiding therapeutic decisions\u003c\/li\u003e\r\n \t\u003cli\u003eServes as a valuable resource for those looking to integrate liquid biopsy into their clinical practice or research endeavors\u003c\/li\u003e\r\n \t\u003cli\u003eCovers the full spectrum of liquid biopsy applications, from early detection to treatment monitoring and personalized therapy\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n \r\n\u003ch3\u003eProduct Details\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003ePublisher ‏ : ‎ Academic Press\u003c\/li\u003e\r\n \t\u003cli\u003ePublication date ‏ : ‎ December 22, 2025\u003c\/li\u003e\r\n \t\u003cli\u003eEdition ‏ : ‎ 1st\u003c\/li\u003e\r\n \t\u003cli\u003eLanguage ‏ : ‎ English\u003c\/li\u003e\r\n \t\u003cli\u003eISBN-10 ‏ : ‎ 0443274967\u003c\/li\u003e\r\n \t\u003cli\u003eISBN-13 ‏ : ‎ 978-0443274961\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663482671433,"sku":"MED-AMB05983","price":15.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Liquid-biopsy-in-Cancer-Management.jpg?v=1781875430"},{"product_id":"uchicago-medicine-10th-annual-updates-from-ash-2024-practice-changing-abstracts-2025","title":"UChicago Medicine 10th Annual Updates from ASH 2024 Practice-Changing Abstracts 2025","description":"\u003ch3\u003eUChicago Medicine 10th Annual Updates from ASH 2024 Practice-Changing Abstracts 2025\u003c\/h3\u003e\r\n+ Include: 12 Videos (.mp4) + 12 Audios (.mp3) + 12 Subtitles (.vtt) + 1 PDFs, size: 6.29 GB\r\n\r\n+ Target Audience: hematologists, medical oncologists, pathologists\r\n\r\n+ Information:\r\n\r\n1. Overview\r\n\r\nThe UChicago Medicine 10th Annual Updates from ASH 2024 Practice-Changing Abstracts 2025 provides a comprehensive review of the most impactful clinical data presented at the American Society of Hematology annual meeting. The course highlights key advancements in the treatment of hematologic malignancies, emphasizing new therapeutic protocols and the integration of novel therapies into clinical practice.\r\n\u003ch3\u003eCourse Date: 02\/28\/2025\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eJoin us for an event that unites community-based providers and academic oncologists, all dedicated to enhancing the care and outcomes of patients with hematologic malignancies. This activity will explore\u003c\/li\u003e\r\n \t\u003cli\u003ethe latest treatment options and medical advancements aimed at reducing cancer-related deaths. You’ll gain insights into groundbreaking therapies like CAR T-cell therapy, novel immunotherapies, and\u003c\/li\u003e\r\n \t\u003cli\u003etargeted agents that represent the forefront of managing both newly diagnosed and relapsed blood cancers.\u003c\/li\u003e\r\n \t\u003cli\u003eStay informed with the latest scientific updates and innovative strategies that directly impact your practice. Participants will engage in discussions about rapidly evolving treatment landscapes, evaluate\u003c\/li\u003e\r\n \t\u003cli\u003ecritical considerations for sequencing novel agents, and refine practice paradigms that elevate patient care across all treatment settings.\u003c\/li\u003e\r\n \t\u003cli\u003eThis is your chance to enhance your knowledge of best practices for treating hematologic cancers while learning when to refer patients for specialized quaternary care and clinical trial opportunities. Don’t\u003c\/li\u003e\r\n \t\u003cli\u003emiss out on this chance to stay ahead in your field—register today to secure your spot and transform your approach to patient management!\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003e2. Learning Objectives\u003c\/h3\u003e\r\nAfter this activity, participants will be able to:\r\n\u003cul\u003e\r\n \t\u003cli\u003eRecall international trends in the care of hematologic malignancies;\u003c\/li\u003e\r\n \t\u003cli\u003eIdentify the emerging treatment strategies, the role of targeted agents in therapeutic paradigms for patients with myeloid malignancies, and available clinical trial options and other approaches to patients with\u003c\/li\u003e\r\n \t\u003cli\u003erelapsed\/refractory disease;\u003c\/li\u003e\r\n \t\u003cli\u003eState the optimal patient selection, timing, and regimens for stem cell transplantation with high-risk and relapsed\/refractory disease;\u003c\/li\u003e\r\n \t\u003cli\u003eDescribe the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common benign hematologic diseases including newly approved therapeutic classes;\u003c\/li\u003e\r\n \t\u003cli\u003eDiscuss evolving treatment paradigms and therapy sequencing for novel agents in the care of patients with multiple myeloma, including approved and emerging CAR T-cell therapies, as well as bispecific\u003c\/li\u003e\r\n \t\u003cli\u003eantibodies with varied therapeutic targets;\u003c\/li\u003e\r\n \t\u003cli\u003eIllustrate how cutting-edge data presented at the 2024 Annual Meeting of the American Society of Hematology can apply to clinical practice;\u003c\/li\u003e\r\n \t\u003cli\u003eInterpret emerging clinical trial data in the context of CAR T-cell therapy for lymphoid malignancies and its place in evolving hematologic malignancy treatment standards;\u003c\/li\u003e\r\n \t\u003cli\u003eEvaluate the available treatments to care for patients with lymphoma based on optimal treatment sequencing, novel agents and their role in earlier lines of therapy, and how these change best practices for\u003c\/li\u003e\r\n \t\u003cli\u003eevidence-based care of both newly diagnosed and relapsed\/refractory cases.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003e3. Target Audience\u003c\/h3\u003e\r\nBest for hematologists and oncologists who want updates on practice-changing trials, cellular therapies, and toxicity management.\r\n\r\nThis activity is designed for hematologists, medical oncologists, pathologists, fellow and resident trainees, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals dedicated to treating hematologic cancers.\r\n\u003ch3\u003e4. Topics\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e01 Allied Health Session\u003c\/li\u003e\r\n \t\u003cli\u003e02.1 Pharmacy Session Toxicity Management\u003c\/li\u003e\r\n \t\u003cli\u003e02.2 Pharmacy Session Toxicity Management\u003c\/li\u003e\r\n \t\u003cli\u003e03 HL \u0026amp; NHL\u003c\/li\u003e\r\n \t\u003cli\u003e04 Updates in Myelofibrosis, MPN, MDS\u003c\/li\u003e\r\n \t\u003cli\u003e05 Updates in AML\u003c\/li\u003e\r\n \t\u003cli\u003e06 Updates in Myeloma\u003c\/li\u003e\r\n \t\u003cli\u003e07.1 Bispecific Panel\u003c\/li\u003e\r\n \t\u003cli\u003e07.2 Bispecific Panel\u003c\/li\u003e\r\n \t\u003cli\u003e07.3 Bispecific Panel\u003c\/li\u003e\r\n \t\u003cli\u003e08 Updates in Cellular and Gene Therapy\u003c\/li\u003e\r\n \t\u003cli\u003e09 Updates in Transplantation\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663482540361,"sku":"MED-AMB06130","price":15.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/UChicago-Medicine-10th-Annual-Updates-from-ASH-2024-Practice-Changing-Abstracts-2025.png?v=1781875431"},{"product_id":"hematopathology-3rd-edition-original-pdf-from-publisher","title":"Hematopathology, 3rd Edition (Original PDF from Publisher)","description":"\u003cstrong\u003eby Elaine Sarkin Jaffe MD, Daniel A. Arber MD, Elias Campo MD, Leticia Quintanilla-Fend MD, Attilio Orazi MD, Lisa M. Rimsza MD, Steven H. Swerdlow MD\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv\u003e\n\u003cdiv\u003e**Selected for 2025 Doody’s Core Titles® with \"Essential Purchase\" designation in Surgical Pathology** \u003cbr\u003e\u003cbr\u003eCovering the broad range of benign and malignant disorders that affect the hematopoietic system, Hematopathology, 3rd Edition, remains your #1 source of authoritative information in this fast-changing field. Edited by Dr. Elaine Jaffe and a team of globally renowned, expert co-editors, it offers a wealth of up-to-date information in an easily accessible format, equipping you to deliver more accurate and actionable pathology reports. Comprehensive in scope, this highly illustrated, practical text is a must-have resource for residents and practicing pathologists alike.\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eHelps you navigate the latest changes in the classification of hematolymphoid neoplasms, providing guidance for use of both the International Consensus Classification (ICC) and 5th edition of the WHO classification\u003c\/li\u003e\n\u003cli\u003eIncorporates the latest molecular\/cytogenetic information, regarding newly recognized entities and the latest diagnostic criteria\u003c\/li\u003e\n\u003cli\u003eProvides you with today's most effective guidance in evaluating specimens from the lymph nodes, bone marrow, peripheral blood, and more, with authoritative information on the pathogenesis, clinical and pathologic diagnosis, and treatment for each\u003c\/li\u003e\n\u003cli\u003eDetails the latest insights on the molecular biology of benign and malignant hematologic disorders\u003c\/li\u003e\n\u003cli\u003eFeatures more than 1,100 high-quality color images that mirror the findings you encounter in practice\u003c\/li\u003e\n\u003cli\u003eUses an easy-to-navigate, templated format with standard headings in each chapter.\u003c\/li\u003e\n\u003cli\u003eIncludes information on disease progression and prognosis, helping you better understand the clinical implications of diagnosis\u003c\/li\u003e\n\u003cli\u003eShares the knowledge and expertise of new editors, Drs. Lisa Rimsza, Attilio Orazi, and Steven Swerdlow, providing expertise in molecular diagnostics, bone marrow and lymph node biopsies\u003c\/li\u003e\n\u003cli\u003eAn eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud. Additional digital ancillary content may publish up to 6 weeks following the publication date\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663482573129,"sku":"MED-AMB05857","price":40.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Hematopathology-3rd-Edition-Original-PDF-from-Publisher.webp?v=1781875430"},{"product_id":"moffitt-cancer-center-20th-annual-clinical-breakthroughs-and-challenges-in-hematologic-malignancies-2025","title":"Moffitt Cancer Center 20th Annual Clinical Breakthroughs and Challenges in Hematologic Malignancies 2025","description":"\u003cdiv\u003e\n\u003cdiv class=\"prod-edition\"\u003e\n\u003ch3 class=\"product_title entry-title\"\u003eMoffitt Cancer Center 20th Annual Clinical Breakthroughs and Challenges in Hematologic Malignancies 2025\u003c\/h3\u003e\n\u003cstrong\u003eInclude: 14 videos + 14 audios + 14 file sub vtt + 14 pdfs, size: 3.89 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eTarget Audience: hematologists, oncologists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eInformation:\u003c\/strong\u003e\n\u003cbr\u003e\u003cp data-path-to-node=\"2\"\u003eThis annual conference is a premier forum designed to present the most recent diagnostic and therapeutic advances in hematologic malignancies. Hosted by the \u003cb data-index-in-node=\"157\" data-path-to-node=\"2\"\u003eMoffitt Cancer Center\u003c\/b\u003e, one of the nation’s leading cancer research institutes, the 2025 event continued its tradition of offering “breakthrough” updates that bridge the gap between research and bedside practice. The program is structured around interactive debates and “State of the Art” lectures, providing a comprehensive review of lymphoid and myeloid malignancies, plasma cell dyscrasias, and the evolving landscape of cellular immunotherapies.\u003c\/p\u003e\n\u003ch3 data-path-to-node=\"3\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"3\"\u003e+ What You Will Learn\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp data-path-to-node=\"4\"\u003eAttendees were able to:\u003c\/p\u003e\n\u003cul data-path-to-node=\"5\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,0,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,0,0\"\u003eEvaluate\u003c\/b\u003e the latest clinical data regarding \u003cb data-index-in-node=\"44\" data-path-to-node=\"5,0,0\"\u003eCAR T-cell therapy\u003c\/b\u003e and \u003cb data-index-in-node=\"67\" data-path-to-node=\"5,0,0\"\u003ebispecific antibodies\u003c\/b\u003e, specifically their sequencing and toxicity management in lymphoma and myeloma.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,1,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,1,0\"\u003eDiscuss\u003c\/b\u003e the role of \u003cb data-index-in-node=\"20\" data-path-to-node=\"5,1,0\"\u003eMeasurable Residual Disease (MRD)\u003c\/b\u003e testing in guiding treatment decisions for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,2,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,2,0\"\u003eIdentify\u003c\/b\u003e new therapeutic targets and agents for \u003cb data-index-in-node=\"48\" data-path-to-node=\"5,2,0\"\u003eRelapsed\/Refractory\u003c\/b\u003e Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,3,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,3,0\"\u003eAnalyze\u003c\/b\u003e the “Hot Topics” in blood cancers, including the management of \u003cb data-index-in-node=\"71\" data-path-to-node=\"5,3,0\"\u003eclonal hematopoiesis\u003c\/b\u003e and its risk implications for older adults.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,4,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,4,0\"\u003eDebate\u003c\/b\u003e controversial management strategies, such as the use of hypomethylating agents prior to transplant in high-risk MDS, through interactive pro\/con sessions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,5,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,5,0\"\u003eImplement\u003c\/b\u003e best practices for managing complications of novel immunotherapies, including \u003cb data-index-in-node=\"88\" data-path-to-node=\"5,5,0\"\u003eCytokine Release Syndrome (CRS)\u003c\/b\u003e and neurotoxicity (ICANS).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"6\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"6\"\u003e+ Event Details\u003c\/b\u003e\u003c\/h3\u003e\n\u003cul data-path-to-node=\"7\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"7,0,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"7,0,0\"\u003eDate:\u003c\/b\u003e January 25, 2025\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"7,1,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"7,1,0\"\u003eLocation:\u003c\/b\u003e Florida (Historically held at venues like \u003ci data-index-in-node=\"52\" data-path-to-node=\"7,1,0\"\u003eThe Don CeSar\u003c\/i\u003e in St. Pete Beach or \u003ci data-index-in-node=\"87\" data-path-to-node=\"7,1,0\"\u003eDisney’s Grand Floridian\u003c\/i\u003e in Orlando; the 21st Annual is confirmed for St. Pete Beach).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cb data-index-in-node=\"0\" data-path-to-node=\"7,3,0\"\u003eOrganizer:\u003c\/b\u003e Moffitt Cancer Center\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"8\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"8\"\u003e+ Who Should Attend\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp data-path-to-node=\"9\"\u003eThe conference is tailored for the interdisciplinary hematology-oncology team:\u003c\/p\u003e\n\u003cul data-path-to-node=\"10\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,0,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,0,0\"\u003eHematologists\u003c\/b\u003e and Medical Oncologists\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,1,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,1,0\"\u003eOncology Nurses\u003c\/b\u003e and Nurse Practitioners\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,2,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,2,0\"\u003ePhysician Assistants\u003c\/b\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,3,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,3,0\"\u003ePharmacists\u003c\/b\u003e specializing in oncology\/hematology\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,4,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,4,0\"\u003eResearch Scientists\u003c\/b\u003e and Fellows\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"11\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"11\"\u003e+ Why Attend\u003c\/b\u003e\u003c\/h3\u003e\n\u003cul data-path-to-node=\"12\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"12,0,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"12,0,0\"\u003eCutting-Edge Science:\u003c\/b\u003e Moffitt Cancer Center is a leader in cellular therapy (CAR T), and this conference provides direct access to the faculty driving these innovations.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"12,1,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"12,1,0\"\u003eDebate Format:\u003c\/b\u003e Unlike standard lecture series, this event features “Interactive Debates” (e.g., \u003ci data-index-in-node=\"96\" data-path-to-node=\"12,1,0\"\u003eTransplant vs. CAR T in Myeloma\u003c\/i\u003e), which help clinicians understand the nuance behind conflicting guidelines.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"12,2,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"12,2,0\"\u003eASH Updates:\u003c\/b\u003e Held shortly after the American Society of Hematology (ASH) annual meeting, this course serves as a critical “post-ASH” review, distilling thousands of abstracts into actionable clinical pearls for the coming year.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eManagement of First MM Relapse Debate – Cilta-Cel for All – No\u003c\/li\u003e\n\u003cli\u003eManagement of First MM Relapse Debate – Cilta-Cel for All – Yes\u003c\/li\u003e\n\u003cli\u003eState-of-the-Art – Understanding Precursor States – CHIP and CCUS\u003c\/li\u003e\n\u003cli\u003e2025 Updates on Treating Anemia in LR-MDS\u003c\/li\u003e\n\u003cli\u003eDebate – Should MRD Status Be Used to Alter Treatment Decisions in High-Risk MDS \u0026amp; AML – Yes\u003c\/li\u003e\n\u003cli\u003eDebate – Should MRD Status Be Used to Alter Treatment Decisions in High-Risk MDS \u0026amp; AML – No\u003c\/li\u003e\n\u003cli\u003eBeyond CAR-T – Management of Post-BCMA CAR-T Relapse in RRMM\u003c\/li\u003e\n\u003cli\u003eHow I Treat High-Risk Multiple Myeloma – Interactive Case Discussion\u003c\/li\u003e\n\u003cli\u003eAQUILA Trial – Daratumumab vs. Active Monitoring in SMM – Perspectives for Practice\u003c\/li\u003e\n\u003cli\u003eSummary of Data for Transplant-Ineligible NDMM – Proposed SoC Approach\u003c\/li\u003e\n\u003cli\u003eLR-MDS Updates + Panel Discussion – Focus on Ph3 IMerge Trial\u003c\/li\u003e\n\u003cli\u003eRevmibeni for KMT2Ar RR Acute Leukemia – AUGMENT-101 Trial – Impact on Treatment Landscape\u003c\/li\u003e\n\u003cli\u003eClinical Application of Practice-Changing SWOG S1826 Trial – Nivo+AVD vs. BV+AVD in 1L Advanced Stage cHL\u003c\/li\u003e\n\u003cli\u003eGolcadomide + R-CHOP in High-Risk, Untreated Aggressive B-cell Lymphoma – Panel Discussion on Future of 1L Therapy in DLBCL\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663482605897,"sku":"MED-AMB05880","price":30.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/file_00000000f68072439c71e9dfa9644da8-1.png?v=1781875433"},{"product_id":"hematopathology-4th-edition-original-pdf-from-publisher","title":"Hematopathology, 4th Edition (Original PDF from Publisher)","description":"\u003cstrong\u003eby Eric D. Hsi MD, Sa A. Wang MD, John R. Goldblum MD FCAP FASCP FACG\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv\u003e\n\u003cdiv\u003ePart of the popular Foundations in Diagnostic Pathology Series, Hematopathology, Fourth Edition, is a practical and affordable resource that is ideal for study and review as well as everyday clinical practice. With its highly templated format, clearly written text, and concise summary tables, this user-friendly reference helps both trainees and practicing pathologists form accurate diagnoses, avoid pitfalls, and confidently sign out pathology reports on these often difficult and challenging cases. \u003cbr\u003e\u003cul\u003e\n\u003cli\u003eUses a highly templated format that includes clinical, imaging, and management\/prognostic features; pathologic features; ancillary studies; differential diagnosis; and selected bibliography\u003c\/li\u003e\n\u003cli\u003eFocuses on the specific features of various entities, including differential diagnoses\u003c\/li\u003e\n\u003cli\u003eSupplements traditional morphologic diagnostic pathology with clinical, immunohistochemical, and molecular genetic information throughout\u003c\/li\u003e\n\u003cli\u003eIncludes new information on the molecular biology of benign and malignant hematologic disorders\u003c\/li\u003e\n\u003cli\u003eContains numerous quick-reference summary boxes that provide concise and handy key points on the clinical features and pathological features of each disease within hematopathology\u003c\/li\u003e\n\u003cli\u003eFeatures hundreds of full-color photomicrographs and gross photographs that depict important pathologic features, enabling you to form a differential diagnosis and compare your findings with actual cases\u003c\/li\u003e\n\u003cli\u003eReflects updated disease classifications according to the 5th edition of World Health Organization (WHO) and The International Consensus Classification (ICC)\u003c\/li\u003e\n\u003cli\u003eOffers contributions from internationally recognized pathologists, keeping you up to date with the latest information in the field\u003c\/li\u003e\n\u003cli\u003eAn eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud. Additional digital ancillary content may publish up to 6 weeks following the publication date\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663482802505,"sku":"MED-AMB05854","price":30.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Hematopathology-4th-Edition-Original-PDF-from-Publisher.webp?v=1781875431"},{"product_id":"moffitt-cancer-center-cell-coast-conference-2025","title":"Moffitt Cancer Center Cell Coast Conference 2025","description":"\u003cdiv\u003e\n\u003cdiv class=\"prod-edition\"\u003e\n\u003ch1 class=\"product_title entry-title\"\u003eMoffitt Cancer Center Cell Coast Conference 2025\u003c\/h1\u003e\n\u003cstrong\u003e+ Include: 23 Videos (.mp4) + 23 Audios (.mp3) + 23 Subtitles (.vtt) + 21 PDFs, size: 13.2 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Target Audience: hematologists, oncologists, and cellular therapy practitioners\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003ch2 data-path-to-node=\"0\"\u003e1. Overview\u003c\/h2\u003e\n\u003cp data-path-to-node=\"1\"\u003eThe Moffitt Cancer Center Cell Coast Conference 2025 is a premier event dedicated to the latest breakthroughs in cellular cancer therapies. This course brings together leading experts to explore emerging targets, advanced engineering strategies, and next-generation modalities like CAR-T, bispecific antibodies, and TIL therapies, aiming to enhance treatment efficacy and patient care.\u003c\/p\u003e\n\u003cdiv class=\"Grid__row___c486 Grid__small___c486\"\u003e\n\u003cdiv class=\"Grid__column___c486 Grid__small___c486 Grid__col_12___c486\" id=\"widget:4bb55e0a-059f-40e3-885f-56862216ba4c\"\u003e\n\u003cdiv data-cvent-id=\"widget-EventDescription-widget:4bb55e0a-059f-40e3-885f-56862216ba4c\"\u003e\n\u003cdiv class=\"Description__text___5a94\"\u003e\n\u003cdiv\u003e\n\u003cdiv class=\"ag87-crtemvc-hsbk\"\u003e\n\u003cdiv class=\"css-vsf5of\"\u003e\n\u003cp class=\"carina-rte-public-DraftStyleDefault-block\"\u003eJoin us for the 2\u003csup\u003end\u003c\/sup\u003e Annual Cell Coast Conference, where leading experts, researchers, and industry pioneers will converge to explore the latest breakthroughs in cellular cancer therapy. This premier event will feature cutting-edge discussions on emerging targets, advanced engineering strategies, and next-generation therapeutic modalities, all aimed at enhancing the efficacy and delivery of cellular therapies.\u003c\/p\u003e\n\u003cp class=\"carina-rte-public-DraftStyleDefault-block\"\u003eAttendees will engage with top-tier experts and industry leaders through four dynamic session tracks:\u003c\/p\u003e\n\u003cul class=\"carina-rte-public-DraftStyleDefault-ul\"\u003e\n\u003cli\u003eNovel Targets and Approaches\u003c\/li\u003e\n\u003cli\u003eAdvanced Engineering and Modalities\u003c\/li\u003e\n\u003cli\u003eOptimizing Delivery and Efficacy\u003c\/li\u003e\n\u003cli\u003eInteractive Debates and Controversies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"Grid__row___c486 Grid__small___c486\"\u003e\n\u003cdiv class=\"Grid__column___c486 Grid__small___c486 Grid__col_12___c486\" id=\"widget:31757634-29fe-4311-9e86-c2892d7617e8\"\u003e\n\u003cdiv class=\"css-87ndg2\" data-cvent-id=\"widget-NucleusText-widget:31757634-29fe-4311-9e86-c2892d7617e8\"\u003e\n\u003cdiv class=\"css-umqnq5\"\u003e\n\u003cdiv class=\"css-vsf5of\"\u003e\n\u003cp class=\"carina-rte-public-DraftStyleDefault-block\"\u003eThe 2\u003csup\u003end\u003c\/sup\u003e Annual Cell Coast Conference provides an unparalleled opportunity to gain insights from world-renowned experts, participate in collaborative discussions, and network with peers driving innovation in the field. Whether you’re a researcher, clinician, or industry professional, this conference will equip you with the latest knowledge and strategies to accelerate the development of next-generation cellular therapies for cancer. Don’t miss this opportunity to be at the forefront of transformative cancer treatment advancements!\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp data-path-to-node=\"1\"\u003e\u003cb data-index-in-node=\"386\" data-path-to-node=\"1\"\u003eCourse Dates:\u003c\/b\u003e October 17–18, 2025\u003c\/p\u003e\n\u003ch2 data-path-to-node=\"2\"\u003e2. Learning Objectives\u003c\/h2\u003e\n\u003cul data-path-to-node=\"3\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"3,0,0\"\u003eEvaluate the efficacy and toxicity management of bispecific antibody therapies for Non-Hodgkin Lymphoma and Multiple Myeloma.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"3,1,0\"\u003eAnalyze updates in CAR-T cell therapies for ALL, solid tumors, and autoimmune diseases, including in-vivo and armored CAR-T strategies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"3,2,0\"\u003eDiscuss the operationalization of new therapies like Tarlatamab and the logistics of clinical care for cell therapy patients.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"3,3,0\"\u003eReview novel cellular therapies for sarcoma and the future of Tumor Infiltrating Lymphocyte (TIL) therapy in lung and bladder cancers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"3,4,0\"\u003eCompare CAR-T versus BiTEs for hematologic malignancies and assess biomarkers for toxicity and response.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-path-to-node=\"4\"\u003e3. Target Audience\u003c\/h2\u003e\n\u003cdiv\u003eBest for hematologists, oncologists, and cellular therapy practitioners who want updates on CAR-T, bispecific antibodies, and TIL therapies.\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003eThis conference is specifically crafted for professionals in the field, including cellular therapy practitioners, hematologists, community oncologists, pharmacists, advanced practice professionals, and dedicated oncology nurses.  Particular attention will be paid to the interface between referring providers and cellular therapists, including when and how to refer patients.\u003c\/div\u003e\n\u003ch2 data-path-to-node=\"6\"\u003e4. Topics\u003c\/h2\u003e\n\u003col data-path-to-node=\"8\" start=\"1\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,0,0\"\u003eBispecific Antibody Therapy in Non-Hodgkin Lymphoma and Toxicity Management\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,1,0\"\u003eOperationalization of Tarlatamab Therapy at Moffitt Cancer Center\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,2,0\"\u003eBispecific Antibody Therapy for Relapsed Refractory Multiple Myeloma\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,3,0\"\u003eKeynote Speaker Combination CAR T and anti-IFNG Strategies for the Management of Advanced Cancers\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,4,0\"\u003eNovel Cellular Therapies for Sarcoma\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,5,0\"\u003eCAR-T Cell Updates in ALL\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,6,0\"\u003eGPC3 CAR T Cells for the Management of Advanced Cancers\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,7,0\"\u003eCAR-T for Autoimmune Diseases\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,8,0\"\u003eBiomarkers for Toxicity and Response in CAR-T for Multiple Myeloma\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,9,0\"\u003eIn-Vivo CAR-T\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,10,0\"\u003eClaudin 18.2 for Gastrointestinal Malignancies\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,11,0\"\u003eT Cell Fitness What’s Next after BCMA CAR\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,12,0\"\u003eArmored CAR-T Strategies for Advanced Cancers\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,13,0\"\u003eAllogeneic “off the shelf” IO approaches for MDS AML\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,14,0\"\u003eCAR-NK Strategies for the Management of Advanced Cancers\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,15,0\"\u003eBladder Til Trial\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,16,0\"\u003eFuture of TIL Therapy\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,17,0\"\u003eNovel TIL Therapies in Lung Cancer\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,18,0\"\u003eCAR-T for Glioblastoma\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,19,0\"\u003eGCC19 CAR T Trial\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,20,0\"\u003ePractical Logistics of Clinical Care for Cell Therapy Patients\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,21,0\"\u003eCAR-T vs BiTEs for Hematologic Malignancies (Part 1)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"8,22,0\"\u003eCAR-T vs BiTEs for Hematologic Malignancies (Part 2)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663482900809,"sku":"MED-AMB05802","price":30.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Moffitt-Cancer-Center-Cell-Coast-Conference-2025.jpg?v=1781875432"},{"product_id":"2025-fundamentals-of-hct-original-pdf-from-publisher","title":"2025 Fundamentals of HCT (Original PDF from Publisher)","description":"\u003cdiv\u003e\n\u003cdiv class=\"prod-edition\"\u003e\n\u003cdiv class=\"ma-product\"\u003e\u003csection\u003e\n\u003ch3\u003e2025 Fundamentals of HCT (Original PDF from Publisher)\u003c\/h3\u003e\n\u003cbr\u003eThe\u003cem\u003e 2025 Fundamentals of HCT eBook \u003c\/em\u003eoffers up-to-date clinical information covering the full transplant journey—from pre-transplant consultation to post-transplant care. With \u003cstrong\u003e32 focused chapters\u003c\/strong\u003e, this resource includes essential topics such as:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eIntroduction to Transplantation\u003c\/li\u003e\n\u003cli\u003eIndications for HCT in ALL, AML, MDS, MF, Lymphoma, Multiple Myeloma, CML and CLL\u003c\/li\u003e\n\u003cli\u003eIEC Products and Indications\u003c\/li\u003e\n\u003cli\u003eIEC Toxicity Management\u003c\/li\u003e\n\u003cli\u003eStem Cell Mobilization\u003c\/li\u003e\n\u003cli\u003eAcute and Chronic GVHD\u003c\/li\u003e\n\u003cli\u003eVaccinations in HCT and Cellular Therapy\u003c\/li\u003e\n\u003cli\u003eLong-term Follow-up and Survivorship\u003c\/li\u003e\n\u003cli\u003eSpecial Populations in HCT: Pediatrics\u003c\/li\u003e\n\u003cli\u003e*New in the 2025 edition* - Special Populations in HCT: Geriatrics\u003c\/li\u003e\n\u003cli\u003eAnd more!\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003eDesigned for healthcare professionals, this eBook is a go-to guide for anyone involved in HCT or cellular therapy.\u003cbr\u003e\u003cbr\u003e\u003c\/section\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663482868041,"sku":"MED-AMB05786","price":80.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/2025-Fundamentals-of-HCT-Original-PDF-from-Publisher.jpg?v=1781875431"},{"product_id":"moffitt-cancer-center-cell-coast-conference-2024","title":"Moffitt Cancer Center Cell Coast Conference 2024","description":"\u003cdiv class=\"prod-edition\"\u003e\n\u003cdiv class=\"field field--name-field-heading field--type-heading field--label-hidden field__item\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003cdiv class=\"elementor-element elementor-element-bbb44b8 elementor-widget elementor-widget-heading\" data-element_type=\"widget\" data-id=\"bbb44b8\" data-widget_type=\"heading.default\"\u003e\n\u003cdiv class=\"bundle--paragraph_component paragraph paragraph--type--paragraph-component paragraph--view-mode--default\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003ch1 class=\"product_title entry-title\"\u003eMoffitt Cancer Center Cell Coast Conference 2024\u003c\/h1\u003e\n\u003cstrong\u003e+ Include: 15 videos + 15 audios + 15 file sub vtt + 17 pdfs, size: 5.99 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Target Audience: medical oncologists, hematologists, cellular therapy specialists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cp data-path-to-node=\"2\"\u003eHeld in the fall of 2024, this conference was launched to spotlight the rapid evolution of cellular therapies, including \u003cb data-index-in-node=\"121\" data-path-to-node=\"2\"\u003eCAR T-cell therapy\u003c\/b\u003e, \u003cb data-index-in-node=\"141\" data-path-to-node=\"2\"\u003eTumor-Infiltrating Lymphocytes (TILs)\u003c\/b\u003e, and \u003cb data-index-in-node=\"184\" data-path-to-node=\"2\"\u003eT-cell Receptor (TCR)\u003c\/b\u003e therapies. The event, themed “Spotlight Breakthroughs in Cellular Immunotherapy,” focused on operationalizing these complex treatments for broader patient access. It provided a unique forum for discussing “real-world” data—moving beyond the controlled environment of clinical trials to examine how these therapies perform in standard clinical settings for both hematologic and solid tumor malignancies.\u003c\/p\u003e\n\u003ch3 data-path-to-node=\"3\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"3\"\u003e+ What You Will Learn\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp data-path-to-node=\"4\"\u003eAttendees were able to:\u003c\/p\u003e\n\u003cul data-path-to-node=\"5\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,0,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,0,0\"\u003eEvaluate\u003c\/b\u003e real-world outcomes of CAR T-cell therapy in Multiple Myeloma and Lymphoma, comparing them to pivotal trial data.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,1,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,1,0\"\u003eAssess\u003c\/b\u003e the operational challenges of delivering TIL therapy for metastatic melanoma and its emerging role in lung cancer.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,2,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,2,0\"\u003eIdentify\u003c\/b\u003e strategies for managing unique toxicities associated with bispecific antibodies and cellular products, such as Cytokine Release Syndrome (CRS) and neurotoxicity.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,3,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,3,0\"\u003eDiscuss\u003c\/b\u003e the integration of community oncologists with academic cellular therapy centers to streamline patient referrals and long-term follow-up.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,4,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,4,0\"\u003eExamine\u003c\/b\u003e the potential of TCR therapies for solid tumors, specifically reviewing the FDA approval of afamitresgene autoleucel for synovial sarcoma.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,5,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,5,0\"\u003eAnalyze\u003c\/b\u003e the logistics of “Point of Care” CAR T manufacturing and its potential to reduce costs and wait times.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"6\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"6\"\u003e+ Event Details\u003c\/b\u003e\u003c\/h3\u003e\n\u003cul data-path-to-node=\"7\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"7,0,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"7,0,0\"\u003eDate:\u003c\/b\u003e October 2024 (Inaugural Event)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"7,1,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"7,1,0\"\u003eLocation:\u003c\/b\u003e Moffitt Cancer Center, Tampa, Florida\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"8\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"8\"\u003e+ Who Should Attend\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp data-path-to-node=\"9\"\u003eThe conference was designed for the broad oncology community involved in advanced cancer care:\u003c\/p\u003e\n\u003cul data-path-to-node=\"10\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,0,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,0,0\"\u003eMedical Oncologists\u003c\/b\u003e (Academic and Community-based)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,1,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,1,0\"\u003eHematologists\u003c\/b\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,2,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,2,0\"\u003eCellular Therapy Specialists\u003c\/b\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,3,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,3,0\"\u003eResearch Scientists\u003c\/b\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,4,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,4,0\"\u003eNurses and Advanced Practice Providers\u003c\/b\u003e managing immunotherapy patients\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,5,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,5,0\"\u003ePharmacists\u003c\/b\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"11\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"11\"\u003e+ Why Attend\u003c\/b\u003e\u003c\/h3\u003e\n\u003cul data-path-to-node=\"12\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"12,0,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"12,0,0\"\u003eInaugural Energy:\u003c\/b\u003e As the first event of its kind from Moffitt, it set the stage for a new “Cell Coast” hub of innovation, offering unique networking with the leaders who pioneered TIL therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"12,1,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"12,1,0\"\u003eSolid Tumor Focus:\u003c\/b\u003e Unlike many cell therapy meetings that focus solely on blood cancers, this conference placed significant emphasis on the “next frontier”—treating solid tumors like lung cancer and sarcoma with engineered cells.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"12,2,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"12,2,0\"\u003ePractical Operations:\u003c\/b\u003e The agenda included dedicated sessions on “Operational Readiness,” addressing the business and logistical hurdles (e.g., bed capacity, manufacturing delays) that clinics face when adopting these therapies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eUpdates on Approved CAR-T for Lymphoma\u003c\/li\u003e\n\u003cli\u003eCAR-T for ALL\u003c\/li\u003e\n\u003cli\u003eCAR-T Strategies for Multiple Myeloma\u003c\/li\u003e\n\u003cli\u003eBi-specifics for Myeloma\u003c\/li\u003e\n\u003cli\u003eCellular Therapies for Myeloid Malignancies\u003c\/li\u003e\n\u003cli\u003eMelanoma TILs\u003c\/li\u003e\n\u003cli\u003eSurgical Considerations for TIL Procurement\u003c\/li\u003e\n\u003cli\u003eNovel Cell Therapies for Thoracic Malignancies\u003c\/li\u003e\n\u003cli\u003eAfami-cel TCR for Sarcoma\u003c\/li\u003e\n\u003cli\u003eIntravesical TIL for Bladder Cancer\u003c\/li\u003e\n\u003cli\u003ePoint of Care CAR T Manufacturing\u003c\/li\u003e\n\u003cli\u003eReal World CAR-T for Multiple Myeloma\u003c\/li\u003e\n\u003cli\u003eInfections Occurring in our ICE T Patient Population\u003c\/li\u003e\n\u003cli\u003eCAR-T in Autoimmune Diseases\u003c\/li\u003e\n\u003cli\u003eNK Cellular Therapies\u003c\/li\u003e\n\u003cli\u003eBusiness Operations of Cellular Therapies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663482966345,"sku":"MED-AMB05616","price":20.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Moffitt-Cancer-Center-Cell-Coast-Conference-2024.jpg?v=1781875432"},{"product_id":"ohi-s-library-of-oral-pathology-management-of-precancerous-and-cancerous-oral-lesions","title":"OHI-S Library of Oral Pathology Management of Precancerous and Cancerous Oral Lesions","description":"\u003cdiv class=\"grid-x grid-margin-x\"\u003e\n\u003cdiv class=\"cell initial-12 medium-8\"\u003e\n\u003cdiv class=\"pnllearningActivityInformationClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnllearningActivityInformation_0\"\u003e\n\u003cdiv class=\"pnlLearningActivityInformationDescriptionClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnlLearningActivityInformationDescription_0\"\u003e\n\u003cdiv class=\"pnllearningActivityInformationClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnllearningActivityInformation_0\"\u003e\n\u003cdiv class=\"pnlLearningActivityInformationDescriptionClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnlLearningActivityInformationDescription_0\"\u003e\n\u003cdiv class=\"prod-edition\"\u003e\n\u003cdiv class=\"field field--name-field-heading field--type-heading field--label-hidden field__item\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003cdiv class=\"elementor-element elementor-element-bbb44b8 elementor-widget elementor-widget-heading\" data-element_type=\"widget\" data-id=\"bbb44b8\" data-widget_type=\"heading.default\"\u003e\n\u003cdiv class=\"bundle--paragraph_component paragraph paragraph--type--paragraph-component paragraph--view-mode--default\"\u003e\n\u003cdiv class=\"elementor-element elementor-element-371ff86 elementor-widget elementor-widget-heading\" data-element_type=\"widget\" data-id=\"371ff86\" data-widget_type=\"heading.default\"\u003e\n\u003cdiv class=\"custom-single-product product type-product post-465185 status-publish first instock product_cat-hot-books product_cat-anesthesiology product_cat-cardiology product_cat-hematology product_cat-medical-reference-terminology product_cat-vascular-medicine has-post-thumbnail sale downloadable virtual taxable purchasable product-type-simple\" id=\"product-465185\"\u003e\n\u003cdiv class=\"afk-single-product-outer\"\u003e\n\u003cdiv class=\"akf-p-f-box d-flex f-wrap j-c-b\"\u003e\n\u003cdiv class=\"akf-right\"\u003e\n\u003cdiv class=\"woo-tab-container custom woo-tc-j\"\u003e\n\u003cdiv class=\"tabcontent active\" id=\"descriptionTab\"\u003e\n\u003cdiv class=\"prod-desc\"\u003e\n\u003cbr\u003e\u003cbr\u003eOHI-S Library of Oral Pathology Management of Precancerous and Cancerous Oral Lesions\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eInclude: 4 videos + 4 audios + 4 file sub vtt, size: 1.76 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eTarget Audience: pediatric dentists, periodontists, oral and maxillofacial surgeons, general dentists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e Information:\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003e3 lessons + 1 free \u003cspan data-v-49dfad2a=\"\"\u003e(3h 25min)\u003c\/span\u003e\u003cbr\u003e\u003cbr\u003eEverything from diagnosis to treatment of the most common precancerous and cancerous oral diseases by Dr. Ashley Clark — A diplomate of the American Board of Oral and Maxillofacial Pathology!\u003cbr\u003e\u003cbr\u003eDuring the course you will learn the protocols of:\u003cbr\u003e\u003cbr\u003e– Diagnosis of leukoplakia\u003cbr\u003e\u003cbr\u003e– Detection of squamous cell carcinoma of the oral cavity\u003cbr\u003e\u003cbr\u003e– Differential diagnosis of ulcerative lesions\u003cbr\u003e\u003cbr\u003e– Diagnosis and treatment of salivary glands pathology\u003cbr\u003e\u003cbr\u003e– Diagnosis and study of histopathology\u003cbr\u003e\u003cbr\u003e– X-ray diagnosis of lesions.\u003cbr\u003e\u003cbr\u003eThe course covers all questions related to precancerous \u0026amp; cancerous lesions of the oral cavity and protocols for their early diagnosis and treatment.\u003cbr\u003e\u003cbr\u003eThe \u003cem\u003eOHI‑S Library of Oral Pathology: Management of Precancerous and Cancerous Oral Lesions\u003c\/em\u003e course is best for oral pathologists, oral medicine specialists, oral surgeons, and general dentists who want structured, training in diagnosing and managing oral precancerous and cancerous conditions. It emphasizes evidence‑based protocols, interdisciplinary collaboration, and practical case management to improve patient outcomes.\u003cbr\u003e\u003ch3\u003e👩‍⚕️ Who Should Enroll\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eOral pathologists \u0026amp; oral medicine specialists focusing on diagnosis and management of oral precancerous and malignant lesions.\u003c\/li\u003e\n\u003cli\u003eOral \u0026amp; maxillofacial surgeons performing biopsies, resections, and surgical management of oral cancers.\u003c\/li\u003e\n\u003cli\u003eGeneral dentists \u0026amp; prosthodontists who need to recognize early signs of precancerous lesions and refer appropriately.\u003c\/li\u003e\n\u003cli\u003ePeriodontists managing gingival lesions with potential malignant transformation.\u003c\/li\u003e\n\u003cli\u003eResidents \u0026amp; fellows in oral pathology, oral medicine, or oral surgery seeking advanced training.\u003c\/li\u003e\n\u003cli\u003eDental hygienists \u0026amp; clinical staff supporting early detection and patient education.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e📚 What You’ll Learn\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003ePrecancerous lesions: leukoplakia, erythroplakia, oral lichen planus, and their malignant potential.\u003c\/li\u003e\n\u003cli\u003eCancerous lesions: squamous cell carcinoma and other oral malignancies.\u003c\/li\u003e\n\u003cli\u003eDiagnostic protocols: clinical, histopathological, and adjunctive diagnostic tools.\u003c\/li\u003e\n\u003cli\u003eManagement strategies: surgical, medical, and adjunctive therapies.\u003c\/li\u003e\n\u003cli\u003eInterdisciplinary collaboration: integrating pathology, surgery, oncology, and restorative dentistry.\u003c\/li\u003e\n\u003cli\u003eCase‑based lessons: real examples of diagnosis, treatment, and long‑term follow‑up.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"product-program__lesson\" data-v-9ad12abf=\"\"\u003e\n\u003cdiv class=\"product-program__lesson\" data-v-9ad12abf=\"\"\u003e\n\u003ch3 class=\"o-typography__heading3 product-program__lesson-title\" data-v-05addd47=\"\" data-v-9ad12abf=\"\"\u003e\n\u003cspan class=\"product-program__lesson-number\" data-v-9ad12abf=\"\"\u003eLesson 1.\u003c\/span\u003eLeukoplakia \u0026amp; oral cancer\u003c\/h3\u003e\n\u003cdiv class=\"ql-editor product-program__lesson-description\" data-v-9ad12abf=\"\"\u003e\n\u003cbr\u003e\u003cbr\u003e– Introduction to the classification and the diagnosis protocols of oral and oropharyngeal squamous cell carcinoma\u003cbr\u003e\u003cbr\u003e– The etiology of human papillomavirus\u003cbr\u003e\u003cbr\u003e– Clinical features of potentially malignant disorders of the oral cavity\u003cbr\u003e\u003cbr\u003e– Clinical features of oral dysplasia\u003cbr\u003e\u003cbr\u003e– Lesions of leukoplakia\u003cbr\u003e\u003cbr\u003e– Thin leukoplakia: hyperkeratosis, acanthosis, carcinoma-in-situ\u003cbr\u003e\u003cbr\u003e– Thick leukoplakia: mild dysplasia, mild dysplasia with hyperkeratosis\u003cbr\u003e\u003cbr\u003e– Veruciform leukoplakia: severe dysplasia\u003cbr\u003e\u003cbr\u003e– Erythroleukoplakia: severe dysplasia, squamous cell carcinoma\u003cbr\u003e\u003cbr\u003e– Common locations in which leukoplakia is encountered\u003cbr\u003e\u003cbr\u003e– The appropriate treatment plan for patients with leukoplakia\u003cbr\u003e\u003cbr\u003e– Lesions of oral squamous cell carcinoma\u003cbr\u003e\u003cbr\u003e– Methods on how to help prevent squamous cell carcinoma in your patient population.\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e\u003cem\u003eRecommended for:\u003c\/em\u003e\u003c\/strong\u003e Pediatric dentists, Periodontists, Oral and maxillofacial surgeons, General dentists.\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-program__lesson\" data-v-9ad12abf=\"\"\u003e\n\u003ch3 class=\"o-typography__heading3 product-program__lesson-title\" data-v-05addd47=\"\" data-v-9ad12abf=\"\"\u003e\n\u003cspan class=\"product-program__lesson-number\" data-v-9ad12abf=\"\"\u003eLesson 2.\u003c\/span\u003eUlcers of the oral cavity\u003c\/h3\u003e\n\u003cdiv class=\"ql-editor product-program__lesson-description\" data-v-9ad12abf=\"\"\u003e\n\u003cbr\u003e\u003cbr\u003e– Ulcerative conditions of the oral cavity\u003cbr\u003e\u003cbr\u003e– The differential diagnosis for ulcerative lesions\u003cbr\u003e\u003cbr\u003e– Diagnosis, treatment protocols, and case presentation of desquamative gingivitis\u003cbr\u003e\u003cbr\u003e– Differential diagnosis of desquamative gingivitis\u003cbr\u003e\u003cbr\u003e– Diagnosis, treatment protocols, and case presentation of lichen planus:\u003cbr\u003e\u003cbr\u003e– Reticular form\u003cbr\u003e\u003cbr\u003e– Papules form\u003cbr\u003e\u003cbr\u003e– Plaque-like form\u003cbr\u003e\u003cbr\u003e– Atrophic form\u003cbr\u003e\u003cbr\u003e– Ulcerative form\u003cbr\u003e\u003cbr\u003e– Bullous form.\u003cbr\u003e\u003cbr\u003e– Diagnosis, treatment protocols, and case presentation of mucous membrane pemphigoid (MMP)\u003cbr\u003e\u003cbr\u003e– Diagnosis, treatment protocols, and case presentation of Pemphigus vulgaris\u003cbr\u003e\u003cbr\u003e– The differences between acute and chronic ulcerative conditions\u003cbr\u003e\u003cbr\u003e– Diagnosis, treatment protocols, and case presentation of recurrent aphthous ulceration (RAU): minor and major form\u003cbr\u003e\u003cbr\u003e– Diagnosis, treatment protocols, and case presentation of herpes simplex virus and recurrent herpes simplex\u003cbr\u003e\u003cbr\u003e– Treatment plan for patients with acute ulcers\u003cbr\u003e\u003cbr\u003e– Treatment plan for patients with chronic ulcers\u003cbr\u003e\u003cbr\u003e– The follow-up measures for patients with oral ulcerations.\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e\u003cem\u003eRecommended for:\u003c\/em\u003e\u003c\/strong\u003e Pediatric dentists, Periodontists, Oral and maxillofacial surgeons, General dentists.\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-program__lesson\" data-v-9ad12abf=\"\"\u003e\n\u003ch3 class=\"o-typography__heading3 product-program__lesson-title\" data-v-05addd47=\"\" data-v-9ad12abf=\"\"\u003e\n\u003cspan class=\"product-program__lesson-number\" data-v-9ad12abf=\"\"\u003eLesson 3.\u003c\/span\u003eCommon epithelial, mesenchymal, and salivary lesions of the oral cavity\u003c\/h3\u003e\n\u003cdiv class=\"ql-editor product-program__lesson-description\" data-v-9ad12abf=\"\"\u003e\n\u003cbr\u003e\u003cbr\u003e– Pigmented lesions of the oral cavity and their differential diagnosis:\u003cbr\u003e\u003cbr\u003e– Amalgam tattoos: diagnosis, treatment protocols, and clinical presentation\u003cbr\u003e\u003cbr\u003e– Oral Melanotic macule: diagnosis, treatment protocols, and clinical presentation\u003cbr\u003e\u003cbr\u003e– Acquired melanocytic nevus: diagnosis, treatment protocols, and clinical presentation\u003cbr\u003e\u003cbr\u003e– Melanoma: diagnosis, treatment protocols, and clinical presentation.\u003cbr\u003e\u003cbr\u003e– Human papillomavirus: the difference between low-risk and high-risk HPV strains\u003cbr\u003e\u003cbr\u003e– The papillary lesions of the oral cavity and their differential diagnosis:\u003cbr\u003e\u003cbr\u003e– Squamous papilloma: diagnosis, treatment protocols, and clinical presentation\u003cbr\u003e\u003cbr\u003e– Verruca vulgaris: diagnosis, treatment protocols, and clinical presentation\u003cbr\u003e\u003cbr\u003e– Condyloma acuminatum: diagnosis, treatment protocols, and clinical presentation.\u003cbr\u003e\u003cbr\u003e– Differential diagnosis of mesenchymal lesions: fibromas and bumps on the gum\u003cbr\u003e\u003cbr\u003e– Salivary pathology: mucoceles and xerostomia\u003cbr\u003e\u003cbr\u003e– Treatment plan for patients with common oral lesions\u003cbr\u003e\u003cbr\u003e– Clinical cases and conclusion.\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e\u003cem\u003eRecommended for:\u003c\/em\u003e\u003c\/strong\u003e Pediatric dentists, Periodontists, Oral and maxillofacial surgeons, General dentists.\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-program__lesson\" data-v-9ad12abf=\"\"\u003e\n\u003ch3 class=\"o-typography__heading3 product-program__lesson-title\" data-v-05addd47=\"\" data-v-9ad12abf=\"\"\u003e\n\u003cspan class=\"product-program__lesson-number\" data-v-9ad12abf=\"\"\u003eLesson 4.\u003c\/span\u003eCommon radiographic oral pathology\u003c\/h3\u003e\n\u003cdiv class=\"ql-editor product-program__lesson-description\" data-v-9ad12abf=\"\"\u003e\n\u003cbr\u003e\u003cbr\u003e– Radiographic features, diagnosis, and management of radiolucent defects:\u003cbr\u003e\u003cbr\u003e– stafne defect.\u003cbr\u003e\u003cbr\u003e– Radiographic features, diagnosis, and management of multilocular radiolucent lesions:\u003cbr\u003e\u003cbr\u003e– ameloblastoma\u003cbr\u003e\u003cbr\u003e– central giant cell granuloma\u003cbr\u003e\u003cbr\u003e– hemangioma\u003cbr\u003e\u003cbr\u003e– odontogenic keratocyst.\u003cbr\u003e\u003cbr\u003e– Radiographic features, diagnosis, and management of common radiopaque lesions:\u003cbr\u003e\u003cbr\u003e– condensing osteitis\u003cbr\u003e\u003cbr\u003e– idiopathic osteosclerosis\u003cbr\u003e\u003cbr\u003e– cemento-osseous dysplasia\u003cbr\u003e\u003cbr\u003e– focal cemento-osseous dysplasia\u003cbr\u003e\u003cbr\u003e– periapical cemento-osseous dysplasia\u003cbr\u003e\u003cbr\u003e– florid cemento-osseous dysplasia\u003cbr\u003e\u003cbr\u003e– cemento blastoma\u003cbr\u003e\u003cbr\u003e– osteoma.\u003cbr\u003e\u003cbr\u003e– The difference between lesions with a similar radiographic presentation\u003cbr\u003e\u003cbr\u003e– When radiographic lesions do need a biopsy?\u003cbr\u003e\u003cbr\u003e– Follow-up measures regarding radiographic pathology\u003cbr\u003e\u003cbr\u003e– Syndromes associated with radiographic pathology.\u003cbr\u003e\u003cbr\u003e\u003ci\u003e\u003cstrong\u003eRecommended for:\u003c\/strong\u003e\u003c\/i\u003e Pediatric dentists, Periodontists, Oral and maxillofacial surgeons, General dentists.\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663483097417,"sku":"MED-AMB05581","price":40.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/OHI-S-Library-of-Oral-Pathology-Management-of-Precancerous-and-Cancerous-Oral-Lesions.webp?v=1781875432"},{"product_id":"memorial-sloan-kettering-cancer-center-advancing-osteosarcoma-care-from-bench-to-bedside-2025","title":"Memorial Sloan Kettering Cancer Center Advancing Osteosarcoma Care From Bench to Bedside 2025","description":"\u003cdiv class=\"grid-x grid-margin-x\"\u003e\n\u003cdiv class=\"cell initial-12 medium-8\"\u003e\n\u003cdiv class=\"pnllearningActivityInformationClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnllearningActivityInformation_0\"\u003e\n\u003cdiv class=\"pnlLearningActivityInformationDescriptionClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnlLearningActivityInformationDescription_0\"\u003e\n\u003cdiv class=\"pnllearningActivityInformationClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnllearningActivityInformation_0\"\u003e\n\u003cdiv class=\"pnlLearningActivityInformationDescriptionClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnlLearningActivityInformationDescription_0\"\u003e\n\u003cdiv class=\"prod-edition\"\u003e\n\u003cdiv class=\"field field--name-field-heading field--type-heading field--label-hidden field__item\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003cdiv class=\"elementor-element elementor-element-bbb44b8 elementor-widget elementor-widget-heading\" data-element_type=\"widget\" data-id=\"bbb44b8\" data-widget_type=\"heading.default\"\u003e\n\u003cdiv class=\"bundle--paragraph_component paragraph paragraph--type--paragraph-component paragraph--view-mode--default\"\u003e\n\u003cdiv class=\"elementor-element elementor-element-371ff86 elementor-widget elementor-widget-heading\" data-element_type=\"widget\" data-id=\"371ff86\" data-widget_type=\"heading.default\"\u003e\n\u003cdiv class=\"custom-single-product product type-product post-465185 status-publish first instock product_cat-hot-books product_cat-anesthesiology product_cat-cardiology product_cat-hematology product_cat-medical-reference-terminology product_cat-vascular-medicine has-post-thumbnail sale downloadable virtual taxable purchasable product-type-simple\" id=\"product-465185\"\u003e\n\u003cdiv class=\"afk-single-product-outer\"\u003e\n\u003cdiv class=\"akf-p-f-box d-flex f-wrap j-c-b\"\u003e\n\u003cdiv class=\"akf-right\"\u003e\n\u003cdiv class=\"woo-tab-container custom woo-tc-j\"\u003e\n\u003cdiv class=\"tabcontent active\" id=\"descriptionTab\"\u003e\n\u003cdiv class=\"prod-desc\"\u003e\n\u003ch3\u003eMemorial Sloan Kettering Cancer Center Advancing Osteosarcoma Care From Bench to Bedside 2025\u003c\/h3\u003e\n\u003cstrong\u003eInclude: 23 videos + 17 pdfs, size: 7.59 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e Target Audience: oncologists, orthopedic surgeons\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003eDate \u0026amp; Location Monday, October 27, 2025, 7:50 AM – 5:00 PM, Zuckerman Research Center, 417 East 68th Street, New York, NY\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cem\u003eSpecialties\u003c\/em\u003e – Anatomic Pathology, Anesthesiology, Behavioral Care, Biostatistics, Cardiology, Cardiothoracic Surgery, Case Management, Cellular Therapeutics, Clinical Pathology, Computational Biology, Critical Care, Cytopathology, Diagnostic Radiology, ENT, Gastroenterology, General Surgery, Genetics, Head and Neck Surgery, Hospice and Palliative Medicine, Hospitalist, Immunotherapy, Integrative Medicine, Interventional Radiology, Medical Oncology, Molecular Biology, Molecular Pathology, Neurology, Neuroradiology, Neurosurgery, Nuclear Medicine, Nurse Anesthetist, Nurse Practitioner, Nursing, Oncology and Hematology, Orthopedic Surgery, Pain Medicine, Pathology, Patient or Caregiver, Pediatric Oncology, Pediatric Surgery, Pediatrics, Pharmacology and Medication Management, Physical Medicine and Rehabilitation, Physician Assistant, Plastic and Maxillofacial Surgery, Plastic Surgery, Preventive and Occupational Medicine, Psychiatry, Psychology, Pulmonary Medicine, Pulmonology, Radiation Oncology, Respiratory Therapy, Social Work, Solid Tumor Oncology, Spine Surgery, Sports Medicine, Surgical Oncology, Surgical Pathology, Thoracic Medical Oncology, Thoracic Surgery, Vascular Surgery\u003c\/div\u003e\n\u003cstrong\u003eOverview\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eThe management of pediatric osteosarcoma patients is best accomplished within a well-integrated, multidisciplinary team. This comprehensive one-day symposium is designed to equip healthcare professionals with the \u003cstrong\u003elatest insights into advances, best practices, and ongoing challenges that impact both clinical outcomes and the overall patient experience\u003c\/strong\u003e.\u003cbr\u003e\u003cbr\u003eJointly presented by the Departments of Surgery and Pediatrics at Memorial Sloan Kettering Cancer Center, the program underscores the importance of a coordinated approach among diverse team members. Focused topics will cover\u003cstrong\u003e \u003c\/strong\u003eevidence-based advances in medical management, including \u003cstrong\u003eclinical trial updates\u003c\/strong\u003e, \u003cstrong\u003esurgical innovations\u003c\/strong\u003e, \u003cstrong\u003ediagnostic techniques\u003c\/strong\u003e, and \u003cstrong\u003erecent translational research initiatives\u003c\/strong\u003e. A special segment will \u003cstrong\u003efeature the patient and family perspective\u003c\/strong\u003e, offering valuable insight into the lived experience of care.\u003cbr\u003e\u003cbr\u003eThe overarching goal is to provide attendees with the tools and strategies needed to deliver state-of-the-art, collaborative care to enhance quality of life for this unique patient population, and\u003cstrong\u003e explore scientific advancements moving us closer to cure.\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eFollowing the symposium, registrants will receive \u003cstrong\u003eaccess to an online syllabus \u003c\/strong\u003efeaturing select PDF slides from faculty presentations and recorded session videos.\u003cbr\u003e\u003cbr\u003eThe \u003cstrong\u003etarget audience\u003c\/strong\u003e for this symposium includes physicians, nurse practitioners, physician assistants, nurses, social workers, physical therapists, psychologists, and students who care for the pediatric osteosarcoma patient.\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eObjectives\u003c\/strong\u003e\u003c\/div\u003e\n\u003col\u003e\n\u003cli\u003eDiscuss the multidisciplinary approach to managing complex pediatric osteosarcoma cases\u003c\/li\u003e\n\u003cli\u003eReview current treatments and recent advances in the medical management of pediatric osteosarcoma\u003c\/li\u003e\n\u003cli\u003eIdentify advanced surgical techniques for both primary tumors and metastatic disease in pediatric osteosarcoma\u003c\/li\u003e\n\u003cli\u003eDiscuss ongoing and emerging research initiatives in pediatric osteosarcoma\u003c\/li\u003e\n\u003cli\u003eDescribe the importance of the patient and family experience in the care of pediatric osteosarcoma\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cstrong\u003e Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003ch3 class=\"boxAgendaTitle\"\u003eMonday, October 27, 2025\u003c\/h3\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"12u\"\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eOsteosarcoma: History and Progress\u003c\/strong\u003e\u003cbr\u003e8:00AM – 8:20AM\u003cbr\u003ePaul A Meyers, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eOsteosarcoma: Pathological Diagnosis and Molecular Correlates\u003c\/strong\u003e\u003cbr\u003e8:30AM – 8:50AM\u003cbr\u003eMeera Hameed, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eMaking the Diagnosis Visible: Imaging Osteosarcoma from Detection to Recurrence\u003c\/strong\u003e\u003cbr\u003e8:50AM – 9:10AM\u003cbr\u003eSinchun Hwang, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eOrthopedic Surgery Principles and Emerging Techniques\u003c\/strong\u003e\u003cbr\u003e9:10AM – 9:30AM\u003cbr\u003eDaniel E Prince, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eFoundations of Osteosarcoma: Comprehensive Insights into Diagnosis and Management Q\u0026amp;A and Discussion\u003c\/strong\u003e\u003cbr\u003e9:30AM – 9:40AM\u003cbr\u003eJ. Ted T Gerstle, MD (Moderator)\u003cbr\u003eDamon Reed, MD (Moderator)\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eThe Surgical Management of Osteosarcoma Metastases\u003c\/strong\u003e\u003cbr\u003e9:55AM – 10:15AM\u003cbr\u003eJoshua Honeyman, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eUnderstanding then Anticipating Osteosarcoma Heterogeneity\u003c\/strong\u003e\u003cbr\u003e10:15AM – 10:35AM\u003cbr\u003eDamon Reed, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eNavigating Resistance: Therapeutic Approaches for Advanced Osteosarcoma Q\u0026amp;A and Discussion\u003c\/strong\u003e\u003cbr\u003e10:35AM – 10:45AM\u003cbr\u003eCarol Morris, MD, MS (Moderator)\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eFrom Biopsy to Therapy: Interventional Radiology in the Multidisciplinary Treatment of Osteosarcoma\u003c\/strong\u003e\u003cbr\u003e10:45AM – 11:05AM\u003cbr\u003eErnesto Santos Martin, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eUtilization of Radiotherapy for the Treatment of Osteosarcoma\u003c\/strong\u003e\u003cbr\u003e11:05AM – 11:25AM\u003cbr\u003eChristopher B Jackson, MD, MS\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003ePalliative Care for Advanced Osteosarcoma\u003c\/strong\u003e\u003cbr\u003e11:25AM – 11:45AM\u003cbr\u003eDana Greenfield, MD, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eNavigating Resistance: Therapeutic Approaches for Advanced Osteosarcoma Q\u0026amp;A and Discussion II\u003c\/strong\u003e\u003cbr\u003e11:45AM – 11:55AM\u003cbr\u003eCarol Morris, MD, MS (Moderator)\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eTargeting Master Regulators in Osteosarcoma: Dissecting Transcriptional Heterogeneity for Precision Therapy\u003c\/strong\u003e\u003cbr\u003e12:55PM – 1:15PM\u003cbr\u003eJovana Pavisic, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eModeling Osteosarcoma: Insights into Tumor Heterogeneity\u003c\/strong\u003e\u003cbr\u003e1:15PM – 1:35PM\u003cbr\u003eFilemon Dela Cruz, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eTargeting Residual Disease in Osteosarcoma Using Proteomic Approaches\u003c\/strong\u003e\u003cbr\u003e1:35PM – 1:55PM\u003cbr\u003eAsmin Tulpule, MD, PhD, physician\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eDriving Discovery: The Role of the Translational Medicine in Osteosarcoma Q\u0026amp;A and Discussion\u003c\/strong\u003e\u003cbr\u003e1:55PM – 2:05PM\u003cbr\u003eJ. Ted T Gerstle, MD (Moderator)\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eEnhanced Image Analysis: Radiomics and Artificial Intelligence\u003c\/strong\u003e\u003cbr\u003e2:05PM – 2:25PM\u003cbr\u003eGerald Behr, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eCellular Therapy for Pediatric Solid Tumors\u003c\/strong\u003e\u003cbr\u003e2:25PM – 2:45PM\u003cbr\u003eAli Cihan, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eDriving Discovery: The Role of the Translational Medicine in Osteosarcoma Q\u0026amp;A and Discussion II\u003c\/strong\u003e\u003cbr\u003e2:45PM – 2:55PM\u003cbr\u003eJ. Ted T Gerstle, MD (Moderator)\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eRehabilitation Considerations in Sarcoma Care\u003c\/strong\u003e\u003cbr\u003e3:10PM – 3:30PM\u003cbr\u003eDeborah Cassidy, DO\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eBeyond the Bone: Addressing the Cognitive and Emotional Needs of Patients with Osteosarcoma\u003c\/strong\u003e\u003cbr\u003e3:30PM – 3:50PM\u003cbr\u003eJulia A. Kearney , MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eHealing the Whole: Integrating Supportive Care in Osteosarcoma Q\u0026amp;A and Discussion\u003c\/strong\u003e\u003cbr\u003e3:50PM – 4:00PM\u003cbr\u003ePaulette Kelly, MSN, FNP-BC (Moderator)\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003ePatient Stories and Reflections\u003c\/strong\u003e\u003cbr\u003e4:00PM – 4:55PM\u003cbr\u003eChristopher Calby , MBA\u003cbr\u003eMaryeliza Mc Eachen, BSN (Moderator)\u003cbr\u003eMichael Very, PA\u003cbr\u003eChristina Yerdon, DPM\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663483130185,"sku":"MED-AMB05577","price":40.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Memorial-Sloan-Kettering-Cancer-Center-Advancing-Osteosarcoma-Care-From-Bench-to-Bedside-2025.jpg?v=1781875433"},{"product_id":"uscap-thorax-revisited-2026","title":"USCAP Thorax Revisited 2026","description":"\u003cdiv class=\"prod-edition\"\u003e\n\u003cdiv class=\"field field--name-field-heading field--type-heading field--label-hidden field__item\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003cdiv class=\"elementor-element elementor-element-bbb44b8 elementor-widget elementor-widget-heading\" data-element_type=\"widget\" data-id=\"bbb44b8\" data-widget_type=\"heading.default\"\u003e\n\u003cdiv class=\"bundle--paragraph_component paragraph paragraph--type--paragraph-component paragraph--view-mode--default\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003ch1\u003eUSCAP Thorax Revisited 2026\u003c\/h1\u003e\n\u003cstrong\u003e+ Include: 10 videos + 20 pdfs, size:  GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Target Audience: pathologists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Information:\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eOriginal release date: January 12, 2026\u003cbr\u003e\u003cbr\u003eAccurate diagnosis of pleural disease is crucial to patient care. Pathologists are also increasingly asked to order and interpret molecular testing for lung carcinomas and other pulmonary tumors. Led by expert pathologists, this course will review common diagnostic pitfalls in thoracic pathology, cytology, and immunohistochemistry, along with new cases of mediastinal tumors, pleural tumors, and non-neoplastic lung disease. As molecular testing becomes more mainstream, interpreting these tests for lung carcinomas and other pulmonary tumors is of vital importance. Faculty will discuss issues related to molecular testing with a focus on what to order, when to order, and how to interpret the results. This course will feature lectures and interactive case-based discussions.\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eTarget Audience\u003c\/strong\u003e\u003cbr\u003ePracticing academic and community pathologists, and pathologists-in-training\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eLearning Objectives\u003c\/strong\u003e\u003cbr\u003eUpon completion of this educational activity, learners will be able to:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eUnderstand when molecular testing is needed for thoracic tumors, what tests are appropriate, and how to interpret the results.\u003c\/li\u003e\n\u003cli\u003eBecome familiar with morphologic features of various prevascular mediastinal lesions for establishing a reasonable differential diagnosis. Based on that differential diagnosis the participants will learn to apply reasonable small panels of ancillary tests, including immunostains and potentially cytogenetics (especially chromosome 12p alterations for germ cell tumors).\u003c\/li\u003e\n\u003cli\u003eBecome familiar with morphologic features of various non neoplastic lung diseases. Cases selected will span the spectrum of cellular and fibrotic interstitial pneumonias, smoking related disease, cystic lung disease, benign lymphoid lesions (and some neoplastic mimics), vascular disease, drug reactions, the lung in systemic disease, and various granulomatous diseases. These cases form the bulk of cases sent to our large consultation practice indicating that pathologists struggle with how to report their findings and to communicate the clinical significance of what they are seeing.\u003c\/li\u003e\n\u003cli\u003eUnderstand the various types of pleural lesions encountered in everyday practice, their morphologic differential and mimics, and what adjunctive tests are or are not useful in working up such cases.\u003c\/li\u003e\n\u003cli\u003eGain familiarity with the basics of thoracic cytology (lavage, EBUS, effusion) specimens, understand issues related to specimen preparation, and how and when to apply immunostains or FISH.\u003c\/li\u003e\n\u003cli\u003eLearn efficient use of immunostains for thoracic lesions and learn to recognize problems and misleading results with such stains.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"product-program__lesson\" data-v-9ad12abf=\"\"\u003e\n\u003cul\u003e\n\u003cli data-end=\"130\" data-start=\"63\"\u003e\n\u003cp data-end=\"130\" data-start=\"66\"\u003e\u003cstrong data-end=\"99\" data-start=\"66\"\u003eBasics of Molecular Pathology\u003c\/strong\u003e – Yin (Rex) P. Hung, MD, PhD\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"171\" data-start=\"131\"\u003e\n\u003cp data-end=\"171\" data-start=\"134\"\u003e\u003cstrong data-end=\"149\" data-start=\"134\"\u003eMediastinum\u003c\/strong\u003e – Anja C. Roden, MD\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"213\" data-start=\"172\"\u003e\n\u003cp data-end=\"213\" data-start=\"175\"\u003e\u003cstrong data-end=\"191\" data-start=\"175\"\u003eIHC Pitfalls\u003c\/strong\u003e – Anja C. Roden, MD\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"253\" data-start=\"214\"\u003e\n\u003cp data-end=\"253\" data-start=\"217\"\u003e\u003cstrong data-end=\"227\" data-start=\"217\"\u003ePleura\u003c\/strong\u003e – Andrew Churg, MD, PhD\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"295\" data-start=\"254\"\u003e\n\u003cp data-end=\"295\" data-start=\"257\"\u003e\u003cstrong data-end=\"269\" data-start=\"257\"\u003eCytology\u003c\/strong\u003e – Andrew Churg, MD, PhD\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"377\" data-start=\"296\"\u003e\n\u003cp data-end=\"377\" data-start=\"299\"\u003e\u003cstrong data-end=\"355\" data-start=\"299\"\u003eGross–Microscopic Correlations in Thoracic Pathology\u003c\/strong\u003e – Anja C. Roden, MD\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"433\" data-start=\"378\"\u003e\n\u003cp data-end=\"433\" data-start=\"381\"\u003e\u003cstrong data-end=\"407\" data-start=\"381\"\u003eNon-Neoplastic: Part 1\u003c\/strong\u003e – Henry D. Tazelaar, MD\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"489\" data-start=\"434\"\u003e\n\u003cp data-end=\"489\" data-start=\"437\"\u003e\u003cstrong data-end=\"463\" data-start=\"437\"\u003eNon-Neoplastic: Part 2\u003c\/strong\u003e – Henry D. Tazelaar, MD\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"553\" data-start=\"490\"\u003e\n\u003cp data-end=\"553\" data-start=\"493\"\u003e\u003cstrong data-end=\"522\" data-start=\"493\"\u003eMolecular Testing: Part 1\u003c\/strong\u003e – Yin (Rex) P. Hung, MD, PhD\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"618\" data-start=\"554\"\u003e\n\u003cp data-end=\"618\" data-start=\"558\"\u003e\u003cstrong data-end=\"587\" data-start=\"558\"\u003eMolecular Testing: Part 2\u003c\/strong\u003e – Yin (Rex) P. Hung, MD, PhD\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663483195721,"sku":"MED-AMB05557","price":120.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/USCAP-Thorax-Revisited-2026.jpg?v=1781875433"},{"product_id":"scripps-cancer-care-symposium-2025","title":"Scripps Cancer Care Symposium 2025","description":"\u003cdiv class=\"prod-edition\"\u003e\n\u003cdiv class=\"field field--name-field-heading field--type-heading field--label-hidden field__item\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003cdiv class=\"elementor-element elementor-element-bbb44b8 elementor-widget elementor-widget-heading\" data-element_type=\"widget\" data-id=\"bbb44b8\" data-widget_type=\"heading.default\"\u003e\n\u003cdiv class=\"bundle--paragraph_component paragraph paragraph--type--paragraph-component paragraph--view-mode--default\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003ch3\u003eScripps Cancer Care Symposium 2025\u003c\/h3\u003e\n\u003cstrong\u003eInclude: 14 videos + 15 pdfs, size: 4.75 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eTarget Audience: oncology nurses, nurse practitioners, physician assistants, clinical nurse specialists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e Information:\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eScripps Cancer Care Symposium: A Nursing \u0026amp; Advanced Practice Provider Collaboration PRESENTED BY SCRIPPS CANCER CENTER\u003cbr\u003e\u003cbr\u003eOctober 10–11, 2025 Hyatt Regency Mission Bay • San Diego, California\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eConference Overview\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eScripps Cancer Center’s Annual Cancer Care Symposium is tailored for nurses, nurse practitioners, physician assistants, clinical nurse specialists, and other healthcare professionals who care for cancer patients. Over the course of this two-day conference, attendees will learn from expert faculty representing various practice settings across the continuum of care, as they discuss the latest clinical developments and treatment advancements in hematology and oncology. Participants will leave equipped with practical strategies and tools to enhance the quality of life and outcomes for cancer patients. Additionally, the symposium will address the importance of self-care and professional resilience.\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eEducational Objectives\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eAfter attending this live activity, participants should be able to:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eAnalyze current issues and emerging trends in cancer care.\u003c\/li\u003e\n\u003cli\u003eExplore new therapeutic options for treating various common malignancies.\u003c\/li\u003e\n\u003cli\u003eOutline evidence-based standards of care, including innovations in diagnosis and treatment.\u003c\/li\u003e\n\u003cli\u003eDetermine methods to implement evidence-based cancer care into practice.\u003c\/li\u003e\n\u003cli\u003eAdopt self-care practices to enhance professional resilience.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003eThe \u003cem\u003eScripps Cancer Care Symposium 2025\u003c\/em\u003e is best for oncology nurses, nurse practitioners, physician assistants, clinical nurse specialists, and other advanced practice providers who care for cancer patients and want CME‑accredited updates on the latest treatments, supportive care strategies, and multidisciplinary collaboration.\u003cbr\u003e\u003ch3\u003e👩‍⚕️ Who Should Attend\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eOncology nurses and advanced practice providers (NPs, PAs, CNSs) directly involved in cancer patient care.\u003c\/li\u003e\n\u003cli\u003eNurse educators and coordinators seeking structured updates to improve patient education and outcomes.\u003c\/li\u003e\n\u003cli\u003eAllied health professionals working in oncology clinics, infusion centers, or cancer support programs.\u003c\/li\u003e\n\u003cli\u003eResidents and fellows in oncology nursing or advanced practice training preparing for independent practice.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e📚 What You’ll Learn\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eLatest clinical developments in hematology and oncology: new therapies, clinical trial updates, and treatment advances.\u003c\/li\u003e\n\u003cli\u003eSupportive care strategies: symptom management, survivorship, and quality‑of‑life improvement.\u003c\/li\u003e\n\u003cli\u003eMultidisciplinary collaboration: integrating nursing and advanced practice roles across the continuum of cancer care.\u003c\/li\u003e\n\u003cli\u003ePractical tools and strategies: enhancing patient outcomes and safety in daily practice.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eTopics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eDAY ONE: GENERAL ONCOLOGY NURSING Friday, October 10, 2025\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e7 a.m. Registration, Breakfast \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e7:50 a.m. Welcome \u0026amp; Morning Announcements\u003c\/li\u003e\n\u003cli\u003e8 a.m. Patient Perspective Story Cindy Gipson\u003c\/li\u003e\n\u003cli\u003e9 a.m. Overview of New Advances in Cellular Therapy James Mason, MD\u003c\/li\u003e\n\u003cli\u003e10 a.m. Break \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e10:30 a.m. Symptom Management Through Nutrition Alison Meagher, MS, RD\u003c\/li\u003e\n\u003cli\u003e11:30 a.m. Interventions for Underserved Patient Populations Marin Xavier, MD\u003c\/li\u003e\n\u003cli\u003e12:30 p.m. Lunch\u003c\/li\u003e\n\u003cli\u003e1:30 p.m. From Burnout to Balance: Resilience Jeffrey Kendall, Psy.D\u003c\/li\u003e\n\u003cli\u003e2:30 p.m. How to Approach Breast Cancer in 2025 Farah Nasraty, MD\u003c\/li\u003e\n\u003cli\u003e3:30 p.m. Break \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e3:45 p.m. Culture of Wellness: Teamwork, Compassion, and Accountability Trang Dinh-Noonan, MSN, RN, OCN, ASPMN and Paige Sinclair, MSN, RN-BC\u003c\/li\u003e\n\u003cli\u003e4:45 p.m. Adjourn\u003c\/li\u003e\n\u003cli\u003e5 p.m. Poster Presentations \u0026amp; Networking Reception\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cstrong\u003eDAY TWO: ONCOLOGY ADVANCED PRACTICE Saturday, October 11, 2025\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e7 a.m. Breakfast \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e7:50 a.m. Welcome \u0026amp; Morning Announcements\u003c\/li\u003e\n\u003cli\u003e8 a.m. Integrative Oncology Deena O’Shea, RN, MSN\u003c\/li\u003e\n\u003cli\u003e9 a.m. Pharmacology Updates: What’s New in Cancer Treatment Teresa Knoop, MSN, RN\u003c\/li\u003e\n\u003cli\u003e10 a.m. Break \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e10:30 a.m. Advances in Theranostics Nikunj Patel, MD\u003c\/li\u003e\n\u003cli\u003e11:30 a.m. Fertility Preservation in Oncology H. Irene Su, MD\u003c\/li\u003e\n\u003cli\u003e12:30 p.m. Lunch\u003c\/li\u003e\n\u003cli\u003e1:30 p.m. AI Impact on Oncology Care Sanjay Juneja, MD\u003c\/li\u003e\n\u003cli\u003e2:30 p.m. Advances in Radiation Oncology Shane Mesko, MD\u003c\/li\u003e\n\u003cli\u003e3:30 p.m. Break \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e3:45 p.m. Updates on Ambulatory CAR T-cell Therapy Tracy Fulton, DNP, RN\u003c\/li\u003e\n\u003cli\u003e4:45 p.m. Final Adjournment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cstrong\u003eTopics, times and speakers are subject to change.\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"TyagGW_tableContainer\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663483228489,"sku":"MED-AMB05510","price":45.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Scripps-Cancer-Care-Symposium-2025.webp?v=1781875433"},{"product_id":"docmeded-2025-jason-l-hornick-m-d-ph-d-expert-series-practical-soft-tissue-pathology","title":"DocmedED 2025 Jason L. Hornick, M.D., Ph.D. Expert Series – Practical Soft Tissue Pathology","description":"\u003cdiv class=\"grid-x grid-margin-x\"\u003e\n\u003cdiv class=\"cell initial-12 medium-8\"\u003e\n\u003cdiv class=\"pnllearningActivityInformationClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnllearningActivityInformation_0\"\u003e\n\u003cdiv class=\"pnlLearningActivityInformationDescriptionClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnlLearningActivityInformationDescription_0\"\u003e\n\u003cdiv class=\"pnllearningActivityInformationClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnllearningActivityInformation_0\"\u003e\n\u003cdiv class=\"pnlLearningActivityInformationDescriptionClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnlLearningActivityInformationDescription_0\"\u003e\n\u003cdiv class=\"prod-edition\"\u003e\n\u003cdiv class=\"field field--name-field-heading field--type-heading field--label-hidden field__item\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003cdiv class=\"elementor-element elementor-element-bbb44b8 elementor-widget elementor-widget-heading\" data-element_type=\"widget\" data-id=\"bbb44b8\" data-widget_type=\"heading.default\"\u003e\n\u003cdiv class=\"bundle--paragraph_component paragraph paragraph--type--paragraph-component paragraph--view-mode--default\"\u003e\n\u003cdiv class=\"elementor-element elementor-element-371ff86 elementor-widget elementor-widget-heading\" data-element_type=\"widget\" data-id=\"371ff86\" data-widget_type=\"heading.default\"\u003e\n\u003cdiv class=\"custom-single-product product type-product post-465185 status-publish first instock product_cat-hot-books product_cat-anesthesiology product_cat-cardiology product_cat-hematology product_cat-medical-reference-terminology product_cat-vascular-medicine has-post-thumbnail sale downloadable virtual taxable purchasable product-type-simple\" id=\"product-465185\"\u003e\n\u003cdiv class=\"afk-single-product-outer\"\u003e\n\u003cdiv class=\"akf-p-f-box d-flex f-wrap j-c-b\"\u003e\n\u003cdiv class=\"akf-right\"\u003e\n\u003cdiv class=\"woo-tab-container custom woo-tc-j\"\u003e\n\u003cdiv class=\"tabcontent active\" id=\"descriptionTab\"\u003e\n\u003cdiv class=\"prod-desc\"\u003e\n\u003ch3\u003eDocmedED 2025 Jason L. Hornick, M.D., Ph.D. Expert Series – Practical Soft Tissue Pathology\u003c\/h3\u003e\n\u003cstrong\u003e Include: 13 videos + 1 pdf, size: 5 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eTarget Audience: practicing pathologists, pathology fellows, and surgical pathologists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eInformation:\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e* WARNING: Cutaneous Mesenchymal Tumors: What’s New? Jason L. Hornick, M.D., Ph.D. (this video error from DocmedED)\u003c\/strong\u003e\n\u003cbr\u003e\u003cdl class=\"clearfix\"\u003e\n\u003cdt\u003eReleased: 09\/15\/25\u003c\/dt\u003e\n\u003c\/dl\u003e\n\u003cdiv\u003e\n\u003ch3\u003e\n\u003ca name=\"nine\"\u003e\u003c\/a\u003e\u003cspan class=\"main\"\u003eAbout This Teaching Activity ▼\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"one\" id=\"about\"\u003e\n\u003cbr\u003e\u003cbr\u003eThis activity is primarily intended and designed to educate pathologists.\u003cbr\u003e\u003cdiv\u003e\n\u003ch3\u003e\u003cspan class=\"main\"\u003eScientific Sponsor ▼\u003c\/span\u003e\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"one\" id=\"ss\"\u003e\n\u003cbr\u003e\u003cbr\u003eEducational Symposia\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003cdiv\u003e\n\u003ch3\u003e\n\u003ca name=\"nine\"\u003e\u003c\/a\u003e\u003cspan class=\"main\"\u003eEducational Objectives ▼\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"one\" id=\"eo\"\u003e\n\u003cbr\u003e\u003cbr\u003eAt the completion of this CME teaching activity, you should be able to:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eApply a pattern-based approach to the differential diagnosis of soft tissue tumors.\u003c\/li\u003e\n\u003cli\u003eDiscuss the differential diagnosis of cutaneous mesenchymal tumors.\u003c\/li\u003e\n\u003cli\u003eDescribe the key features of pleomorphic soft tissue tumors.\u003c\/li\u003e\n\u003cli\u003eRecognize histologic and genetic subtypes of gastrointestinal stromal tumors.\u003c\/li\u003e\n\u003cli\u003eApply a pattern-based diagnostic approach to vascular and nerve sheath tumors.\u003c\/li\u003e\n\u003cli\u003eApply immunohistochemistry for the diagnosis of soft tissue tumors.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003eDocmedED’s 2025 Jason L. Hornick, M.D., Ph.D. Expert Series — Practical Soft Tissue Pathology is best for practicing pathologists, pathology fellows, and surgical pathologists who need a contemporary, case‑driven update on soft tissue tumor diagnosis that aligns with the WHO 2025 classification updates.\u003cbr\u003e\u003ch3\u003eWho this series is best for\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePracticing anatomic pathologists and surgical pathologists\u003c\/strong\u003e who sign out soft tissue specimens and want to reduce diagnostic uncertainty.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFellows and senior residents\u003c\/strong\u003e preparing for boards or seeking a concentrated, expert‑led review.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOncologic clinicians and multidisciplinary tumor boards\u003c\/strong\u003e who want clearer clinicopathologic correlation for management decisions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eWhat the course covers\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eComprehensive, pattern‑based soft tissue tumor review\u003c\/strong\u003e with emphasis on diagnostic pitfalls, immunohistochemistry selection, and molecular testing strategies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFocused modules on head and neck mesenchymal tumors, cutaneous mesenchymal lesions, and WHO 2025 classification changes\u003c\/strong\u003e, taught by Jason L. Hornick and other experts to translate new taxonomy into practical reporting approaches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cstrong\u003eTopics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eMesenchymal Tumors of the Head and Neck: Clues and Pitfalls Jason L. Hornick, M.D., Ph.D.\u003c\/li\u003e\n\u003cli\u003eMesenchymal Tumors of the Head and Neck: Clues and Pitfalls Jason L. Hornick, M.D., Ph.D.\u003c\/li\u003e\n\u003cli\u003eCutaneous Mesenchymal Tumors: What’s New? Jason L. Hornick, M.D., Ph.D. (this video error from DocmedED)\u003c\/li\u003e\n\u003cli\u003eGastrointestinal Mesenchymal Tumors: What Do We Need to Know? Jason L. Hornick, M.D., Ph.D.\u003c\/li\u003e\n\u003cli\u003eNerve Sheath Tumors: Key Features and Problems Jason L. Hornick, M.D., Ph.D.\u003c\/li\u003e\n\u003cli\u003eVascular Tumors: Vasoformative and Not So Much Jason L. Hornick, M.D., Ph.D.\u003c\/li\u003e\n\u003cli\u003eEpithelioid Tumors: Diagnostic Challenges and How to Prevent Disaster Jason L. Hornick, M.D., Ph.D.\u003c\/li\u003e\n\u003cli\u003eMyxoid Tumors of Skin and Soft Tissue: From Benign to Malignant Jason L. Hornick, M.D., Ph.D.\u003c\/li\u003e\n\u003cli\u003eRound Cell Sarcomas: Histologic Clues and Ancillary Testing Jason L. Hornick, M.D., Ph.D.\u003c\/li\u003e\n\u003cli\u003ePleomorphic Sarcomas: It Is Easier Than You Think! Jason L. Hornick, M.D., Ph.D.\u003c\/li\u003e\n\u003cli\u003eSpindle Cell Tumors of Adults, Part II: Differential Diagnosis and Best Markers Jason L. Hornick, M.D., Ph.D.\u003c\/li\u003e\n\u003cli\u003eSpindle Cell Tumors of Adults, Part I: Differential Diagnosis and Best Markers Jason L. Hornick, M.D., Ph.D.\u003c\/li\u003e\n\u003cli\u003eIntroduction to Soft Tissue Pathology: The New 2026 WHO Classification, Grading, and a Pattern-Based Approach Jason L. Hornick, M.D., Ph.D.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663483261257,"sku":"MED-AMB05576","price":40.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/DocmedED-2025-Jason-L.-Hornick-M.D.-Ph.D.-Expert-Series-Practical-Soft-Tissue-Pathology.jpg?v=1781875433"},{"product_id":"harvard-critical-issues-in-tumor-microenvironment-angiogenesis-metastasis-and-immunology-2025","title":"Harvard Critical Issues in Tumor Microenvironment Angiogenesis, Metastasis and Immunology 2025","description":"\u003cdiv class=\"grid-x grid-margin-x\"\u003e\r\n\u003cdiv class=\"cell initial-12 medium-8\"\u003e\r\n\u003cdiv id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnllearningActivityInformation_0\" class=\"pnllearningActivityInformationClass\"\u003e\r\n\u003cdiv id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnlLearningActivityInformationDescription_0\" class=\"pnlLearningActivityInformationDescriptionClass\"\u003e\r\n\u003cdiv id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnllearningActivityInformation_0\" class=\"pnllearningActivityInformationClass\"\u003e\r\n\u003cdiv id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnlLearningActivityInformationDescription_0\" class=\"pnlLearningActivityInformationDescriptionClass\"\u003e\r\n\u003cdiv class=\"prod-edition\"\u003e\r\n\u003cdiv class=\"field field--name-field-heading field--type-heading field--label-hidden field__item\"\u003e\r\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\r\n\u003cdiv class=\"elementor-element elementor-element-bbb44b8 elementor-widget elementor-widget-heading\" data-id=\"bbb44b8\" data-element_type=\"widget\" data-widget_type=\"heading.default\"\u003e\r\n\u003cdiv class=\"bundle--paragraph_component paragraph paragraph--type--paragraph-component paragraph--view-mode--default\"\u003e\r\n\u003cdiv class=\"elementor-element elementor-element-371ff86 elementor-widget elementor-widget-heading\" data-id=\"371ff86\" data-element_type=\"widget\" data-widget_type=\"heading.default\"\u003e\r\n\u003cdiv id=\"product-465185\" class=\"custom-single-product product type-product post-465185 status-publish first instock product_cat-hot-books product_cat-anesthesiology product_cat-cardiology product_cat-hematology product_cat-medical-reference-terminology product_cat-vascular-medicine has-post-thumbnail sale downloadable virtual taxable purchasable product-type-simple\"\u003e\r\n\u003cdiv class=\"afk-single-product-outer \"\u003e\r\n\u003cdiv class=\"akf-p-f-box d-flex f-wrap j-c-b\"\u003e\r\n\u003cdiv class=\"akf-right\"\u003e\r\n\u003cdiv class=\"woo-tab-container custom woo-tc-j\"\u003e\r\n\u003cdiv id=\"descriptionTab\" class=\"tabcontent active\"\u003e\r\n\u003cdiv class=\"prod-desc\"\u003e\r\n\u003cdiv id=\"product-458243\" class=\"custom-single-product product type-product post-458243 status-publish first instock product_cat-cardiology product_cat-pediatrics product_cat-vascular-medicine has-post-thumbnail sale downloadable virtual taxable purchasable product-type-simple\"\u003e\r\n\u003cdiv class=\"afk-single-product-outer \"\u003e\r\n\u003cdiv class=\"akf-p-f-box d-flex f-wrap j-c-b\"\u003e\r\n\u003cdiv class=\"akf-right\"\u003e\r\n\u003cdiv class=\"woo-tab-container custom woo-tc-j\"\u003e\r\n\u003cdiv id=\"descriptionTab\" class=\"tabcontent active\"\u003e\r\n\u003cdiv class=\"prod-desc\"\u003e\r\n\u003cdiv id=\"bylineInfo\" class=\"a-section a-spacing-micro bylineHidden feature\"\u003e\r\n\u003cdiv id=\"bylineInfo\" class=\"a-section a-spacing-micro bylineHidden feature\"\u003e\r\n\u003cdiv id=\"bylineInfo\" class=\"a-section a-spacing-micro bylineHidden feature\"\u003e\r\n\u003cdiv id=\"bylineInfo\" class=\"a-section a-spacing-micro bylineHidden feature\"\u003e\r\n\u003ch3\u003eHarvard Critical Issues in Tumor Microenvironment Angiogenesis, Metastasis and Immunology 2025\u003c\/h3\u003e\r\n\u003cstrong\u003eInclude: 20 videos + 20 sub file vtt + 14 pdfs, size: 21.26 GB\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eTarget Audience: oncologists, cancer researchers, immunologists\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eInformation:\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eCritical Issues in Tumor Microenvironment: Angiogenesis, Metastasis and Immunology \u003cem\u003e40th Annual Offering \u003c\/em\u003eNovember 10 – 14, 2025\u003c\/strong\u003e\r\n\r\nThe “40th Annual Critical Issues in Tumor Microenvironment: Angiogenesis, Metastasis and Immunology” course, directed by Professor Rakesh K. Jain, will continue to offer the best in critical analysis of what is currently known about the tumor microenvironment, including lectures covering: angiogenesis, metastasis, immunology, metabolism, microbiome, chronobiology, carcinoma-associated fibroblasts, cancer-neuroscience, adoptive cell therapies including chimeric antigen receptor (CAR) T-cells, and integrating physical sciences and AI in oncology. The faculty is internationally recognized. They will present the latest findings from their laboratories and clinics. The goal of this course is to highlight key gaps in present knowledge of cancer and outline future directions for research at the bench and in the clinic.\r\n\r\nThe course will return to a four-day in-person format. Learning formats will include didactic lectures, trainee-led Q\u0026amp;A and group discussions. The faculty will encourage an open discussion and will provide critical comments on challenges and future opportunities in research in cancer and in the establishment of novel therapeutic approaches and biomarkers to guide treatment. The aim of this course is to analyze and synthesize the most up-to-date findings. Our faculty will present valuable information in a systematic and comprehensive framework, along with a critical review of various measurement techniques. This course is dedicated to helping to improve clinical translation of this knowledge and competence, leading to improved cancer treatment.\r\n\r\nTo celebrate the 40\u003csup\u003eth\u003c\/sup\u003e anniversary, we have added a 5\u003csup\u003eth\u003c\/sup\u003e Trainee-focused day to our course where the course participants will have the opportunity to present a scientific poster during a poster symposium, along with attend a roundtable discussion session on career guidance for  biomedical scientists and engineers.\r\n\u003ch4\u003eLEARNING OBJECTIVES:\u003c\/h4\u003e\r\n\u003cem\u003eUpon completion of our Critical Issues in Tumor Microenvironment course, participants will be able to:\u003c\/em\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIdentify pharmacological approaches to normalize the tumor microenvironment, including tumor-associated blood vessels, fibroblasts and the extracellular matrix\u003c\/li\u003e\r\n \t\u003cli\u003eEvaluate molecularly targeted agents approved or currently in clinical development in combination with immunotherapies for cancer treatment and incorporate them into practice.\u003c\/li\u003e\r\n \t\u003cli\u003eAssess relevant, state-of-the-art, or translational pre-clinical models of anti-cancer therapies for adult and pediatric malignancies.\u003c\/li\u003e\r\n \t\u003cli\u003eRecognize the steps and determinants of the metastatic process of cancer.\u003c\/li\u003e\r\n \t\u003cli\u003eIdentify emerging determinants of immunotherapy outcomes, including blood vessels, fibroblasts, extracellular matrix, neuronal-tumor interactions, circadian cycle, microbiome, and discuss potential approaches to harness them.\u003c\/li\u003e\r\n \t\u003cli\u003eCompare correlative studies of biomarkers and their response and resistance to immunotherapies in cancer patients.\u003c\/li\u003e\r\n \t\u003cli\u003eEvaluate state-of-the-art genetic and imaging techniques and their applications in pre-clinical and clinical studies.\u003c\/li\u003e\r\n \t\u003cli\u003eUnderstand the applications of AI in cancer care and research\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eWho Should Attend This Course?\u003c\/h4\u003e\r\nThe course is directed at physicians and researchers.\r\n\r\nThe \u003cem\u003eHarvard Critical Issues in Tumor Microenvironment: Angiogenesis, Metastasis and Immunology 2025\u003c\/em\u003e course is best for oncologists, cancer researchers, immunologists, translational scientists, and advanced trainees who want cutting‑edge, multidisciplinary insights into tumor biology, angiogenesis, metastasis, immunology, and emerging therapies.\r\n\u003ch3\u003e👩‍⚕️ Who Should Attend\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMedical oncologists and hematologists seeking deeper understanding of tumor biology to guide clinical practice.\u003c\/li\u003e\r\n \t\u003cli\u003eCancer researchers and translational scientists working on angiogenesis, metastasis, immunotherapy, and tumor microenvironment.\u003c\/li\u003e\r\n \t\u003cli\u003eImmunologists and molecular biologists studying immune regulation and cancer immunotherapy.\u003c\/li\u003e\r\n \t\u003cli\u003eRadiation and surgical oncologists interested in how microenvironmental factors influence treatment outcomes.\u003c\/li\u003e\r\n \t\u003cli\u003ePharmaceutical and biotech professionals developing anti‑cancer drugs, biologics, and cell therapies.\u003c\/li\u003e\r\n \t\u003cli\u003eGraduate students, postdocs, and fellows in oncology, immunology, or biomedical sciences preparing for academic or industry careers.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003e📚 What You’ll Learn\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eTumor microenvironment fundamentals: angiogenesis, metastasis, immunology, metabolism, microbiome, and chronobiology.\u003c\/li\u003e\r\n \t\u003cli\u003eEmerging therapeutic strategies: adoptive cell therapies (CAR‑T, TCR), checkpoint inhibitors, and novel biologics.\u003c\/li\u003e\r\n \t\u003cli\u003eCancer neuroscience and fibroblast biology: how stromal and neural interactions drive tumor progression.\u003c\/li\u003e\r\n \t\u003cli\u003eIntegration of physical sciences and AI in oncology: innovative approaches to modeling and predicting tumor behavior.\u003c\/li\u003e\r\n \t\u003cli\u003eClinical translation: bridging laboratory discoveries with patient care to improve cancer treatment outcomes.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n \r\n\r\n\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\r\n\u003ch4\u003eMonday, November 10, 2025\u003c\/h4\u003e\r\n\u003ctable\u003e\r\n\u003ctbody\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e9:00 A.M\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eCheck-in\/Registration, Continental Breakfast\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e10:00 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eOpening Remarks\u003c\/strong\u003e\u003c\/b\u003e Rakesh K. Jain\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e10:10 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eTumor Microenvironment I: Angiogenesis and Vascular Function\u003c\/strong\u003e\u003c\/b\u003e Rakesh K. Jain\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e11:20 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eQ\u0026amp;A\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e11:35 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cem\u003eBreak\u003c\/em\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e11:50 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eTumor Microenvironment II: Vascular Normalization and Immunotherapy \u003c\/strong\u003e\u003c\/b\u003e Rakesh K. Jain\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e1:10  P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eQ\u0026amp;A\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e1:25 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cem\u003eLunch Break – Boxed lunches provided\u003c\/em\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e2:25 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eTumor Microenvironment III: Extracellular Matrix, Lymphatics and Metastasis\u003c\/strong\u003e\u003c\/b\u003e Rakesh K. Jain\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e3:45 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eQ\u0026amp;A\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e4:00 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cem\u003eBreak\u003c\/em\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e4:30 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eCancer Immunology and Immunotherapy Overview\u003c\/strong\u003e\u003c\/b\u003e Arlene Sharpe\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e5:35 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eQ\u0026amp;A\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e5:50 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cem\u003eAdjourn\u003c\/em\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003c\/tbody\u003e\r\n\u003c\/table\u003e\r\n\u003ch4\u003eTuesday, November 11, 2025\u003c\/h4\u003e\r\n\u003ctable\u003e\r\n\u003ctbody\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e9:00 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eContinental Breakfast\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e10:00 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eCircadian Clock  and Metabolic Vulnerabilities of Cancer\u003c\/strong\u003e\u003c\/b\u003e\u003cb\u003e\u003cstrong\u003e \u003c\/strong\u003e\u003c\/b\u003eChi Van Dang\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e11:05 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eQ\u0026amp;A\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e11:20 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cem\u003eBreak\u003c\/em\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e11:50 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eSkull Bone Marrow as a Site for Immuno-Surveillance of Healthy Brain and Brain Tumors \u003c\/strong\u003e\u003c\/b\u003eJonathan Kipnis\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e12:55 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eQ\u0026amp;A\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e1:10 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cem\u003eLunch Break – on your own\u003c\/em\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e2:10 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eDeterminants of How Tumors Use Metabolism to Support Growth \u003c\/strong\u003e\u003c\/b\u003eMatthew Vander Heiden\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e3:15 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eQ\u0026amp;A\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e3:30 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cem\u003eBreak\u003c\/em\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e4:00 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eUsing Cell Transfer to Remodel the Tumor Microenvrionment\u003c\/strong\u003e\u003c\/b\u003e Carl June\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e5:05 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eQ\u0026amp;A\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e5:20 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cem\u003eAdjourn\u003c\/em\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003c\/tbody\u003e\r\n\u003c\/table\u003e\r\n\u003ch4\u003eWednesday, November 12, 2025\u003c\/h4\u003e\r\n\u003ctable\u003e\r\n\u003ctbody\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e9:00 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eContinental Breakfast\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e10:00 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eAI in Basic and Clinical Oncology\u003c\/strong\u003e\u003c\/b\u003e Eliezer Van Allen\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e11:05 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eQ\u0026amp;A\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e11:20 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cem\u003eBreak\u003c\/em\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e11:50 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eMicrobiota: a Key Orchestrator of Cancer Therapy \u003c\/strong\u003e\u003c\/b\u003eGiorgio Trinchieri\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e12:55 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eQ\u0026amp;A\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e1:10  P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cem\u003eLunch Break – on your own\u003c\/em\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e2:10 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eIdentifying Immune Vulnerabilities in Solid Tumors \u003c\/strong\u003e\u003c\/b\u003eLisa Coussens\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e3:15 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eQ\u0026amp;A\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e3:30 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cem\u003eBreak\u003c\/em\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e4:00 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eRREBELLIOUS INTERFERENCE: Challenging old paradigms and discovering new strategies for targeting pediatric brain tumors \u003c\/strong\u003e\u003c\/b\u003eRobert Wechsler-Reya\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e5:05 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eQ\u0026amp;A\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e5:20 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cem\u003eAdjourn\u003c\/em\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003c\/tbody\u003e\r\n\u003c\/table\u003e\r\n\u003ch4\u003eThursday, November 13, 2025\u003c\/h4\u003e\r\n\u003ctable\u003e\r\n\u003ctbody\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e9:00 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eContinental Breakfast\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e10:00 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eDissecting the Ecosystem of Gliomas by Single-Cell and Spatial Genomics \u003c\/strong\u003e\u003c\/b\u003eMario Suva\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e11:05 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eQ\u0026amp;A\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e11:20 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cem\u003eBreak\u003c\/em\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e11:50 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eMechanisms of Malignant Progression \u003c\/strong\u003e\u003c\/b\u003eRobert Weinberg\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e12:55 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eQ\u0026amp;A\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e1:10  P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cem\u003eLunch Break – on your own\u003c\/em\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e2:10 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eFibroblast Heterogeneity in Solid Tumors: Implications for Pancreatic Cancer \u003c\/strong\u003e\u003c\/b\u003eDavid Tuveson\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e3:15 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eQ\u0026amp;A\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e3:30 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cem\u003eBreak\u003c\/em\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e4:00 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eNeural Influences on Primary and Metastatic Brain Tumors\u003c\/strong\u003e\u003c\/b\u003e Frank Winkler\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e5:05 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eQ\u0026amp;A\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e5:20 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eSummary and closing remarks\u003c\/strong\u003e\u003c\/b\u003e Rakesh K. Jain\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003c\/tbody\u003e\r\n\u003c\/table\u003e\r\n\u003ch4\u003eFriday , November 14th, 2025\u003c\/h4\u003e\r\n\u003ctable width=\"1186\"\u003e\r\n\u003ctbody\u003e\r\n\u003ctr\u003e\r\n\u003ctd width=\"161\"\u003e\u003cb\u003e\u003cstrong\u003e9:00  A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003ePoster set up\/ \u003cb\u003e\u003cstrong\u003eContinental Breakfast\u003c\/strong\u003e\u003c\/b\u003e\n\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e10:00 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eLessons\u003c\/strong\u003e\u003c\/b\u003e \u003cb\u003e\u003cstrong\u003efrom the Clinic: Novel Diagnostics and Therapeutic Outcomes \u003c\/strong\u003e\u003c\/b\u003eGeorge Sledge\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e11:20 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cem\u003eBreak\u003c\/em\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e11:50 A.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eEmerging strategies to improve CAR-T cell therapy for glioblastoma and other solid tumors \u003c\/strong\u003e\u003c\/b\u003eHideho Okada\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e1:10 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cem\u003eLunch Break – Boxed lunches will be provided\u003c\/em\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e2:10 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003ePoster Session\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e3:10 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003ePoster Award Presentation\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e3:30 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eCareer Round Table Discussion\u003c\/strong\u003e\u003c\/b\u003e\r\n\r\nAcademia: Frank Winkler, MD, PhD |Eva Sevick-Muraca, PhD | Melody Swartz, PhD\r\n\r\nIndustry: George Sledge, MD | Zohreh Amoozgar, PhD\r\n\r\nLaw Firm: Carla Mouta-Bellum, PhD, JD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e5:00 P.M.\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eNetworking Reception\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003c\/tbody\u003e\r\n\u003c\/table\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663483326793,"sku":"MED-AMB05396","price":100.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Harvard-Critical-Issues-in-Tumor-Microenvironment-Angiogenesis-Metastasis-and-Immunology-2025_a9f67751-a695-4210-baee-dc6acebaef99.jpg?v=1781875433"},{"product_id":"keck-usc-the-usc-peter-a-singer-thyroid-symposium-2025","title":"Keck USC The USC Peter A. Singer Thyroid Symposium 2025","description":"\u003cdiv id=\"panel-70-0-0-1\" class=\"so-panel widget widget_sow-editor\" data-index=\"1\"\u003e\r\n\u003cdiv class=\"native default panel-widget-style panel-widget-style-for-70-0-0-1\"\u003e\r\n\u003cdiv class=\"so-widget-sow-editor so-widget-sow-editor-base\"\u003e\r\n\u003cdiv class=\"siteorigin-widget-tinymce textwidget\"\u003e\r\n\u003ch1 class=\"product_title entry-title\"\u003eKeck USC The USC Peter A. Singer Thyroid Symposium 2025\u003c\/h1\u003e\r\n\u003cstrong\u003e+ Include: 9 videos + 9 audios + 9 file sub vtts + 2 pdfs, size: 2.41 GB\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003e+ Target Audience: endocrinologists, thyroid surgeons, internists, oncologists, advanced practice providers\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003e+ Information:\u003c\/strong\u003e\r\n\u003cdiv class=\"activitysectionbold\"\u003e\r\n\r\nDate \u0026amp; Location Saturday, May 31, 2025, 7:00 AM – 3:00 PM, Aresty Conference Center – USC Health Sciences Campus, Los Angeles, CA\r\n\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eOverview\u003c\/strong\u003e\u003c\/div\u003e\r\nContinuing our dedication to providing a comprehensive and current update in the management of thyroid disease in 2025, the USC Peter A. Singer Thyroid Symposium will present forward-looking perspectives on the most current state ofthyroid medicine informed by evidenced-based management strategies, with didactic and panel sessions emphasizing clinical experience, challenging cases, along with audience questions to inform solutions to complex clinical scenarios.\r\n\r\nClinical care of patients with thyroid disorders continues to change and develop in complexity. In this 2025 edition, we will highlight key areas for specialists and general providers alike: how molecular testing is altering thyroid cancer management, evaluation of thyroid nodules, interpreting usual thyroid function tests, understanding thyroglobulin measurement, current and future treatments for thyroid eye disease, subclinical thyroid disease and pregnancy, how endocrine-disrupting chemicals impact the thyroid, and essential questions about thyroidectomy to optimal advise patients.\r\n\r\nThe Thyroid Symposium will again be a hybrid program, offering options for in-person or virtual attendance.\r\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eObjectives\u003c\/strong\u003e\u003c\/div\u003e\r\n\u003cdiv\u003e\r\n\r\nBy the end of the course, participants will be able to:\r\n\r\n\u003c\/div\u003e\r\n\u003col\u003e\r\n \t\u003cli\u003eSelect use of molecular testing to optimally inform management of thyroid cancers.\u003c\/li\u003e\r\n \t\u003cli\u003eApply understanding of thyroglobulin measurement to the ordering and interpretation of thyroglobulin in patients with thyroid cancer.\u003c\/li\u003e\r\n \t\u003cli\u003eRecognize common questions and answers about thyroid surgery to improve patient discussions about undergoing thyroidectomy for thyroid conditions.\u003c\/li\u003e\r\n \t\u003cli\u003eInterpret uncommon patterns of thyroid function tests and how to perform diagnostic evaluations of them.\u003c\/li\u003e\r\n \t\u003cli\u003eDecide optimal management strategies for large thyroid nodules.\u003c\/li\u003e\r\n \t\u003cli\u003eReview current evidence for the role of endocrine-disrupting chemicals in thyroid health.\u003c\/li\u003e\r\n \t\u003cli\u003eInterpret uncommon patterns of thyroid function tests and how to perform diagnostic evaluations of them.\u003c\/li\u003e\r\n \t\u003cli\u003eDetermine treatment recommendations for subclinical thyroid disease in people desiring fertility.\u003c\/li\u003e\r\n \t\u003cli\u003eCouncil patients on available options for thyroid eye disease treatment and initiate management.\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\nThe \u003cem\u003eKeck USC Peter A. Singer Thyroid Symposium 2025\u003c\/em\u003e is best for endocrinologists, thyroid surgeons, internists, oncologists, advanced practice providers, and allied health professionals who want CME‑accredited, expert‑led updates on thyroid cancer, thyroid surgery, thyroid function testing, endocrine disruptors, and fertility‑related thyroid disease.\r\n\u003ch3\u003e Who Should Attend\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eEndocrinologists and thyroid specialists managing thyroid cancer, nodules, and subclinical thyroid disease.\u003c\/li\u003e\r\n \t\u003cli\u003eSurgeons (ENT, endocrine, general) performing thyroidectomy and counseling patients on surgical options.\u003c\/li\u003e\r\n \t\u003cli\u003eOncologists interested in molecular testing and thyroglobulin measurement in thyroid cancer.\u003c\/li\u003e\r\n \t\u003cli\u003eInternists and hospitalists who encounter thyroid disorders in inpatient and outpatient settings.\u003c\/li\u003e\r\n \t\u003cli\u003eAdvanced practice providers (NPs, PAs) working in endocrinology or oncology.\u003c\/li\u003e\r\n \t\u003cli\u003eResidents and fellows in endocrinology, oncology, or surgery preparing for board exams.\u003c\/li\u003e\r\n \t\u003cli\u003eAllied health professionals involved in thyroid disease management and patient education.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n \r\n\r\n\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e01 Diagnosis, Genetics, Action! The Role of Molecular Testing in Thyroid Cancer Management\u003c\/li\u003e\r\n \t\u003cli\u003e02 Key Insights for Thyroglobulin Testing and Interpretation in 2025\u003c\/li\u003e\r\n \t\u003cli\u003e03 Essential Surgical Inquiries Addressing Commonly Overlooked Questions Before Thyroidectomy\u003c\/li\u003e\r\n \t\u003cli\u003e04 What’s the Big Deal Best Practices for Managing Large Thyroid Nodules\u003c\/li\u003e\r\n \t\u003cli\u003e05 Hazardous Materials The Impact of Endocrine Disrupting Chemicals on Thyroid Health\u003c\/li\u003e\r\n \t\u003cli\u003e06 Making Sense of Unusual TFTs Explanations and Evaluations\u003c\/li\u003e\r\n \t\u003cli\u003e07 To Treat or Not to Treat Subclinical Thyroid Disease and Fertility\u003c\/li\u003e\r\n \t\u003cli\u003e08 All Eyes on TED Current and Future Treatments for Thyroid Eye Disease\u003c\/li\u003e\r\n \t\u003cli\u003e09 On the Hot Seat Tackling Challenging Thyroid Cases in Clinical Practice for the Panel\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663483490633,"sku":"MED-AMB05328","price":25.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Keck-USC-The-USC-Peter-A.-Singer-Thyroid-Symposium-2025.jpg?v=1781875434"},{"product_id":"rna-therapeutics-institute-rna-therapeutics-from-concept-to-clinic-2025","title":"RNA Therapeutics Institute RNA Therapeutics From Concept to Clinic 2025","description":"\u003cdiv class=\"prod-filesize\"\u003e\n\u003cdiv class=\"prod-edition\"\u003e\n\u003ch1 class=\"product_title entry-title\"\u003eRNA Therapeutics Institute RNA Therapeutics From Concept to Clinic 2025\u003c\/h1\u003e\n\u003cstrong\u003e+ Include: 3 videos + 1 pdf, size: 83.51 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Target Audience: R\u0026amp;D scientists, CMC\/quality leaders, translational and clinical teams, regulatory\/strategy professionals, manufacturing\/operations managers\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cp data-end=\"406\" data-start=\"80\"\u003eA translational, bench-to-bedside program covering the full lifecycle of RNA medicines. Faculty connect platform science (siRNA, ASO, mRNA, saRNA, emerging circular RNA) with delivery, CMC, regulatory strategy, and clinical development—so teams can move candidates efficiently and safely toward approval.\u003c\/p\u003e\n\u003cp data-end=\"433\" data-start=\"408\"\u003e\u003cstrong data-end=\"431\" data-start=\"408\"\u003eWhat You Will Learn\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"1353\" data-start=\"434\"\u003e\n\u003cli data-end=\"553\" data-start=\"434\"\u003e\n\u003cp data-end=\"553\" data-start=\"436\"\u003eModality selection \u0026amp; design: choosing siRNA vs. ASO vs. (sa)mRNA vs. circRNA; chemistries, modifications, stability\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"660\" data-start=\"554\"\u003e\n\u003cp data-end=\"660\" data-start=\"556\"\u003eDelivery systems: LNPs, GALNAc conjugates, polymer\/peptide carriers, local vs. systemic administration\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"776\" data-start=\"661\"\u003e\n\u003cp data-end=\"776\" data-start=\"663\"\u003ePreclinical translation: in vitro\/in vivo models, PK\/PD, biodistribution, immunogenicity, off-target assessment\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"885\" data-start=\"777\"\u003e\n\u003cp data-end=\"885\" data-start=\"779\"\u003eCMC fundamentals: process development, analytics, release\/stability testing, scale-up, and tech transfer\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"999\" data-start=\"886\"\u003e\n\u003cp data-end=\"999\" data-start=\"888\"\u003eClinical development: FIH design, dose selection, biomarkers, patient selection, endpoints, safety monitoring\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1115\" data-start=\"1000\"\u003e\n\u003cp data-end=\"1115\" data-start=\"1002\"\u003eRegulatory \u0026amp; quality: IND\/IMPD strategy, comparability, potency assays, pharm-tox expectations, risk management\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1232\" data-start=\"1116\"\u003e\n\u003cp data-end=\"1232\" data-start=\"1118\"\u003eManufacturing operations: raw materials, supply chain, single-use workflows, contamination control, cost drivers\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1353\" data-start=\"1233\"\u003e\n\u003cp data-end=\"1353\" data-start=\"1235\"\u003eData \u0026amp; tools: sequence optimization, secondary structure prediction, bioinformatics\/AI for target\/off-target profiling\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"1374\" data-start=\"1355\"\u003e\u003cstrong data-end=\"1372\" data-start=\"1355\"\u003eEvent Details\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"1650\" data-start=\"1375\"\u003e\n\u003cli data-end=\"1448\" data-start=\"1375\"\u003e\n\u003cp data-end=\"1448\" data-start=\"1377\"\u003eFormat: Case-based lectures, panel Q\u0026amp;A, and short technical workshops\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1556\" data-start=\"1449\"\u003e\n\u003cp data-end=\"1556\" data-start=\"1451\"\u003eStructure: Concept\/design → delivery\/PKPD → CMC\/manufacturing → clinical\/regulatory → commercialization\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1650\" data-start=\"1557\"\u003e\n\u003cp data-end=\"1650\" data-start=\"1559\"\u003eTakeaways: Checklists, study-design templates, and CMC\/quality worksheets for immediate use\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"1878\" data-start=\"1652\"\u003e\u003cstrong data-end=\"1673\" data-start=\"1652\"\u003eWho Should Attend\u003c\/strong\u003e\u003cbr\u003eR\u0026amp;D scientists, CMC\/quality leaders, translational and clinical teams, regulatory\/strategic affairs, manufacturing\/operations managers, platform founders, investors, and trainees entering the RNA space.\u003c\/p\u003e\n\u003cp data-end=\"1896\" data-start=\"1880\"\u003e\u003cstrong data-end=\"1894\" data-start=\"1880\"\u003eWhy Attend\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"2135\" data-start=\"1897\"\u003e\n\u003cli data-end=\"1972\" data-start=\"1897\"\u003e\n\u003cp data-end=\"1972\" data-start=\"1899\"\u003eReplace trial-and-error with validated design and development playbooks\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2052\" data-start=\"1973\"\u003e\n\u003cp data-end=\"2052\" data-start=\"1975\"\u003eAnticipate regulatory and manufacturing pitfalls early to de-risk timelines\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2135\" data-start=\"2053\"\u003e\n\u003cp data-end=\"2135\" data-start=\"2055\"\u003eAlign discovery, CMC, and clinical groups around practical, decision-ready tools\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003e*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the Detail section below\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eJune 25, 2025.mp4\u003c\/li\u003e\n\u003cli\u003eJune 26, 2025.mp4\u003c\/li\u003e\n\u003cli\u003eJune 27, 2025.mp4\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663483523401,"sku":"MED-AMB05295","price":40.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/RNA-Therapeutics-Institute-RNA-Therapeutics-From-Concept-to-Clinic-2025.jpg?v=1781875435"},{"product_id":"scripps-md-anderson-cancer-center-oncology-update-2025","title":"Scripps MD Anderson Cancer Center Oncology Update 2025","description":"\u003cdiv class=\"a-section a-spacing-micro bylineHidden feature\" id=\"bylineInfo\" style=\"text-align: left;\"\u003e\n\u003cdiv class=\"a-section a-spacing-micro bylineHidden feature\" id=\"bylineInfo\"\u003e\n\u003ch3\u003eScripps MD Anderson Cancer Center Oncology Update 2025\u003c\/h3\u003e\n\u003cstrong\u003eInclude: 13 videos + 14 pdfs, size: 2.89 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eTarget Audience: oncologists, hematologists, internists, advanced practice providers, and trainees\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eInformation:\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eOncology Review 2025 Presented by Scripps Cancer Center\u003cbr\u003e\u003cbr\u003eScripps Cancer Center’s 2025 Oncology Review is a dynamic one-day conference designed to provide physicians and advanced practice providers with a comprehensive overview of the latest advancements in the treatment of lung, pancreatic, colorectal, and breast cancers. Led by a multidisciplinary team of expert\u003cbr\u003emedical oncologists, radiation oncologists, and surgeons, the program will highlight cutting-edge clinical data and practice-changing insights from recently published studies and major national conference presentations.\u003cbr\u003e\u003cbr\u003eThrough a combination of interactive casebased discussions and engaging didactic lectures,\u003cbr\u003eparticipants will gain valuable insights into managing complex clinical scenarios and translating evidencebased knowledge into real-world practice. Attendees will leave equipped with practical tools and strategies to enhance patient outcomes, improve quality of life, and raise the standard of care for individuals facing these challenging malignancies\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eEducational Objectives\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eAfter attending this live activity, participants should be able to:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eIntegrate evidence-based treatment strategies into clinical practice to optimize patient outcomes and clinical care.\u003c\/li\u003e\n\u003cli\u003eEvaluate the latest advances in clinical oncology research and their implications for patient care.\u003c\/li\u003e\n\u003cli\u003eExamine the impact of novel diagnostic techniques in the management and assessment of various oncologic malignancies.\u003c\/li\u003e\n\u003cli\u003eRecognize and manage common and more recently appreciated side effects of cancer therapy including cardiotoxicities and immunerelated adverse events.\u003c\/li\u003e\n\u003cli\u003eImplement multidisciplinary collaboration and shared decision making into the management of complex patient cases and addressing treatment-related complications.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003eThe Scripps MD Anderson Cancer Center \u003cem\u003eOncology Update 2025\u003c\/em\u003e is best for oncologists, hematologists, internists, advanced practice providers, and trainees who want CME‑accredited, expert‑led updates on the latest advances in cancer care, delivered in collaboration with MD Anderson Cancer Center.\u003cbr\u003e\u003ch3\u003e👩‍⚕️ Who Should Attend\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eMedical oncologists and hematologists managing patients with solid tumors and hematologic malignancies.\u003c\/li\u003e\n\u003cli\u003eInternal medicine physicians and subspecialists who co‑manage cancer patients or encounter oncologic issues in practice.\u003c\/li\u003e\n\u003cli\u003eAdvanced practice providers (NPs, PAs, CNSs) working in oncology clinics or infusion centers.\u003c\/li\u003e\n\u003cli\u003eResidents and fellows in hematology\/oncology training programs preparing for board exams or subspecialty practice.\u003c\/li\u003e\n\u003cli\u003eOncology nurses and pharmacists involved in cancer care delivery and supportive therapy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e📚 What You’ll Learn\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eLatest clinical trial data and FDA approvals in oncology and hematology.\u003c\/li\u003e\n\u003cli\u003eUpdates in immunotherapy, targeted therapy, and cellular therapies (CAR‑T, bispecifics, checkpoint inhibitors).\u003c\/li\u003e\n\u003cli\u003eBest practices in supportive care: symptom management, survivorship, and toxicity mitigation.\u003c\/li\u003e\n\u003cli\u003eMultidisciplinary approaches to cancer care, integrating surgery, radiation, and systemic therapy.\u003c\/li\u003e\n\u003cli\u003eCase‑based discussions highlighting diagnostic and therapeutic challenges.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cstrong\u003e Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e7 a.m. Registration, Breakfast \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e8 a.m. Welcome \u0026amp; Educational Overview\u003c\/li\u003e\n\u003cli\u003e8:10 a.m. Advances in Thoracic Surgical Techniques Monterey – Stephen Swisher, MD (MD Anderson) San Diego – Mark Onaitis, MD (UCSD) Newport Beach – Stephen Swisher, MD (MD Anderson)\u003c\/li\u003e\n\u003cli\u003e8:40 a.m. Radiation Use in Primary Lung Cancer and Oligometastatic Disease Monterey – Shane Mesko, MD (Scripps) San Diego – Shane Mesko, MD (Scripps) Newport Beach – Shane Mesko, MD (Scripps)\u003c\/li\u003e\n\u003cli\u003e9:10 a.m. New Systemic Therapies for Non-small Cell Lung Cancer Monterey – Jacob New, MD (Scripps) San Diego – Aditya Sarvaria, MD (Scripps) Newport Beach – Aditya Sarvaria, MD (Scripps)\u003c\/li\u003e\n\u003cli\u003e9:40 a.m. CASE PRESENTATIONS: Lung Cancer\u003c\/li\u003e\n\u003cli\u003e10:10 a.m. Break \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e10:30 a.m. Advancing Surgical Techniques for Pancreatic Cancer Monterey – Monica Dua, MD (Stanford) San Diego – Jared Forrester, MD (Hoag) Newport Beach – Jared Forrester, MD (Hoag)\u003c\/li\u003e\n\u003cli\u003e11 a.m. Changes in Colorectal Cancer Multidisciplinary Treatments Monterey – Tyler Johnson, MD (Stanford) San Diego – Shane Mesko, MD (Scripps) Newport Beach – Shane Mesko, MD (Scripps)\u003c\/li\u003e\n\u003cli\u003e11:30 a.m. Systemic Treatments for Pancreatic and Colorectal Cancer Monterey – Tyler Johnson, MD (Stanford) San Diego – Darren Sigal, MD (Scripps) Newport Beach – Darren Sigal, MD (Scripps)\u003c\/li\u003e\n\u003cli\u003eNoon CASE PRESENTATIONS: Pancreatic and Colorectal Cancer\u003c\/li\u003e\n\u003cli\u003e12:30 p.m. Lunch\u003c\/li\u003e\n\u003cli\u003e1:30 p.m. Advances in Breast Surgery Monterey – Frederick Dirbas, MD (Stanford) San Diego – Jennifer Baker, MD (UCLA) Newport Beach – Kelly Hunt, MD (MD Anderson)\u003c\/li\u003e\n\u003cli\u003e2 p.m. Evolving Changes in Radiation Use for Breast Cancer Monterey – Thomas Buchholz, MD (Scripps) San Diego – Thomas Buchholz, MD (Scripps) Newport Beach – Thomas Buchholz, MD (Scripps)\u003c\/li\u003e\n\u003cli\u003e2:30 p.m. Treatments for ER+ Breast Cancer Monterey – Vicente Valero, MD (MD Anderson) San Diego – Farah Nasraty, MD (Scripps) Newport Beach – Aditya Bardia, MD (UCLA)\u003c\/li\u003e\n\u003cli\u003e3 p.m. Break \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e3:15 p.m. Treatments for HER2+ Breast Cancer Monterey – Vicente Valero, MD (MD Anderson) San Diego – Farah Nasraty, MD (Scripps) Newport Beach – Aditya Bardia, MD (UCLA)\u003c\/li\u003e\n\u003cli\u003e3:45 p.m. CASE PRESENTATIONS: Breast Cancer\u003c\/li\u003e\n\u003cli\u003e4:15 p.m. Adjourn Topics, times and speakers are subject to change\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663483556169,"sku":"MED-AMB05271","price":40.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Scripps-MD-Anderson-Cancer-Center-Oncology-Update-2025.webp?v=1781875434"},{"product_id":"memorial-sloan-kettering-cancer-center-state-of-the-art","title":"Memorial Sloan Kettering Cancer Center State-of-the-Art in Benign Hematology, Hemostasis, and Thrombosis 2025","description":"\u003cdiv class=\"prod-edition\"\u003e\n\u003ch3 class=\"product_title entry-title\"\u003eMemorial Sloan Kettering Cancer Center State-of-the-Art in Benign Hematology, Hemostasis, and Thrombosis 2025\u003c\/h3\u003e\n\u003cstrong\u003e+ Include: 11 videos + 12 pdfs, size: 6.4 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Target Audience: general medicine, hematology\/oncology, fellows, hospitalists, nocturnists, emergency medicine providers\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003eDate \u0026amp; Location Sunday, October 26, 2025, 9:00 AM – 5:30 PM, Zuckerman Research Center, 417 East 68th Street, New York, NY\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cem\u003eSpecialties\u003c\/em\u003e – Emergency Medicine, Hematology, Hematopathology, Hospitalist, Immunotherapy, Internal Medicine, Interventional Radiology, Leukemia, Nurse Practitioner, Oncology and Hematology, Physician Assistant, Pulmonary Medicine, Transfusion Medicine\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eOverview\u003c\/strong\u003e\u003c\/div\u003e\n\u003cbr\u003eThis one-day symposium will provide a state-of-the-art update in benign hematology, with a particular focus on emerging therapeutic strategies. The program will feature in-depth presentations by expert faculty, with dedicated time for interactive discussion and Q\u0026amp;A.\u003cbr\u003e\u003cbr\u003eNow in its 10th year, the 2025 program will focus on:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eComplex management scenarios in hemostasis and thrombosis,\u003c\/strong\u003e including stroke in cancer, cardiac thrombosis, and thrombotic risk in acute lymphoblastic leukemia (ALL)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdvances in management of hemolytic anemias, \u003c\/strong\u003ewith a focus on the therapeutic management of hereditary anemia, paroxysmal nocturnal hemoglobinuria (PNH), cold agglutinin disease, and other complement-mediated hemolytic disorders\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eHematologic complications related to cellular therapies and immunotherapies\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNovel treatment approaches,\u003c\/strong\u003e including factor XI inhibitors and anticomplement agents, and the unique challenges associated with their use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003eThe\u003cstrong\u003e target audience\u003c\/strong\u003e for this symposium includes general medicine, hematology\/oncology, fellows, hospitalists, nocturnists, emergency medicine providers, advanced practice providers and other healthcare professionals who manage and treat thrombotic and bleeding disorders. Please note that this symposium will be offered \u003cstrong\u003eexclusively in person\u003c\/strong\u003e; a virtual attendance option will not be available.\u003cbr\u003e\u003cbr\u003eFollowing the symposium, registrants will receive \u003cstrong\u003eaccess to an online syllabus\u003c\/strong\u003e featuring select PDF slides from faculty presentations and recorded session videos.\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eObjectives\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003eAt the conclusion of this symposium, attendees will be able to:\u003c\/div\u003e\n\u003col\u003e\n\u003cli\u003eDiscuss current updates in the management of challenging benign hematologic conditions, with a focus on emerging therapeutics\u003c\/li\u003e\n\u003cli\u003eAnalyze current data and discuss emerging FXI inhibitors\u003c\/li\u003e\n\u003cli\u003eDescribe anticomplement therapies\u003c\/li\u003e\n\u003cli\u003eRecognize the challenges in diagnosis and management of hematologic complications of immunotherapy\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003ch3 class=\"boxAgendaTitle\"\u003eSunday, October 26, 2025\u003c\/h3\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"12u\"\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eEmerging Data on Factor XI Inhibitors\u003c\/strong\u003e\u003cbr\u003e9:00AM – 9:30AM\u003cbr\u003eJeffrey Zwicker, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eCryptogenic Stroke and Cancer\u003c\/strong\u003e\u003cbr\u003e9:30AM – 10:00AM\u003cbr\u003eBabak Navi, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eBenefits of Extended Post-op Thromboprophylaxis in the Era of Robotic Surgery\u003c\/strong\u003e\u003cbr\u003e11:00AM – 11:30AM\u003cbr\u003eMarc Carrier, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eThrombotic Risk in Acute Lymphoblastic Leukemia\u003c\/strong\u003e\u003cbr\u003e11:30AM – 12:00PM\u003cbr\u003eAvi Leader, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eInherited Hemolytic Anemias: Scientific Advances in Therapeutics\u003c\/strong\u003e\u003cbr\u003e1:30PM – 2:00PM\u003cbr\u003eMohandas Narla, DSc\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eAnticomplement Therapy for Paroxysmal Nocturnal Hemoglobinuria\u003c\/strong\u003e\u003cbr\u003e2:00PM – 2:30PM\u003cbr\u003edavid araten, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eManagement of Cold Agglutinin Disease\u003c\/strong\u003e\u003cbr\u003e2:30PM – 3:00PM\u003cbr\u003eRekha Parameswaran, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eHLH-like Toxicities Secondary to Cancer Immunotherapy\u003c\/strong\u003e\u003cbr\u003e3:30PM – 4:00PM\u003cbr\u003eWilliam Johnson, DO\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eThrombosis Related to Immune Therapy\u003c\/strong\u003e\u003cbr\u003e4:00PM – 4:30PM\u003cbr\u003eJodi Mones, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eUpdates in Immune Thrombocytopenia\u003c\/strong\u003e\u003cbr\u003e4:30PM – 5:00PM\u003cbr\u003eCy R Wilkins, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eTransplant-Associated Thrombotic Microangiopathy\u003c\/strong\u003e\u003cbr\u003e5:00PM – 5:30PM\u003cbr\u003eMohammad Alhomoud, MBBS\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663483621705,"sku":"MED-AMB05250","price":40.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Memorial-Sloan-Kettering-Cancer-Center-State-of-the-Art-in-Benign-Hematology-Hemostasis-and-Thrombosis-2025.jpg?v=1781875434"},{"product_id":"mskcc-msk-department-of-pathology-and-laboratory-medicine-alumni-meeting-2025","title":"MSKCC MSK Department of Pathology and Laboratory Medicine Alumni Meeting 2025","description":"\u003cdiv class=\"grid-x grid-margin-x\"\u003e\n\u003cdiv class=\"cell initial-12 medium-8\"\u003e\n\u003cdiv class=\"pnllearningActivityInformationClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnllearningActivityInformation_0\"\u003e\n\u003cdiv class=\"pnlLearningActivityInformationDescriptionClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnlLearningActivityInformationDescription_0\"\u003e\n\u003cdiv class=\"pnllearningActivityInformationClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnllearningActivityInformation_0\"\u003e\n\u003cdiv class=\"pnlLearningActivityInformationDescriptionClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnlLearningActivityInformationDescription_0\"\u003e\n\u003cdiv class=\"prod-edition\"\u003e\n\u003cdiv class=\"field field--name-field-heading field--type-heading field--label-hidden field__item\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003cdiv class=\"elementor-element elementor-element-bbb44b8 elementor-widget elementor-widget-heading\" data-element_type=\"widget\" data-id=\"bbb44b8\" data-widget_type=\"heading.default\"\u003e\n\u003cdiv class=\"bundle--paragraph_component paragraph paragraph--type--paragraph-component paragraph--view-mode--default\"\u003e\n\u003cdiv class=\"elementor-element elementor-element-371ff86 elementor-widget elementor-widget-heading\" data-element_type=\"widget\" data-id=\"371ff86\" data-widget_type=\"heading.default\"\u003e\n\u003ch1 class=\"product-title product_title entry-title\"\u003eMSKCC MSK Department of Pathology and Laboratory Medicine Alumni Meeting 2025\u003c\/h1\u003e\n\u003cstrong\u003e+ Include: 7 videos + 2 pdfs, size: 3.63 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Target Audience: pathologists, laboratory medicine specialists, trainees\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003eDate \u0026amp; Location Friday, October 24, 2025, 1:00 PM – 5:00 PM, Zuckerman Research Center, 417 East 68th Street, New York, NY\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cem\u003eSpecialties\u003c\/em\u003e – Laboratory Medicine, Pathology\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eOverview\u003c\/strong\u003e\u003c\/div\u003e\n\u003cbr\u003eIn its 49th year, MSK’s \u003cstrong\u003eDepartment of Pathology and Laboratory Medicine Alumni Meeting\u003c\/strong\u003e will feature engaging case presentations designed to foster meaningful discussions on the identification and diagnosis of disease. Attendees will also gain deeper biological insights into rare cancer types. This year’s meeting will be a \u003cstrong\u003eone-day hybrid event\u003c\/strong\u003e, with the option to attend either in person or virtually.\u003cbr\u003e\u003cbr\u003eThe program will also include the presentation of the \u003cstrong\u003eFred W. Stewart Award\u003c\/strong\u003e\u003cstrong\u003e \u003c\/strong\u003eof Memorial Sloan Kettering Cancer Center. This annual award honors a pathologist whose contributions have significantly advanced our understanding of human cancer, with particular emphasis on clinical impact in diagnosis and patient care. The award reflects the traditions and values brought to the Department of Pathology by Dr. Stewart, who served first as an associate of Dr. James Ewing and later as Chairman of the Department for more than 30 years.\u003cbr\u003e\u003cbr\u003eThis year’s award recipient is \u003cstrong\u003eDr. Esther Oliva\u003c\/strong\u003e, member of the Department of Pathology, Director of the Gynecologic Service at Massachusetts General Hospital, and Professor at Harvard Medical School. Dr. Oliva was born in Barcelona, Catalonia (Spain), and trained under three of the world’s most renowned gynecologic pathologists: Dr. Robert E. Scully, Dr. Robert H. Young, and Dr. Jaime Prat. She completed her training in anatomic pathology at Hospital de la Santa Creu i Sant Pau (Barcelona) and Massachusetts General Hospital. Her passion lies in teaching new generations of pathologists from around the world.\u003cbr\u003e\u003cbr\u003eHer research focuses on neoplastic diseases involving the female genital tract—with particular interest in mesenchymal tumors at the morphologic, translational, and molecular levels—as well as diseases of the genitourinary tract. She is a past president of the International Society of Gynecological Pathologists (ISGyP), during which the ISGyP Live program was implemented. Dr. Oliva is also a past member of the Standing Committee for the fifth series of the World Health Organization (WHO) and served as editor of the \u003cem\u003eFemale Genital Tract WHO 5th Series\u003c\/em\u003e. She serves on the editorial boards of \u003cem\u003eThe American Journal of Surgical Pathology\u003c\/em\u003e, \u003cem\u003eModern Pathology\u003c\/em\u003e, \u003cem\u003eInternational Journal of Gynecological Pathology\u003c\/em\u003e, \u003cem\u003eAdvances in Anatomic Pathology\u003c\/em\u003e, and \u003cem\u003eSeminars in Diagnostic Pathology\u003c\/em\u003e. Dr. Oliva is an active member of the United States and Canadian Academy of Pathology (USCAP), where she has served on the Abstract Review Board, Education Committee, and Council. She was the co-director of the Long Course on \u003cem\u003ePractical Topics in Uterine Pathology\u003c\/em\u003e, has taught five short courses, and has served as IAP Vice-Chair for North America.\u003cbr\u003e\u003cbr\u003eDr. Oliva is the editor of the most recent AFIP Fascicle on the \u003cem\u003eUterine Corpus\u003c\/em\u003e and co-editor of several widely used textbooks in gynecologic pathology, including \u003cem\u003eGynecologic Pathology\u003c\/em\u003e (Foundations in Diagnostic Pathology series) and \u003cem\u003eDiagnostic Pathology: Gynecologic\u003c\/em\u003e (Amirsys).\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eObjectives\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003eAt the conclusion of this program, attendees will be able to:\u003c\/div\u003e\n\u003col\u003e\n\u003cli\u003eIdentify pathological features of various cancer types\u003c\/li\u003e\n\u003cli\u003eDescribe ancillary techniques and markers which aid in diagnoses\u003c\/li\u003e\n\u003cli\u003eDiscuss differential diagnoses and pertinent scientific literature\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003ch3 class=\"boxAgendaTitle\"\u003eFriday, October 24, 2025\u003c\/h3\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"12u\"\u003e\n\u003cdiv class=\"boxAgendaTitle\"\u003e\n\u003cdiv\u003eHandouts\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eCase Histories\u003c\/strong\u003e\u003cbr\u003e1:00PM – 1:10PM\u003cbr\u003eHong Zhang, MD (Moderator)\u003cbr\u003eFresia Pareja, MD, PhD (Moderator)\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"12u\"\u003e\n\u003cdiv class=\"boxAgendaTitle\"\u003e\n\u003cdiv\u003eGeneral Session – Videos only\u003c\/div\u003e\n\u003cbr\u003eOnly the presentations from faculty who have given their consent to share will be available on the syllabus.\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eCASE I\u003c\/strong\u003e\u003cbr\u003e1:10PM – 1:30PM\u003cbr\u003eAmir Momeni-Boroujeni, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eCASE II\u003c\/strong\u003e\u003cbr\u003e1:30PM – 1:50PM\u003cbr\u003eJoyce Chen, MD, PhD, MS\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eCASE III\u003c\/strong\u003e\u003cbr\u003e1:50PM – 2:10PM\u003cbr\u003eMaria G Kuba, MD\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eCASE IV\u003c\/strong\u003e\u003cbr\u003e2:10PM – 2:30PM\u003cbr\u003eSarah Chiang, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eCASE V\u003c\/strong\u003e\u003cbr\u003e2:30PM – 2:50PM\u003cbr\u003eM. Herman Chui, MD, FRCPC\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eCASE VI\u003c\/strong\u003e\u003cbr\u003e2:50PM – 3:10PM\u003cbr\u003eJune L Chan, PhD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eFrom Barcelona to Boston: The History of the Two Great Hospitals That Shaped My Professional Career\u003c\/strong\u003e\u003cbr\u003e4:00PM – 5:00PM\u003cbr\u003eEsther Oliva, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663483654473,"sku":"MED-AMB05218","price":25.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/MSKCC-MSK-Department-of-Pathology-and-Laboratory-Medicine-Alumni-Meeting-2025.jpg?v=1781875434"},{"product_id":"icahn-school-of-medicine-myeloid-malignancy-workshop-2025","title":"Icahn School of Medicine Myeloid Malignancy Workshop 2025","description":"\u003cdiv class=\"grid-x grid-margin-x\"\u003e\r\n\u003cdiv class=\"cell initial-12 medium-8\"\u003e\r\n\u003ch1 class=\"product_title entry-title\"\u003eIcahn School of Medicine Myeloid Malignancy Workshop 2025\u003c\/h1\u003e\r\n\u003cstrong\u003e+ Include: 10 videos + 1 pdf, size: 3.48 GB\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003e+ Target Audience: hematologists, oncologists\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003e+ Information:\u003c\/strong\u003e\r\n\u003cdiv class=\"activitysectionbold\"\u003eDate \u0026amp; Location Friday, March 21, 2025, 7:00 AM – 6:00 PM, Leon \u0026amp; Norma Hess Center for Science and Medicine, Davis Auditorium, 1470 Madison Avenue, New York, NY\u003c\/div\u003e\r\n\u003cdiv class=\"activitysectionbold\"\u003eTarget Audience \u003cem\u003eSpecialties\u003c\/em\u003e – Academic\/Research, Genomic Medicine, Geriatric Medicine, Hematology, Internal Medicine, Multiple Specialties, Nurse Practitioner, Nursing, Oncology, Pathology, Pharmacist, Physician Assistant\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eCourse Overview\u003c\/strong\u003e\u003c\/div\u003e\r\nThis workshop will include speakers with international recognition for excellence in science and clinical care of myeloid malignancies. Given the relative rarity of each disease, rapid pace of scientific discovery over the last several years, recent approval of novel agents, and the multitude of investigational agents in late-stage clinical development it is imperative to provide cutting edge updates in a focused manner. The target audience for this CME-accredited event will include clinical and laboratory-based physicians, trainees, laboratory investigators, pharmacists, nurses, nurse practitioners, physician assistants, and patients. The event would take place in a lecture hall on the campus of Mount Sinai. The talks will be 30 minutes in duration and followed by 10-minute question and answer sessions. The event will be moderated by John Mascarenhas, Marina Kremyanskaya and Ruben Mesa and the audience will be encouraged to participate in Q\u0026amp;A sessions. Additionally, there will be audience response system (ARS) questions before and after to gauge impact on learning.\r\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eObjectives\u003c\/strong\u003e\u003c\/div\u003e\r\n\u003col\u003e\r\n \t\u003cli\u003eUnderstand modern laboratory tools for exploring myeloid malignancy pathway for therapeutic targeting\u003c\/li\u003e\r\n \t\u003cli\u003eRecognize the appropriate evidence-based therapies for patients with myeloid leukemia\u003c\/li\u003e\r\n \t\u003cli\u003eUnderstand complex cellular mechanisms driving thrombosis in myeloproliferative neoplasms\u003c\/li\u003e\r\n \t\u003cli\u003eIdentify patient specific approaches and therapeutic options for patients with myelodysplastic syndromes\u003c\/li\u003e\r\n \t\u003cli\u003eDiscuss the emerging results of laboratory and clinical studies providing insights into biology and potential interventions in CHIP\/CCUS\u003c\/li\u003e\r\n \t\u003cli\u003eIdentify treatment goals for systemic mastocytosis that incorporate next generation kit inhibitors.\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\nThe Icahn School of Medicine’s Myeloid Malignancy Workshop 2025 is best for hematologists, oncologists, clinician-scientists, fellows, and researchers focused on myeloid cancers who want cutting-edge updates on diagnostics, therapeutics, and clinical trials.\r\n\u003ch3\u003e\n\u003cimg class=\"emoji\" role=\"img\" draggable=\"false\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/17.0.2\/svg\/1f469-200d-2695-fe0f.svg\" alt=\"👩‍⚕️\"\u003e Who Should Attend\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eHematologists and oncologists treating patients with AML, MDS, MPNs, and other myeloid malignancies\u003c\/li\u003e\r\n \t\u003cli\u003eFellows and residents specializing in hematology-oncology or internal medicine\u003c\/li\u003e\r\n \t\u003cli\u003eClinical researchers and translational scientists working on novel therapies and molecular targets\u003c\/li\u003e\r\n \t\u003cli\u003ePharmaceutical professionals involved in drug development for hematologic cancers\u003c\/li\u003e\r\n \t\u003cli\u003eAdvanced practice providers and oncology nurses supporting myeloid cancer care\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003e\n\u003cimg class=\"emoji\" role=\"img\" draggable=\"false\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/17.0.2\/svg\/1f4da.svg\" alt=\"📚\"\u003e What You’ll Learn\u003c\/h3\u003e\r\nThis workshop delivers focused, high-level insights into the rapidly evolving landscape of myeloid malignancies. Key highlights include:\r\n\u003cul\u003e\r\n \t\u003cli\u003eUpdates on newly approved agents and investigational therapies in late-stage development\u003c\/li\u003e\r\n \t\u003cli\u003eAdvances in molecular diagnostics, risk stratification, and personalized treatment\u003c\/li\u003e\r\n \t\u003cli\u003eMultidisciplinary perspectives from internationally recognized experts in clinical care and research\u003c\/li\u003e\r\n \t\u003cli\u003eDiscussions on clinical trial design, patient selection, and outcome optimization\u003c\/li\u003e\r\n \t\u003cli\u003eNetworking opportunities with leaders in academic and industry settings\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\r\n\u003ch3 class=\"boxAgendaTitle\"\u003eFriday, March 21, 2025\u003c\/h3\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"12u\"\u003e\r\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cul\u003e\r\n \t\u003cli class=\"10u\"\u003e7:45AM – 8:45AM Registration and Breakfast\u003c\/li\u003e\r\n \t\u003cli class=\"10u\"\u003e8:45AM – 9:00AM Introduction John Mascarenhas, MD Marina Kremyanskaya, MD Ruben A. Mesa, MD\u003c\/li\u003e\r\n \t\u003cli class=\"10u\"\u003e9:00AM – 9:40AM Recent Insights into Myeloid Malignancy and Clonal Hematopoiesis from Human iPSC Models Eirini Papapetrou, MD, PhD\u003c\/li\u003e\r\n \t\u003cli class=\"10u\"\u003e9:40AM – 10:20AM CHIP and CCUS Next Steps Kelly Bolton, MD\u003c\/li\u003e\r\n \t\u003cli class=\"10u\"\u003e10:20AM – 11:00AM State of the Art Management for Systemic Mastocytosis Jason Gotlib, MD, MS\u003c\/li\u003e\r\n \t\u003cli class=\"10u\"\u003e11:00AM – 11:30AM Break\u003c\/li\u003e\r\n \t\u003cli class=\"10u\"\u003e11:30AM – 12:10PM Modeling Thrombosis in MPN Joan D Beckman, MD\u003c\/li\u003e\r\n \t\u003cli class=\"10u\"\u003e12:10PM – 12:50PM Novel Approaches and Approvals in MDS Guillermo Garcia-Manero, MD\u003c\/li\u003e\r\n \t\u003cli class=\"10u\"\u003e12:50PM – 1:50PM Lunch\u003c\/li\u003e\r\n \t\u003cli class=\"10u\"\u003e1:50PM – 2:30PM Evolving Paradigm Shifts in CML Jorge Cortes, MD\u003c\/li\u003e\r\n \t\u003cli class=\"10u\"\u003e2:30PM – 3:10PM Deciphering Esoinophilia Amy Klion, MD\u003c\/li\u003e\r\n \t\u003cli class=\"10u\"\u003e3:10PM – 3:30PM Break\u003c\/li\u003e\r\n \t\u003cli class=\"10u\"\u003e3:30PM – 4:10PM Future Directions in AML Therapy Naval Daver, MD\u003c\/li\u003e\r\n \t\u003cli class=\"10u\"\u003e4:10PM – 4:50PM Insights from the Hematopathologist Daniel A. Arber, MD\u003c\/li\u003e\r\n \t\u003cli class=\"10u\"\u003e4:50PM – 5:15PM Awards Presentation and Closing Remarks John Mascarenhas, MD Marina Kremyanskaya, MD Ruben A. Mesa, MD\u003c\/li\u003e\r\n \t\u003cli class=\"10u\"\u003e5:15PM – 5:17PM Adjourn\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663494402377,"sku":"MED-AMB05176","price":20.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Icahn-School-of-Medicine-Myeloid-Malignancy-Workshop-2025_c563c19a-ed1e-4076-9712-f8381b6189a9.jpg?v=1781875435"},{"product_id":"scripps-clinical-hematology-and-oncology-2025","title":"Scripps Clinical Hematology and Oncology 2025","description":"\u003ch1 class=\"product_title entry-title\"\u003eScripps Clinical Hematology and Oncology 2025\u003c\/h1\u003e\n\u003cstrong\u003e+ Include: 41 videos + 1 pdf, size: 22.73 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Target Audience: hematologists, oncologists, internists, advanced practice providers, and trainees\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Information:\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eClinical Hematology \u0026amp; Oncology Presented by Scripps Cancer Center\u003cbr\u003e\u003cbr\u003eFEBRUARY 15-17, 2025 Hyatt Regency La Jolla at Aventine • San Diego, CA\u003cbr\u003e\u003cbr\u003eThe Scripps Cancer Center’s Clinical Hematology and Oncology conference is designed for hematologists, oncologists, surgeons, radiation oncologists, internists, and others desiring an update in these specialty areas. The primary objective of this course is to bring together clinicians and leading experts in diverse areas of hematology and oncology, affording them an intimate environment in which to discuss new clinical developments and significant advances. Our annual program is a nationally accredited continuing medical education conference and is one of the largest annual hematology\/oncology meeting held in the West, among others such as ASH, ASCO and the San Antonio Breast Meeting. This conference is one of the few that combines topics in both hematology and oncology.\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eEducational Objectives\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eAfter attending this live activity, participants should be able to:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eDescribe the clinical and molecular facets of pathogenesis, diagnostic approaches, and therapeutic modalities available for various hematologic disorders.\u003c\/li\u003e\n\u003cli\u003eSelect and apply the changing approaches to hematologic malignancies, particularly as they relate to evidence-based standards of care, including innovations in diagnosis and treatment.\u003c\/li\u003e\n\u003cli\u003eChoose new therapeutic options for the treatment of several common malignancies, understanding appropriate indications and contraindications to these therapeutic approaches.\u003c\/li\u003e\n\u003cli\u003eIntegrate evolving approaches to solid tumors and breast cancer from both a diagnostic, prognostic, and therapeutic perspective.\u003c\/li\u003e\n\u003cli\u003eApply practical expertise gained from the clinical situations discussed in the panel sessions with an emphasis on data-based approaches to patients with common, but serious hematology oncology conditions.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003eThe Scripps \u003cem\u003eClinical Hematology and Oncology Conference 2025\u003c\/em\u003e is best for hematologists, oncologists, internists, advanced practice providers, and trainees who want CME‑accredited, expert‑led updates on the latest therapies, diagnostics, and multidisciplinary management strategies in cancer and blood disorders.\u003cbr\u003e\u003ch3\u003e\n\u003cimg alt=\"👩‍⚕️\" class=\"emoji\" draggable=\"false\" role=\"img\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/1f469-200d-2695-fe0f.svg?v=1770211927\"\u003e Who Should Attend\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eMedical oncologists and hematologists managing patients with solid tumors, leukemias, lymphomas, and other blood disorders.\u003c\/li\u003e\n\u003cli\u003eInternal medicine physicians and subspecialists who co‑manage cancer patients or encounter hematologic issues in practice.\u003c\/li\u003e\n\u003cli\u003eAdvanced practice providers (NPs, PAs, CNSs) working in oncology and hematology clinics.\u003c\/li\u003e\n\u003cli\u003eResidents and fellows in hematology\/oncology training programs preparing for board exams or subspecialty practice.\u003c\/li\u003e\n\u003cli\u003eOncology nurses and pharmacists involved in cancer care delivery and supportive therapy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\n\u003cimg alt=\"📚\" class=\"emoji\" draggable=\"false\" role=\"img\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/1f4da.svg?v=1770211931\"\u003e What You’ll Learn\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eLatest clinical trial data and FDA approvals in hematology and oncology.\u003c\/li\u003e\n\u003cli\u003eUpdates in immunotherapy, targeted therapy, and cellular therapies (CAR‑T, bispecifics).\u003c\/li\u003e\n\u003cli\u003eBest practices in supportive care: symptom management, survivorship, and toxicity mitigation.\u003c\/li\u003e\n\u003cli\u003eMultidisciplinary approaches to cancer care, integrating surgery, radiation, and systemic therapy.\u003c\/li\u003e\n\u003cli\u003eCase‑based discussions highlighting diagnostic and therapeutic challenges.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eSaturday, February 15, 2025\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e7 a.m. Registration, Breakfast \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e7 a.m. Non-CME Breakfast Symposium Hosted by Pfizer\u003c\/li\u003e\n\u003cli\u003e7:55 a.m. Welcome \u0026amp; Educational Overview\u003c\/li\u003e\n\u003cli\u003e8 a.m. Peri-operative Thrombocytopenia Ted Warkentin, MD\u003c\/li\u003e\n\u003cli\u003e8:30 a.m. Hormonal Therapy and Thrombosis Risk Damon Houghton, MD\u003c\/li\u003e\n\u003cli\u003e9 a.m. Barely Abnormal CBCs Alice Ma, MD\u003c\/li\u003e\n\u003cli\u003e9:30 a.m. Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003e10 a.m. Break \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e10:15 a.m. Antiphospholipid Syndrome: 2024 Update Stephan Moll, MD\u003c\/li\u003e\n\u003cli\u003e10:45 a.m. Hypereosinophilic Syndrome Jason Gotlib, MD\u003c\/li\u003e\n\u003cli\u003e11:15 a.m. Investigating Bleeding of an Obscure Cause Menaka Pai, MD\u003c\/li\u003e\n\u003cli\u003e11:45 a.m. Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003eNoon Lunch Noon Non-CME Lunch Symposium Hosted by Agios Pharmaceuticals Noon Non-CME Lunch Symposium Hosted by AstraZeneca\u003c\/li\u003e\n\u003cli\u003e1 p.m. What’s New in AML TBD\u003c\/li\u003e\n\u003cli\u003e1:30 p.m. Should Patients Still Undergo BMT for Myeloma? Morie Gertz, MD\u003c\/li\u003e\n\u003cli\u003e2 p.m. Evolving Therapeutic Approaches in Patients with Low-risk MDS Aref Al-Kali, MD\u003c\/li\u003e\n\u003cli\u003e2:30 p.m. Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003e2:45 p.m. Break \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e3:15 p.m. Clinical Updates in B-ALL Wendy Stock, MD\u003c\/li\u003e\n\u003cli\u003e3:45 p.m. Refractory Diffuse Large Cell Lymphoma Stephen Schuster, MD\u003c\/li\u003e\n\u003cli\u003e4:15 p.m. HLH and HLH-like Inflammatory Syndromes TBD\u003c\/li\u003e\n\u003cli\u003e4:45 p.m. Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003eCONCURRENT BREAKOUT SESSIONS 5:15 p.m.\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eBreakout #1: Interesting Cases in Thrombosis Stephan Moll, MD\u003c\/li\u003e\n\u003cli\u003eBreakout #2: Interesting Cases in Thrombocytopenia Ted Warkentin, MD\u003c\/li\u003e\n\u003cli\u003eBreakout #3: Interesting Cases in Bleeding Alice Ma, MD\u003c\/li\u003e\n\u003cli\u003eBreakout #4: Interesting Cases in Plasma Cell Dyscrasias Morie Gertz, MD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e6:15 p.m. Adjourn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cstrong\u003eSunday, February 16, 2025\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e7 a.m. Breakfast \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e7 a.m. Non-CME Breakfast Symposium Hosted by Pfizer\u003c\/li\u003e\n\u003cli\u003e7:55 a.m. Welcome \u0026amp; Announcements\u003c\/li\u003e\n\u003cli\u003e8 a.m. Ultra Low Her2 Breast Cancer: Pushing the Boundary in IHC 0 and Treatment Implications TBD\u003c\/li\u003e\n\u003cli\u003e8:30 a.m. Changing Landscape of Sequencing in HR Positive, Her2 Negative Metastatic Breast Cancer Aditya Bardia, MD\u003c\/li\u003e\n\u003cli\u003e9 a.m. Sequencing Therapies in Early Triple Negative Breast Cancer Laura Huppert, MD\u003c\/li\u003e\n\u003cli\u003e9:30 a.m. Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003e10 a.m. Break \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e10:30 a.m. Neoadjuvant and Adjuvant Therapy for Melanoma TBD\u003c\/li\u003e\n\u003cli\u003e11 a.m. Management of Variant Histology Renal Cell Carcinoma Sumanta Pal, MD\u003c\/li\u003e\n\u003cli\u003e11:30 a.m. Targeted Therapies in Central Nervous System Metastasis TBD\u003c\/li\u003e\n\u003cli\u003eNoon Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003e12:30 p.m. Lunch\u003c\/li\u003e\n\u003cli\u003e12:30 p.m. Non-CME Lunch Symposium Hosted by Lilly\u003c\/li\u003e\n\u003cli\u003e1:30 p.m. Rectal Cancer—Making Sense of TNT, ctDNA, and Surgery: A Case-based, Multidisciplinary Discussion Michael Overman, MD—Medical Oncology Brian Bednarski, MD—Rectal Surgery Eugene Koay, MD—Radiation Oncology\u003c\/li\u003e\n\u003cli\u003e3 p.m. Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003e3:30 p.m. Break \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e4 p.m. New Targeted Therapies for Gastroesophageal Cancer TBD\u003c\/li\u003e\n\u003cli\u003e4:30 p.m. Updates in Neuroendocrine Tumors Jonathan Strosberg, MD\u003c\/li\u003e\n\u003cli\u003e5 p.m. Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003e5:30 p.m. Adjourn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cstrong\u003eMonday, February 17, 2025\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e7 a.m. Breakfast \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e7:55 a.m. Welcome \u0026amp; Announcements\u003c\/li\u003e\n\u003cli\u003e8 a.m. Role of Immune Therapy in Advanced Endometrial Cancer Ramez Eskander, MD\u003c\/li\u003e\n\u003cli\u003e8:30 a.m. Updates in the Treatment of Metastatic Soft Tissue Sarcoma Mark Agulnik, MD\u003c\/li\u003e\n\u003cli\u003e9 a.m. Genomic Risk Stratification and High Sensitivity Imaging in Localized Prostate Cancer Tanya Barauskas Dorff, MD\u003c\/li\u003e\n\u003cli\u003e9:30 a.m. Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003e10 a.m. Break \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e10:30 a.m. Optimal Management of ALK Rearranged NSCLC Kamya Sankar, MD\u003c\/li\u003e\n\u003cli\u003e11 a.m. Evidence-Based Management of Hormone Deprivation Symptoms After Cancer TBD\u003c\/li\u003e\n\u003cli\u003e11:30 a.m. Management of Common Skin-related Side Effects of Cancer Treatment TBD\u003c\/li\u003e\n\u003cli\u003eNoon Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003e12:30 p.m. Final Adjournment Topics, times, and speakers are subject to change.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663494435145,"sku":"MED-AMB05152","price":70.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Scripps-Clinical-Hematology-and-Oncology-2025.webp?v=1781875435"},{"product_id":"pizzo-poplacks-principles-and-practice-of-pediatric-oncology-9th-edition","title":"Pizzo \u0026 Poplack’s Principles and Practice of Pediatric Oncology, 9th Edition (EPUB)","description":"\u003cdiv class=\"prod-edition\"\u003e\n\u003cdiv class=\"field field--name-field-heading field--type-heading field--label-hidden field__item\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\n\u003cdiv class=\"elementor-element elementor-element-bbb44b8 elementor-widget elementor-widget-heading\" data-element_type=\"widget\" data-id=\"bbb44b8\" data-widget_type=\"heading.default\"\u003e\n\u003cdiv class=\"bundle--paragraph_component paragraph paragraph--type--paragraph-component paragraph--view-mode--default\"\u003e\n\u003cbr\u003e\u003cbr\u003eby SUSAN M. BLANEY, LEE J. HELMAN, PETER C. ADAMSON\u003cbr\u003e\u003cspan class=\"a-text-bold\"\u003ePizzo and Poplack’s Principles and Practice of Pediatric Oncology, 9th Edition\u003c\/span\u003e remains the definitive, comprehensive reference in pediatric oncology. Under the expert editorial leadership of Drs. Susan M. Blaney, Peter C. Adamson, and Lee J. Helman, this edition builds on a legacy of excellence spanning decades. A world-renowned team of international, multidisciplinary experts delivers authoritative, up-to-date insights into the biology and genetics of childhood cancer, diagnostic techniques, and multimodal treatment approaches.\u003cbr\u003e\u003cbr\u003eThe Ninth Edition integrates the latest research breakthroughs, including advances in targeted therapies, immunotherapies, and precision medicine. It also expands its in-depth coverage of supportive care, symptom management, survivorship, and the long-term effects of therapy. This award-winning text continues to be the essential guide for pediatric oncologists, hematologists, researchers, and trainees dedicated to improving outcomes for children with cancer.\u003cbr\u003e\u003cul class=\"a-unordered-list a-vertical\"\u003e\n\u003cli\u003e\u003cspan class=\"a-list-item\"\u003eComprehensive Scope: Covers all aspects of pediatric cancer, from basic biology and genetics to diagnosis, treatment, and long-term survivorship.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan class=\"a-list-item\"\u003eCutting-Edge Updates: Reflects the latest clinical trial data and breakthroughs in targeted and immune-based therapies.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan class=\"a-list-item\"\u003ePrecision Medicine Focus: Highlights biomarker-driven approaches and personalized treatment strategies.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan class=\"a-list-item\"\u003eSupportive Care Expertise: Provides deep guidance on symptom management, palliative care, and psychosocial support for children and families.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan class=\"a-list-item\"\u003eTrusted Authority: Written and edited by leading experts, ensuring evidence-based, multidisciplinary perspectives.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663494467913,"sku":"MED-AMB05148","price":45.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/9781975222567.jpg?v=1781875435"},{"product_id":"devita-hellman-and-rosenbergs-cancer-principles-practice-of-oncology-cancer-principles-and-practice-of-oncology-12th-edition-original-pdf-from-publisher","title":"DeVita, Hellman, and Rosenberg’s Cancer: Principles \u0026 Practice of Oncology (Cancer Principles and Practice of Oncology), 12th Edition (Original PDF from Publisher)","description":"\u003cdiv class=\"prod-title\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv id=\"block-pagetitle\"\u003e\n\u003cdiv class=\"sonopl-product-description-container\"\u003e\n\u003cdiv class=\"sonopl-product-description\"\u003e\n\u003cdiv class=\"sonopl-product-description-intro\"\u003e\n\u003cdiv class=\"custom-single-product product type-product post-358556 status-publish first instock product_cat-hot-books product_cat-obstetrics-gynecology product_cat-radiology-nuclear-medicine product_cat-videos has-post-thumbnail sale downloadable virtual purchasable product-type-simple\" id=\"product-358556\"\u003e\n\u003cdiv class=\"afk-single-product-outer\"\u003e\n\u003cdiv class=\"akf-p-f-box d-flex f-wrap j-c-b\"\u003e\n\u003cdiv class=\"akf-right\"\u003e\n\u003cdiv class=\"woo-tab-container custom woo-tc-j\"\u003e\n\u003cdiv class=\"tabcontent active\" id=\"descriptionTab\"\u003e\n\u003cdiv class=\"prod-desc\"\u003e\n\u003cdiv class=\"sonopl-product-description-container\"\u003e\n\u003cdiv class=\"sonopl-product-description\"\u003e\n\u003cdiv class=\"sonopl-product-description-intro\"\u003e\n\u003cdiv class=\"akf-prod-title\"\u003e\n\u003cimg alt=\"\" class=\"aligncenter wp-image-260386 size-full entered lazyloaded\" data-lazy-src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/9781975184766-originalpdf.jpg?v=1770213908\" data-ll-status=\"loaded\" height=\"974\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/9781975184766-originalpdf.jpg?v=1770213908\" width=\"1335\"\u003e\u003cbr\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003eBy Vincent T. DeVita Jr. MD, Steven A. Rosenberg MD PhD, Theodore S. Lawrence MD PhD\u003cbr\u003eThe standard-setting text in oncology for 40 years, DeVita, Hellman and Rosenberg’s Cancer: Principles and Practice of Oncology, 12th Edition, provides authoritative guidance and strategies for managing every type of cancer by stage and presentation. Drs. Vincent T. DeVita, Jr., Theodore S. Lawrence, and Steven A. Rosenberg oversee an outstanding team of expert contributing authors who keep you up to date and fully informed in this fast-changing field. This award-winning reference is also continually updated on Health Library and VitalSource platforms for the life of the edition.\u003cbr\u003e\u003cul class=\"a-unordered-list a-vertical\"\u003e\n\u003cli\u003eIntegrates basic science into individual cancer chapters for more efficient reference\u003c\/li\u003e\n\u003cli\u003eFeatures quarterly updates that include late-breaking developments in oncology such as new drugs and clinical trials, as well as new case studies and interactive algorithms\u003c\/li\u003e\n\u003cli\u003eOffers balanced, multidisciplinary advice from a surgeon, a medical oncologist, and a radiation oncologist\u003c\/li\u003e\n\u003cli\u003eProvides updated content on immunotherapy and genetics throughout\u003c\/li\u003e\n\u003cli\u003eIncludes important related topics such as cancer screening and prevention, palliative care, supportive oncology, and quality of life issues\u003c\/li\u003e\n\u003cli\u003eNow available in a convenient single volume, or a seven-multivolume option for portability and ease of use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e \u003cbr\u003e\u003ch3\u003eProduct Details\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003ePublisher ‏ : ‎ LWW; Twelfth edition (January 7, 2023)\u003c\/li\u003e\n\u003cli\u003eLanguage ‏ : ‎ English\u003c\/li\u003e\n\u003cli\u003eHardcover ‏ : ‎ 2324 pages\u003c\/li\u003e\n\u003cli\u003eISBN-10 ‏ : ‎ 1975184742\u003c\/li\u003e\n\u003cli\u003eISBN-13 ‏ : ‎ 978-1975184742\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663494533449,"sku":"MED-AMB05111","price":70.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/DeVita-Hellman-and-Rosenbergs-Cancer-Principles-Practice-of-Oncology-Cancer-Principles-and-Practice-of-Oncology-12th-Edition-Original-PDF-from-Publisher.webp?v=1781875434"},{"product_id":"ash-2025-the-67th-annual-meeting-exposition","title":"ASH 2025: THE 67TH ANNUAL MEETING \u0026 EXPOSITION","description":"\u003cdiv class=\"prod-title\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv id=\"block-pagetitle\"\u003e\n\u003cdiv class=\"pnllearningActivityInformationClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnllearningActivityInformation_0\"\u003e\n\u003cdiv class=\"pnlLearningActivityInformationDescriptionClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnlLearningActivityInformationDescription_0\"\u003e\n\u003cdiv class=\"pnllearningActivityInformationClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnllearningActivityInformation_0\"\u003e\n\u003cdiv class=\"pnlLearningActivityInformationDescriptionClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnlLearningActivityInformationDescription_0\"\u003e\n\u003cdiv class=\"product-footer\"\u003e\n\u003cdiv class=\"container\"\u003e\n\u003cdiv class=\"woocommerce-tabs wc-tabs-wrapper container tabbed-content\"\u003e\n\u003cdiv\u003e\n\u003ch3\u003eASH 2025: THE 67TH ANNUAL MEETING \u0026amp; EXPOSITION\u003c\/h3\u003e\n\u003cstrong\u003e+ Include:  videos +  pdf, size:  GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Target Audience: hematologist-oncologists, pathologists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cp data-path-to-node=\"2\"\u003e\u003cstrong\u003eASH 2025: THE 67TH ANNUAL MEETING \u0026amp; EXPOSITION\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3 data-path-to-node=\"3\"\u003e\u003cb\u003e“Defining the Future of Blood: Gene Therapy, Immunotherapy \u0026amp; Beyond”\u003c\/b\u003e\u003c\/h3\u003e\n\u003cbr\u003eConference Dates: December 6 – 9, 2025  Location: New Orleans, Louisiana (Ernest N. Morial Convention Center) Academic Host: American Society of Hematology (ASH)\u003cbr\u003e\u003ch2 data-path-to-node=\"6\"\u003e\n\u003cimg alt=\"ℹ️\" class=\"emoji\" draggable=\"false\" role=\"img\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/2139.svg?v=1770212966\"\u003e General Information\u003c\/h2\u003e\n\u003cp data-path-to-node=\"7\"\u003eWelcome to the “Super Bowl” of Hematology. The \u003cb\u003eASH Annual Meeting\u003c\/b\u003e is the global benchmark where practice-changing data is released. If it happens in blood, it happens here.\u003c\/p\u003e\n\u003cp data-path-to-node=\"8\"\u003eThe 2025 edition in New Orleans marks a pivotal shift: we move from “experimental” gene editing to \u003cb\u003ecommercial reality\u003c\/b\u003e. This course is not just about the science; it is about the \u003cb\u003elogistics of cure\u003c\/b\u003e. From the latest CAR-T constructs for solid tumors to the real-world implementation of CRISPR for Sickle Cell Disease, this curriculum defines the standard of care for the next decade.\u003c\/p\u003e\n\u003cul data-path-to-node=\"9\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"9,0,0\"\u003e\u003cb\u003eFormat:\u003c\/b\u003e Scientific Plenary Sessions + Education Programs + Satellite Symposia.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"9,2,0\"\u003e\u003cb\u003eScope:\u003c\/b\u003e Malignant Hematology (70%) \/ Non-Malignant \u0026amp; Coagulation (30%).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-path-to-node=\"11\"\u003e\n\u003cimg alt=\"👥\" class=\"emoji\" draggable=\"false\" role=\"img\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/1f465.svg?v=1770212969\"\u003e Target Audience\u003c\/h2\u003e\n\u003cp data-path-to-node=\"12\"\u003eThis syllabus is the mandatory annual update for:\u003c\/p\u003e\n\u003col data-path-to-node=\"13\" start=\"1\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"13,0,0\"\u003e\u003cb\u003eHematologist-Oncologists:\u003c\/b\u003e Who need to decide between Bispecific Antibodies and CAR-T therapy for their relapsed Myeloma and Lymphoma patients.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"13,1,0\"\u003e\u003cb\u003ePathologists:\u003c\/b\u003e Integrating AI-driven diagnostics and next-gen sequencing (NGS) into daily reporting.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"13,2,0\"\u003e\u003cb\u003eTransplant Physicians:\u003c\/b\u003e Managing the toxicities of cellular therapies (CRS\/ICANS) in an outpatient setting.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"13,3,0\"\u003e\u003cb\u003eGeneral Practitioners\/Hospitalists:\u003c\/b\u003e Who need to recognize the “red flags” of hematologic emergencies and manage the long-term survivors of gene therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2 data-path-to-node=\"15\"\u003e\n\u003cimg alt=\"🎯\" class=\"emoji\" draggable=\"false\" role=\"img\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/1f3af.svg?v=1770212972\"\u003e Learning Objectives\u003c\/h2\u003e\n\u003cp data-path-to-node=\"16\"\u003eBy analyzing the 2025 Late-Breaking Abstracts, participants will be able to:\u003c\/p\u003e\n\u003col data-path-to-node=\"17\" start=\"1\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"17,0,0\"\u003e\u003cb\u003eRevolutionize Myeloma Care:\u003c\/b\u003e Apply the 2025 algorithms for \u003cb\u003eQuadruplet Therapy\u003c\/b\u003e in newly diagnosed Multiple Myeloma and sequence BCMA-targeted agents in relapse.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"17,1,0\"\u003e\u003cb\u003eImplement Gene Editing:\u003c\/b\u003e Navigate the referral and management pathways for \u003cb\u003eCasgevy (Exa-cel)\u003c\/b\u003e and \u003cb\u003eLyfgenia\u003c\/b\u003e in Sickle Cell Disease and Beta-Thalassemia.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"17,2,0\"\u003e\u003cb\u003eTarget AML Precision:\u003c\/b\u003e Utilize \u003cb\u003eMenin Inhibitors\u003c\/b\u003e for KMT2A-rearranged and NPM1-mutated acute myeloid leukemia.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"17,3,0\"\u003e\u003cb\u003eManage Hemophilia:\u003c\/b\u003e Transition patients from factor replacement to \u003cb\u003eGene Therapy\u003c\/b\u003e (Hemgenix\/Roctavian) and non-factor replacement therapies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2 data-path-to-node=\"19\"\u003e\n\u003cimg alt=\"📚\" class=\"emoji\" draggable=\"false\" role=\"img\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/1f4da.svg?v=1770211931\"\u003e Course Topics \u0026amp; Tracks (2025 Predictions)\u003c\/h2\u003e\n\u003cp data-path-to-node=\"20\"\u003e\u003ci\u003eThe curriculum focuses on the highest-yield clinical areas.\u003c\/i\u003e\u003c\/p\u003e\n\u003ch3 data-path-to-node=\"21\"\u003e\u003cb\u003eTOPIC 1: The Myeloma \u0026amp; Lymphoma Revolution\u003c\/b\u003e\u003c\/h3\u003e\n\u003cul data-path-to-node=\"22\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"22,0,0\"\u003e\u003cb\u003eBispecifics vs. CAR-T:\u003c\/b\u003e The “Great Debate.” When to use “off-the-shelf” antibodies (Teclistamab, Talquetamab) versus autologous cell therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"22,1,0\"\u003e\u003cb\u003eMCL \u0026amp; CLL:\u003c\/b\u003e Moving towards “Chemo-Free” combinations (BTK inhibitors + BCL2 inhibitors) as first-line standards.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"23\"\u003e\u003cb\u003eTOPIC 2: Leukemia \u0026amp; Myeloid Malignancies\u003c\/b\u003e\u003c\/h3\u003e\n\u003cul data-path-to-node=\"24\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"24,0,0\"\u003e\u003cb\u003eAML Updates:\u003c\/b\u003e The rise of “Triplet” therapies (HMA + Venetoclax + Novel Agent) for the unfit patient.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"24,1,0\"\u003e\u003cb\u003eMDS Classification:\u003c\/b\u003e Mastering the new WHO vs. ICC classifications—it’s not just “MDS” anymore; it’s molecularly defined.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"25\"\u003e\u003cb\u003eTOPIC 3: Non-Malignant Hematology (Red Cell \u0026amp; Coag)\u003c\/b\u003e\u003c\/h3\u003e\n\u003cul data-path-to-node=\"26\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"26,0,0\"\u003e\u003cb\u003eSickle Cell Cure:\u003c\/b\u003e Real-world data on the first cohort of patients treated with CRISPR gene editing—safety, off-target effects, and fertility preservation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"26,1,0\"\u003e\u003cb\u003eITP \u0026amp; TTP:\u003c\/b\u003e New agents targeting the complement system and FcRn inhibitors.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"27\"\u003e\u003cb\u003eTOPIC 4: Immuno-Oncology \u0026amp; Toxicity Management\u003c\/b\u003e\u003c\/h3\u003e\n\u003cul data-path-to-node=\"28\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"28,0,0\"\u003e\u003cb\u003eCRS \u0026amp; ICANS:\u003c\/b\u003e 2025 Protocols for managing Cytokine Release Syndrome and Neurotoxicity without admitting every patient to the ICU.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"28,1,0\"\u003e\u003cb\u003eInfection Prevention:\u003c\/b\u003e Prophylaxis strategies for the profoundly immunosuppressed patient on B-cell maturation antigen (BCMA) therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663494566217,"sku":"MED-AMB05121","price":150.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/ASH-2025-THE-67TH-ANNUAL-MEETING-EXPOSITION.png?v=1781875436"},{"product_id":"perez-brady-halperin-and-wazers-principles-and-practice-of-radiation-oncology-2-volume-set","title":"Perez, Brady, Halperin, and Wazer’s Principles and Practice of Radiation Oncology, 2 Volume Set, 8th edition (Converted PDF)","description":"\u003cdiv class=\"pnllearningActivityInformationClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnllearningActivityInformation_0\"\u003e\n\u003cdiv class=\"pnlLearningActivityInformationDescriptionClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnlLearningActivityInformationDescription_0\"\u003e\n\u003cdiv class=\"pnllearningActivityInformationClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnllearningActivityInformation_0\"\u003e\n\u003cdiv class=\"pnlLearningActivityInformationDescriptionClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnlLearningActivityInformationDescription_0\"\u003e\n\u003cdiv class=\"akf-prod-title\"\u003e\n\u003cstrong\u003eBy EDWARD C. HALPERIN MD MA, DAVID E. WAZER MD FASTRO, Brian C. Baumann MD, Rachel C. Blitzblau MD PhD, Natia Esiashvili MD\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eFor nearly 40 years, Perez and Brady's Principles and Practice of Radiation Oncology has been the authoritative ‘book-of-record’ for the field of radiation oncology. Covering both the biological and physical science aspects of this complex field as well as site-specific information on the integrated, multidisciplinary management of patients with cancer, Perez \u0026amp; Brady continues to be the most comprehensive reference available for radiation oncologists and radiation oncology residents. Under the editorial leadership of Drs. Edward C. Halperin, David E. Wazer, and expert associate editors Drs. Brian C. Baumann, Rachel C. Blitzblau, and Natia Esiashvili, the fully revised 8th Edition, now known as Perez, Brady, Halperin, and Wazer’s Principles and Practice of Radiation Oncology, is available as a two-volume hardcover edition: Volume 1 covers The Scientific, Technological, Economic, and Ethical Basis of Radiation Oncology, while Volume 2 covers The Clinical Practice of Radiation Oncology.\u003cbr\u003e\u003cul class=\"a-unordered-list a-vertical\"\u003e\n\u003cli\u003eOffers comprehensive coverage of the current state of knowledge of cancer biology; medical radiation physics; clinical radiation oncology; and radiation oncology economics, ethics, and public policy\u003c\/li\u003e\n\u003cli\u003eProvides a foundational understanding of the natural history of cancer, the physical and technological methods of radiation application, the effects of irradiation on normal tissues, and the most judicious ways in which radiation therapy can be employed in the treatment of patients with cancer, either as a single modality or as part of a multi-modality treatment program\u003c\/li\u003e\n\u003cli\u003eIncludes thorough clinical guidance on the management of each tumor type in site-specific chapters, including epidemiology, pathology, diagnostic work-up, prognostic factors, treatment techniques, applications of surgery, chemotherapy, immunotherapy and biological therapy, end results, and more\u003c\/li\u003e\n\u003cli\u003eContains new chapters on Artificial Intelligence and Data Science, as well as a chapter providing a historical overview of radiation oncology as a medical specialty, of particular interest to residents beginning training and medical students undertaking a radiation oncology clinical clerkship\u003c\/li\u003e\n\u003cli\u003eOffers an increased emphasis on new approaches and technologies, including palliative and supportive care and the role of radiation treatment in non-curative roles\u003c\/li\u003e\n\u003cli\u003eFeatures more than 1,200 full-color illustrations that highlight key concepts in tumor pathogenesis, diagnosis, and targeted radiation therapy\u003c\/li\u003e\n\u003cli\u003eContains a comprehensive and authoritative historical account of the field of radiation oncology\u003c\/li\u003e\n\u003cli\u003eIdeal for radiation oncologists, radiation oncology residents, radiation biologists, medical radiation physicists, oncologists, physicists-in-training, radiation dosimetrists, and nurses and physician assistants working in radiation oncology departments\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eProduct Details\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003ePublisher ‏ : ‎ LWW\u003c\/li\u003e\n\u003cli\u003ePublication date ‏ : ‎ September 6, 2025\u003c\/li\u003e\n\u003cli\u003eEdition ‏ : ‎ Eighth\u003c\/li\u003e\n\u003cli\u003eLanguage ‏ : ‎ English\u003c\/li\u003e\n\u003cli\u003eISBN-10 ‏ : ‎ 1975221265\u003c\/li\u003e\n\u003cli\u003eISBN-13 ‏ : ‎ 978-1975221263\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663494697289,"sku":"MED-AMB05045","price":50.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/978-1975221263-9781975221287.jpg?v=1781875436"},{"product_id":"atlas-of-gynecologic-pathology-a-pattern-based-approach-epub","title":"Atlas of Gynecologic Pathology: A Pattern-Based Approach (EPUB)","description":"\u003cdiv class=\"elementor-element elementor-element-371ff86 elementor-widget elementor-widget-heading\" data-element_type=\"widget\" data-id=\"371ff86\" data-widget_type=\"heading.default\"\u003e\n\u003cdiv class=\"elementor-widget-container\"\u003e\n\u003cdiv class=\"slice__heading\"\u003e\n\u003cdiv class=\"slice__title\"\u003e\n\u003cdiv class=\"woocommerce-tabs wc-tabs-wrapper container tabbed-content\"\u003e\n\u003cdiv class=\"tab-panels\"\u003e\n\u003cdiv aria-labelledby=\"tab-title-description\" class=\"woocommerce-Tabs-panel woocommerce-Tabs-panel--description panel entry-content active\" id=\"tab-description\" role=\"tabpanel\"\u003e\n\u003cdiv class=\"prod-format\"\u003e\n\u003cdiv class=\"column mcb-column mcb-item-s9v2grr2m one-second column_column\"\u003e\n\u003cdiv class=\"column_attr clearfix\"\u003e\n\u003ch1 class=\"product-title product_title entry-title\"\u003eAtlas of Gynecologic Pathology: A Pattern-Based Approach (EPUB)\u003c\/h1\u003e\n\u003cbr\u003eBy Tricia A. Numan MD\u003cbr\u003eClosely mirroring the daily sign-out process, Atlas of Gynecologic Pathology: A Pattern-Based Approach, by Dr. Tricia A. Numan (co-author of Diagnosis of Endometrial Biopsies and Curettings, A Practical Approach), is a highly illustrated, efficient guide to accurate diagnosis. This practical reference uses a proven, pattern-based approach to clearly explain how to interpret challenging cases by highlighting red flags in the clinical chart and locating hidden clues in the slides. Useful as a daily “scope-side guide,” it features numerous clinical and educational features that help you find pertinent information, reach a correct diagnosis, and assemble a thorough and streamlined pathology report.\u003cbr\u003e\u003cbr\u003eMore than 1,400 high-quality photomicrographs capture the subtle morphologic spectrum and if applicable, pertinent immunohistochemical staining patterns encountered in gynecologic pathology, including variations of tumor types, non-tumor pathology, artifacts, and normal histology. Each image is captioned with key diagnostic considerations and includes call-outs showing subtle features and diagnostic clues.\u003cbr\u003ePractical tools throughout the text include:\u003cbr\u003e\u003cbr\u003eTables that emphasize salient clinicopathologic features, management implications, and therapeutic options\u003cbr\u003eDiscussions of how and when to incorporate molecular tools\u003cbr\u003eChecklists for key elements of the diagnostic approach and sample notes for inclusion in pathology reports\u003cbr\u003eRelevant diagnostic algorithms\u003cbr\u003eBrief reviews of normal histology that provide contrast to succeeding patterns\u003cbr\u003e“Pearls and Pitfalls” and “Near Misses” sections with lessons from real life sign-out experience\u003cbr\u003e“Frequently Asked Questions” sections that discuss common diagnostic dilemmas\u003cbr\u003e“Sample Note” sections that offer a template of how to synthesize complicated or especially challenging topics\u003cbr\u003eComprehensive quiz provides experience with high-yield, board-style teaching topics\u003cbr\u003e\u003cbr\u003eEnrich Your Ebook Reading Experience\u003cbr\u003e\u003cbr\u003eRead directly on your preferred device(s),such as computer, tablet, or smartphone.\u003cbr\u003eEasily convert to audiobook,powering your content with natural language text-to-speech.\u003cbr\u003e\u003cbr\u003eProduct Details\u003cbr\u003e\u003cbr\u003ePublisher ‏ : ‎ LWW; 1st edition (July 21, 2023)\u003cbr\u003eLanguage ‏ : ‎ English\u003cbr\u003eHardcover ‏ : ‎ 746 pages\u003cbr\u003eISBN-10 ‏ : ‎ 1975124766\u003cbr\u003eISBN-13 ‏ : ‎ 978-1975124762\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663494795593,"sku":"MED-AMB05044","price":27.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Atlas-of-Gynecologic-Pathology-A-Pattern-Based-Approach-EPUB.webp?v=1781875436"},{"product_id":"george-washington-university-hematology-update-symposium-2025","title":"George Washington University Hematology Update Symposium 2025","description":"\u003cdiv class=\"elementor-element elementor-element-371ff86 elementor-widget elementor-widget-heading\" data-id=\"371ff86\" data-element_type=\"widget\" data-widget_type=\"heading.default\"\u003e\r\n\u003cdiv class=\"elementor-widget-container\"\u003e\r\n\u003cdiv class=\"akf-prod-title\"\u003e\r\n\u003ch1 class=\"product_title entry-title\"\u003eGeorge Washington University Hematology Update Symposium 2025\u003c\/h1\u003e\r\n\u003cstrong\u003e+ Include: 10 videos + 10 audios, size: 1.67 GB\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003e+ Target Audience: hematologists\/oncologists, hospitalists, internists\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003e+ Information:\u003c\/strong\u003e\r\n\u003cp data-start=\"68\" data-end=\"389\"\u003eA concentrated, practice-focused update covering both benign and malignant hematology. Case-based lectures translate the latest evidence and guidelines into clear diagnostic pathways, treatment algorithms, and toxicity management you can apply immediately in clinic, hospital, and infusion settings.\u003c\/p\u003e\r\n\u003cp data-start=\"391\" data-end=\"416\"\u003e\u003cstrong data-start=\"391\" data-end=\"414\"\u003eWhat You Will Learn\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"417\" data-end=\"1004\"\u003e\r\n \t\u003cli data-start=\"417\" data-end=\"499\"\u003e\r\n\u003cp data-start=\"419\" data-end=\"499\"\u003eStreamlined workups for anemia, cytopenias, coagulopathies, and thrombophilias\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli data-start=\"500\" data-end=\"590\"\u003e\r\n\u003cp data-start=\"502\" data-end=\"590\"\u003eEvidence-based VTE care: anticoagulant selection, duration, peri-procedural management\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli data-start=\"591\" data-end=\"668\"\u003e\r\n\u003cp data-start=\"593\" data-end=\"668\"\u003eCurrent standards and emerging options in leukemia, lymphoma, and myeloma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli data-start=\"669\" data-end=\"759\"\u003e\r\n\u003cp data-start=\"671\" data-end=\"759\"\u003eTransfusion medicine pearls: product selection, thresholds, reactions, and stewardship\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli data-start=\"760\" data-end=\"887\"\u003e\r\n\u003cp data-start=\"762\" data-end=\"887\"\u003eTargeted agents and immunotherapies (BTK\/BCL2 inhibitors, bispecifics, CAR-T): when to use and how to manage adverse events\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli data-start=\"888\" data-end=\"1004\"\u003e\r\n\u003cp data-start=\"890\" data-end=\"1004\"\u003eSupportive care essentials: infection prophylaxis, tumor lysis risk mitigation, survivorship, and quality measures\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"1006\" data-end=\"1025\"\u003e\u003cstrong data-start=\"1006\" data-end=\"1023\"\u003eEvent Details\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"1026\" data-end=\"1347\"\u003e\r\n \t\u003cli data-start=\"1026\" data-end=\"1119\"\u003e\r\n\u003cp data-start=\"1028\" data-end=\"1119\"\u003eFormat: Live, case-based lectures with board-style Q\u0026amp;A and practical take-home checklists\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli data-start=\"1120\" data-end=\"1268\"\u003e\r\n\u003cp data-start=\"1122\" data-end=\"1268\"\u003eStructure: Thematic sessions (benign, malignant, thrombosis\/hemostasis, transfusion, supportive care) with concise summaries for rapid reference\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli data-start=\"1269\" data-end=\"1347\"\u003e\r\n\u003cp data-start=\"1271\" data-end=\"1347\"\u003eAccess: Designed for quick implementation in community and academic settings\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"1349\" data-end=\"1575\"\u003e\u003cstrong data-start=\"1349\" data-end=\"1370\"\u003eWho Should Attend\u003c\/strong\u003e\u003cbr data-start=\"1370\" data-end=\"1373\"\u003eHematologists\/oncologists, hospitalists, internists, advanced practice providers, pharmacists, fellows\/trainees, and infusion-center leaders seeking a high-yield, clinically oriented hematology refresh.\u003c\/p\u003e\r\n\u003cp data-start=\"1577\" data-end=\"1593\"\u003e\u003cstrong data-start=\"1577\" data-end=\"1591\"\u003eWhy Attend\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"1594\" data-end=\"1842\"\u003e\r\n \t\u003cli data-start=\"1594\" data-end=\"1666\"\u003e\r\n\u003cp data-start=\"1596\" data-end=\"1666\"\u003eConvert complex trials and guidelines into simple, usable algorithms\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli data-start=\"1667\" data-end=\"1759\"\u003e\r\n\u003cp data-start=\"1669\" data-end=\"1759\"\u003eUpdate diagnostics, therapeutics, and toxicity management across the hematology spectrum\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli data-start=\"1760\" data-end=\"1842\"\u003e\r\n\u003cp data-start=\"1762\" data-end=\"1842\"\u003eLeave with pragmatic tools that improve safety, efficiency, and patient outcomes\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n \r\n\r\n\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\r\n\u003ctable\u003e\r\n\u003ctbody\u003e\r\n\u003ctr\u003e\r\n\u003ctd colspan=\"4\"\u003e\u003cb\u003e\u003cstrong\u003eSaturday, February 15, 2025- Hyatt Regency Bethesda- Salons I-II\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eFile\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eTIME\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eTOPIC\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003ePRESENTER\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e07:00 AM – 08:00 AM\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eBreakfast | Visit Exhibit Hall- Salon III-IV\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eExhibitors | Attendees\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e08:00 AM – 08:15 AM\u003c\/td\u003e\r\n\u003ctd\u003eWelcome | Introduction to Program\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eRobert S. Siegel, MD\u003c\/strong\u003e\u003c\/b\u003e\r\nProfessor of Medicine, Associate Center Director for Education and Training,\r\nThe George Washington University, GW Cancer Center\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e08:15 AM – 09:00 AM\u003c\/td\u003e\r\n\u003ctd\u003eMyeloproliferative Neoplasms\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eAyalew Tefferi, MD\u003c\/strong\u003e\u003c\/b\u003e\r\nBarbara Woodward Lips Professor of Medicine\r\nMayo Clinic\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e \r\n\r\n\u003cb\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/b\u003e\n\u003c\/td\u003e\r\n\u003ctd\u003e09:00 AM – 10:00 AM\u003c\/td\u003e\r\n\u003ctd\u003eMultiple Myeloma\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eKenneth Anderson, MD\u003c\/strong\u003e\u003c\/b\u003e\r\nKraft Family Professor of Medicine\r\nDana-Farber Cancer Institute,\r\nHarvard Medical School\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e10:00 AM – 10:15 AM\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eBreak | Visit Exhibit Hall- Salon III-IV\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eExhibitors | Attendees\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e10:15 AM – 11:00 AM\u003c\/td\u003e\r\n\u003ctd\u003eDisorders of Coagulation\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eKenneth A. Bauer, MD\u003c\/strong\u003e\u003c\/b\u003e\r\nProfessor of Medicine, Harvard Medical School\r\nBeth Israel Deaconess Medical Center\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e5\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e11:00 AM – 11:45 AM\u003c\/td\u003e\r\n\u003ctd\u003eAcute Myeloid Leukemia\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eSamah Nassereddine, MD\u003c\/strong\u003e\u003c\/b\u003e\r\nAssistant Professor of Medicine, The George Washington University, GW Cancer Center\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e \r\n\r\n\u003cb\u003e\u003cstrong\u003e6\u003c\/strong\u003e\u003c\/b\u003e\n\u003c\/td\u003e\r\n\u003ctd\u003e11:45 AM – 12:30 PM\u003c\/td\u003e\r\n\u003ctd\u003eChronic Lymphocytic Leukemia\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eImad A. Tabbara, MD, FACP\u003c\/strong\u003e\u003c\/b\u003e\r\nChief, Division of Hematology\/Oncology of DeCesaris Cancer Institute,\r\nAnne Arundel Medical Center, Clinical Professor of Medicine\r\nGeorge Washington University\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e12:30 PM – 01:30 PM\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eLunch | Visit Exhibit Hall- Salon III-IV\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eExhibitors | Attendees\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e12:30 PM – 01:30 PM\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003eLunch Product Forum sponsored by (tbc)\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e7\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e01:30 PM – 02:30 PM\u003c\/td\u003e\r\n\u003ctd\u003eLymphoma\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eNina Delaney Wagner-Johnston, MD\u003c\/strong\u003e\u003c\/b\u003e\r\nDirector of Lymphoma Drug Development, The Sidney Kimmel Comprehensive Cancer Center, Professor of Oncology, The Johns Hopkins University School of Medicine\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e8\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e02:30 PM – 03:15 PM\u003c\/td\u003e\r\n\u003ctd\u003eBone Marrow Failure\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eMrinal S. Patnaik, MD\u003c\/strong\u003e\u003c\/b\u003e\r\nChair, Acute Leukemia and Myeloid Neoplasms\r\nScientific Director of the Epigenetics Developmental Laboratory and Epigenomics Program\r\nAssociate Professor of Medicine\r\nCollege of Medicine, Mayo Clinic\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e\u003cb\u003e\u003cstrong\u003e9\u003c\/strong\u003e\u003c\/b\u003e\u003c\/td\u003e\r\n\u003ctd\u003e03:15 PM – 03:45 PM\u003c\/td\u003e\r\n\u003ctd\u003eChronic Myelomonocytic Leukemia\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eAyalew Tefferi, MD\u003c\/strong\u003e\u003c\/b\u003e\r\nBarbara Woodward Lips Professor of Medicine\r\nMayo Clinic\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003e \r\n\r\n\u003cb\u003e\u003cstrong\u003e10\u003c\/strong\u003e\u003c\/b\u003e\n\u003c\/td\u003e\r\n\u003ctd\u003e03:45 PM – 4:00 PM\u003c\/td\u003e\r\n\u003ctd\u003eClosing Remarks | Adjournment\u003c\/td\u003e\r\n\u003ctd\u003e\n\u003cb\u003e\u003cstrong\u003eRobert S. Siegel, MD\u003c\/strong\u003e\u003c\/b\u003e\r\nProfessor of Medicine, Associate Center Director for Education and Training,\r\nThe George Washington University, GW Cancer Center\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003c\/tbody\u003e\r\n\u003c\/table\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663494730057,"sku":"MED-AMB05037","price":15.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/George-Washington-University-Hematology-Update-Symposium-2025-1_da59cb64-04c9-4085-a961-ee2446aa8b85.jpg?v=1781875436"},{"product_id":"arrs-radiation-oncology-for-the-diagnostic-radiologist-2025","title":"ARRS Radiation Oncology for the Diagnostic Radiologist 2025","description":"\u003cdiv class=\"elementor-element elementor-element-371ff86 elementor-widget elementor-widget-heading\" data-element_type=\"widget\" data-id=\"371ff86\" data-widget_type=\"heading.default\"\u003e\n\u003cdiv class=\"elementor-widget-container\"\u003e\n\u003ch1 class=\"product-title product_title entry-title\"\u003eARRS Radiation Oncology for the Diagnostic Radiologist 2025\u003c\/h1\u003e\n\u003ch3\u003e\n\u003cstrong\u003eDate of Original Release:\u003c\/strong\u003e Aug 2025\u003c\/h3\u003e\n\u003ch2\u003eLearning Outcomes and Modules\u003c\/h2\u003e\n\u003cbr\u003eAfter completing this course, the learner should be able to:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eDescribe what a radiation oncologist is looking for in a diagnostic radiology report.\u003c\/li\u003e\n\u003cli\u003eDiscuss pre and post treatment imaging pearls and pitfalls in CNS oncologic imaging and common diagnostic challenges in pre and post treatment of lung cancer.\u003c\/li\u003e\n\u003cli\u003eIdentify options for nonoperative management of rectal cancer and the role of MRI in determining suitable candidates.\u003c\/li\u003e\n\u003cli\u003eDescribe utility and rationale for DIL boosts in prostate radiotherapy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSpeakers and Lectures\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eRadiation Oncology: From Head to Toe—\u003cem\u003eChristopher Straka\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eCNS: Common Cancers Treated with Radiation—\u003cem\u003eAaron Simon\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eLung Cancer: Common Changes in Imaging After Stereotactic Radiotherapy—\u003cem\u003eLucas Vitzthum\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eRecent Developments in Rectal Cancer Treatment: Nonoperative Management and the Role of MRI—\u003cem\u003eMichael Sherer\u003c\/em\u003e\n\u003c\/li\u003e\n\u003cli\u003eProstate Cancer: Dominant Intraprostatic Lesion (DIL) Boosts—\u003cem\u003eTyler Seibert\u003c\/em\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663494762825,"sku":"MED-AMB05032","price":45.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/ARRS-Radiation-Oncology-for-the-Diagnostic-Radiologist-2025.webp?v=1781875436"},{"product_id":"2025-asco-annual-meeting","title":"2025 ASCO Annual Meeting","description":"\u003cdiv class=\"celwidget\" data-cel-widget=\"bookDescription_feature_div\" data-csa-c-asin=\"\" data-csa-c-content-id=\"bookDescription\" data-csa-c-id=\"sp3pi4-mkskqy-y4o8kl-7jkh2a\" data-csa-c-is-in-initial-active-row=\"false\" data-csa-c-slot-id=\"bookDescription_feature_div\" data-csa-c-type=\"widget\" data-feature-name=\"bookDescription\" id=\"bookDescription_feature_div\"\u003e\n\u003cdiv class=\"a-expander-collapsed-height a-row a-expander-container a-spacing-base a-expander-partial-collapse-container\" data-a-expander-collapsed-height=\"140\" data-a-expander-name=\"book_description_expander\"\u003e\n\u003cdiv aria-expanded=\"false\" class=\"a-expander-content a-expander-partial-collapse-content\"\u003e\n\u003cdiv class=\"toc-header bottomShadow topPadding\" id=\"toc-header\"\u003e\n\u003cdiv class=\"mura-body\"\u003e\n\u003cdiv class=\"mura-region mura-region-loose\"\u003e\n\u003cdiv class=\"mura-region-local\"\u003e\n\u003cdiv class=\"prod-format\"\u003e\n\u003cdiv class=\"tab-panels\"\u003e\n\u003cdiv class=\"panel entry-content active\" id=\"tab-description\"\u003e\n\u003cdiv class=\"tab-panels\"\u003e\n\u003cdiv class=\"panel entry-content active\" id=\"tab-description\"\u003e\n\u003cdiv class=\"prod-format\"\u003e\n\u003cdiv class=\"woocommerce-tabs wc-tabs-wrapper container tabbed-content\"\u003e\n\u003cdiv class=\"tab-panels\"\u003e\n\u003cdiv aria-labelledby=\"tab-title-description\" class=\"woocommerce-Tabs-panel woocommerce-Tabs-panel--description panel entry-content active\" id=\"tab-description\" role=\"tabpanel\"\u003e\n\u003cdiv class=\"field field--name-field-heading field--type-heading field--label-hidden field__item\"\u003e\n\u003cdiv class=\"field field--name-field-heading field--type-heading field--label-hidden field__item\"\u003e\n\u003cdiv class=\"prod-format\"\u003e\n\u003ch1 class=\"product-title product_title entry-title\"\u003e2025 ASCO Annual Meeting\u003c\/h1\u003e\n\u003cbr\u003eVideos+PPTx\u003cbr\u003e\u003cbr\u003eThe 2025 ASCO Annual Meeting Program will feature over 200 sessions complementing Dr. Robin Zon’s Presidential theme, Driving Knowledge to Action: Building a Better Future\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003cbr\u003eYour all-access pass to the most clinically relevant cancer science. #ASCO25 session highlights include:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003ePlenary Session, featuring the meeting’s most practice-changing and clinically relevant abstract presentations and discussions\u003c\/li\u003e\n\u003cli\u003eOpening Session, featuring the Presidential Address and Karnofsky Award and Lecture\u003c\/li\u003e\n\u003cli\u003eASCO Voices\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663494992201,"sku":"MED-AMB04977","price":90.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/2025-ASCO-Annual-Meeting.png?v=1781875436"},{"product_id":"uscap-challenges-in-hematopathology-tricky-differentials-and-diagnostic-dilemmas-2025","title":"USCAP Challenges in Hematopathology Tricky Differentials and Diagnostic Dilemmas 2025","description":"\u003cdiv\u003e\n\u003cdiv class=\"prod-edition\"\u003e\n\u003cdiv class=\"fl-module fl-module-heading fl-node-figwu4oavj0b\" data-node=\"figwu4oavj0b\"\u003e\n\u003cdiv class=\"fl-module-content fl-node-content\"\u003e\n\u003ch3\u003eUSCAP Challenges in Hematopathology Tricky Differentials and Diagnostic Dilemmas 2025\u003c\/h3\u003e\n\u003cstrong\u003eInclude: 8 videos + 14 pdfs, size: 18.53 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eTarget Audience: pathologists, practicing hematopathologists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eInformation:\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eOriginal release date: \u003c\/strong\u003eNovember 13, 2025\u003cbr\u003e\u003cbr\u003eModern hematopathology is a rapidly evolving field that requires integration of morphologic findings with flow cytometry, immunohistochemistry, and detailed molecular analyses to diagnose and properly classify different entities.\u003cbr\u003e\u003cbr\u003eThis course will highlight common diagnostic scenarios through an interactive case-based format. This course will provide actionable information on use of ancillary studies in workup of lymphoid and myeloid neoplasm (with special emphasis on integration of cytogenetic and molecular findings), as well as non-neoplastic entities. Integration of clinical, radiologic and laboratory findings is critically important in the diagnostic decision making in hematopathology, particularly in areas such as bone marrow pathology and challenging lymphoid neoplasms.\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eTarget Audience\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eThe target audience is pathologists who diagnose lymphoid lesions and bone marrow biopsies, practicing hematopathologists, and hematopathology trainees.\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eLearning Objectives\u003c\/strong\u003e\u003cbr\u003eUpon completion of this educational activity, learners will be able to:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eRecognize pitfalls and challenges of common and rare hematologic disorders\u003c\/li\u003e\n\u003cli\u003eApply targeted and judicious use of ancillary studies in bone marrow and tissue specimens\u003c\/li\u003e\n\u003cli\u003eRecognize reactive proliferations that can mimic lymphoid or myeloid neoplasms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eNon-Neoplastic Lymph Node Disorders (and Beyond) – Anamarija Perry, MD\u003c\/li\u003e\n\u003cli\u003eMyelodysplastic Syndrome (MDS) and Its Many Mimickers – Philipp W. Raess, MD, PhD\u003c\/li\u003e\n\u003cli\u003eMyeloid and Lymphoid Confounders and Mimics – Lori Soma, MD\u003c\/li\u003e\n\u003cli\u003eDealing with Epidermotropism – Problems, Pitfalls, and Practical Solutions – John R. Goodlad, MD, MBChB, FRCPath\u003c\/li\u003e\n\u003cli\u003eEpstein-Barr Virus (EBV) Driven Proliferations – Anamarija Perry, MD\u003c\/li\u003e\n\u003cli\u003eAlmost Acute Myeloid Leukemia (AML)…or Is It? – Philipp W. Raess, MD, PhD\u003c\/li\u003e\n\u003cli\u003ePlasmacytic\/Plasmacytoid\/Plasma Cell Processes – What to Think About Beyond Myeloma – Lori Soma, MD\u003c\/li\u003e\n\u003cli\u003eB-Cell Proliferations in the Skin – John R. Goodlad, MD, MBChB, FRCPath\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663495057737,"sku":"MED-AMB04962","price":80.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/USCAP-Challenges-in-Hematopathology-Tricky-Differentials-and-Diagnostic-Dilemmas-2025.png?v=1781875437"},{"product_id":"the-md-anderson-cancer-center-a-comprehensive-board-review-in-hematology-and-medical-oncology-2025","title":"The MD Anderson Cancer Center A Comprehensive Board Review in Hematology and Medical Oncology 2025","description":"\u003cdiv\u003e\n\u003cdiv class=\"prod-edition\"\u003e\n\u003ch3\u003eThe MD Anderson Cancer Center A Comprehensive Board Review in Hematology and Medical Oncology 2025\u003c\/h3\u003e\n\u003cstrong\u003e86 Videos +113 PDFs\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eTarget Audience: hematology\/oncology physicians, fellows and practicing internists\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003e\n\u003cbr\u003e\u003cbr\u003eDate \u0026amp; Location: Monday, September 15, 2025, 7:00 AM – Saturday, September 20, 2025, 5:30 PM, MD Anderson – Virtual\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"activitysectionbold\"\u003eTarget Audience:\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cem\u003eSpecialties\u003c\/em\u003e – Colon and Rectal Surgery, Gynecologic Oncology, Hematology, Medical Oncology, Neurological Surgery, Obstetrics and Gynecology, Thoracic Surgery, Urology\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cem\u003eProfessions\u003c\/em\u003e – Nurse – APRN, Nurse – LVN, Nurse – RN, Pharmacist, Pharmacy Technician, Physician (MD or DO), Student or Trainee\u003c\/div\u003e\n\u003cdiv class=\"activitysectionbold\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"activitysectionbold\"\u003eOverview\u003c\/div\u003e\n\u003cbr\u003eThe course is a 6-day comprehensive review of current standards and practices in the management of patients with blood disorders and malignancy. The course is designed to enable the participant to effectively prepare for the American Board of Internal Medicine certification and recertification examinations in Hematology and Medical Oncology. Advances in clinical pharmacology, molecular genetics and risk assessment, and radiation oncology will be included.\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003eObjectives\u003c\/div\u003e\n\u003cdiv\u003eAt the conclusion of this activity, learners will be able to:\u003c\/div\u003e\n\u003col\u003e\n\u003cli\u003eApply knowledge gained to prepare for the hematology and medical oncology subspecialty and recertification examinations in hematology and medical oncology.\u003c\/li\u003e\n\u003cli\u003eUtilize current standards of care for patients with cancer, blood disorders and malignancies.\u003c\/li\u003e\n\u003cli\u003eDemonstrate proficiency of knowledge in hematology and medical oncology.\u003c\/li\u003e\n\u003cli\u003eIncorporate recent advances in management of hematologic and oncologic patients.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eTopics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003e\u003cstrong\u003e\u003ca href=\"https:\/\/mdanderson.cloud-cme.com\/course\/courseoverview?P=5\u0026amp;EID=48767\"\u003eSchedule\u003c\/a\u003e\u003c\/strong\u003e\u003c\/em\u003e\n\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663495090505,"sku":"MED-AMB04953","price":100.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/md-anderson-cancer-center-a-comprehensive-board-review-in-hematology-and-medical-oncology-2025-768x768_webp.webp?v=1781875437"},{"product_id":"astro-annual-meeting-on-demand-2025","title":"ASTRO Annual Meeting on Demand 2025","description":"\u003cdiv\u003e\n\u003cdiv class=\"col-lg-12 mt-2 mb-2\" id=\"section2\"\u003e\n\u003cdiv class=\"field-items\"\u003e\n\u003cdiv class=\"field-item even\"\u003e\n\u003ch3\u003eASTRO Annual Meeting on Demand 2025\u003c\/h3\u003e\n\u003cbr\u003eVideos\u003cbr\u003e\u003cbr\u003eThe ASTRO Annual Meeting onDemand extends learning beyond the live meeting dates to vast educational and scientific content by leading experts. You can watch — and rewatch — over 150 session recordings of the top science and education related to the field of radiation oncology. Session recordings and 190+ \u003cem\u003eAMA PRA Category 1™ \u003c\/em\u003eare available at medustudy website at est prices\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003ch4\u003eAnnual Meeting onDemand Conten\u003c\/h4\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"col-lg-6\"\u003e\n\u003cdiv class=\"intro-text\"\u003e\n\u003ch5\u003e\n\u003ci class=\"fas fa-calendar-alt\"\u003e\u003c\/i\u003e 28th September – 1st October, 2025\u003c\/h5\u003e\n\u003ch1\u003eASTRO 2025 67th American Society for Radiation Oncology ASTRO Annual Meeeting\u003c\/h1\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"field-items\"\u003e\n\u003cbr\u003e\u003cbr\u003eWatch Annual Meeting sessions whenever and wherever you choose. The Annual Meeting onDemand is your gateway to the latest education and science in the field. With onDemand you get vast and versatile access to content from the 2025 ASTRO Annual Meeting:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ca data-feathr-click-track=\"true\" data-feathr-link-aids=\"5cf7fbbb5f0575000e7e80bf\" href=\"https:\/\/www.astro.org\/meetings-and-education\/micro-sites\/2025\/annual-meeting\/learn\/education-program\" rel=\"noopener noreferrer\" target=\"_blank\"\u003eEducation Program\u003c\/a\u003e — \u003ca data-feathr-click-track=\"true\" data-feathr-link-aids=\"5cf7fbbb5f0575000e7e80bf\" href=\"https:\/\/amportal.astro.org\/sessions?_TYPE_=Education\u0026amp;searchText=edu\" rel=\"noopener noreferrer\" target=\"_blank\"\u003eEducation Sessions and Panels\u003c\/a\u003e, many of which are case-based, and \u003ca data-feathr-click-track=\"true\" data-feathr-link-aids=\"5cf7fbbb5f0575000e7e80bf\" href=\"https:\/\/amportal.astro.org\/sessions?_TYPE_=Storytelling\u0026amp;searchText=\" rel=\"noopener noreferrer\" target=\"_blank\"\u003eStorytelling\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca data-feathr-click-track=\"true\" data-feathr-link-aids=\"5cf7fbbb5f0575000e7e80bf\" href=\"https:\/\/www.astro.org\/meetings-and-education\/micro-sites\/2025\/annual-meeting\/learn\/scientific-program\" rel=\"noopener noreferrer\" target=\"_blank\"\u003eScientific Program\u003c\/a\u003e — \u003ca data-feathr-click-track=\"true\" data-feathr-link-aids=\"5cf7fbbb5f0575000e7e80bf\" href=\"https:\/\/amportal.astro.org\/sessions\/pl-01-21644\" rel=\"noopener noreferrer\" target=\"_blank\"\u003ePlenary\u003c\/a\u003e, \u003ca data-feathr-click-track=\"true\" data-feathr-link-aids=\"5cf7fbbb5f0575000e7e80bf\" href=\"https:\/\/amportal.astro.org\/sessions\/ct-01-21645\" rel=\"noopener noreferrer\" target=\"_blank\"\u003eClinical Trials\u003c\/a\u003e, \u003ca data-feathr-click-track=\"true\" data-feathr-link-aids=\"5cf7fbbb5f0575000e7e80bf\" href=\"https:\/\/amportal.astro.org\/sessions?_TYPE_=Science+Highlights\u0026amp;searchText=\" rel=\"noopener noreferrer\" target=\"_blank\"\u003eScience Highlights\u003c\/a\u003e, \u003ca data-feathr-click-track=\"true\" data-feathr-link-aids=\"5cf7fbbb5f0575000e7e80bf\" href=\"https:\/\/amportal.astro.org\/sessions?_TYPE_=Scientific\u0026amp;searchText=\" rel=\"noopener noreferrer\" target=\"_blank\"\u003eScientific Sessions\u003c\/a\u003e, \u003ca data-feathr-click-track=\"true\" data-feathr-link-aids=\"5cf7fbbb5f0575000e7e80bf\" href=\"https:\/\/amportal.astro.org\/sessions?searchText=cancer+breakthroughs\" rel=\"noopener noreferrer\" target=\"_blank\"\u003eCancer Breakthroughs\u003c\/a\u003e, \u003ca data-feathr-click-track=\"true\" data-feathr-link-aids=\"5cf7fbbb5f0575000e7e80bf\" href=\"https:\/\/amportal.astro.org\/sessions?_TYPE_=Quick+Pitch\u0026amp;searchText=\" rel=\"noopener noreferrer\" target=\"_blank\"\u003eQuick Pitch Sessions\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca data-feathr-click-track=\"true\" data-feathr-link-aids=\"5cf7fbbb5f0575000e7e80bf\" href=\"https:\/\/amportal.astro.org\/sessions?searchText=Presidential+symposium\" rel=\"noopener noreferrer\" target=\"_blank\"\u003ePresidential Symposium\u003c\/a\u003e and \u003ca data-feathr-click-track=\"true\" data-feathr-link-aids=\"5cf7fbbb5f0575000e7e80bf\" href=\"https:\/\/www.astro.org\/meetings-and-education\/micro-sites\/2025\/annual-meeting\/learn\/education-program\/keynote-speakers\" rel=\"noopener noreferrer\" target=\"_blank\"\u003eKeynote Speakers\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca data-feathr-click-track=\"true\" data-feathr-link-aids=\"5cf7fbbb5f0575000e7e80bf\" href=\"https:\/\/amportal.astro.org\/sessions?_TRACK_=Practical+Radiation+Oncology\u0026amp;searchText=\" rel=\"noopener noreferrer\" target=\"_blank\"\u003ePractical Radiation Oncology Program\u003c\/a\u003e designed for the community practice radiation oncologist\u003c\/li\u003e\n\u003cli\u003e\u003ca data-feathr-click-track=\"true\" data-feathr-link-aids=\"5cf7fbbb5f0575000e7e80bf\" href=\"https:\/\/www.astro.org\/interest-groups\/arro\/about-arro\/arro-annual-seminar\" rel=\"noopener noreferrer\" target=\"_blank\"\u003eARRO Annual Seminar\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663495123273,"sku":"MED-AMB04943","price":100.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Screenshot-2025-10-09-211552-768x768_png.webp?v=1781875437"},{"product_id":"harvard-3rd-annual-update-in-neuro-oncology-2023","title":"Harvard 3rd Annual Update in Neuro-Oncology 2023","description":"\u003cdiv class=\"title\"\u003e\n\u003cdiv class=\"section-heading-wrapper u-margin-l-ver\"\u003e\n\u003ch3\u003eHarvard 3rd Annual Update in Neuro-Oncology 2023\u003c\/h3\u003e\n\u003cstrong\u003eInclude: 39 videos + 32 pdfs, size: 12.05 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eTarget Audience: neurologists, oncologists, neurosurgeons, radiation oncologists, pathologists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e Information:\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eNeuro-oncology is a rapidly evolving multi-disciplinary field, which involves the medical, radiation and surgical management of pediatric and adult patients with primary and metastatic tumors of the central nervous system (CNS) and peripheral nervous system (PNS). In addition, modern molecular neuropathology and neuroradiology concepts are essential for accurate diagnosis and classification. This three-day course, \u003cem\u003eAnnual Update in Neuro-Oncology\u003c\/em\u003e, is designed to provide an international audience with a comprehensive review of the diagnosis and management of pediatric and adult patients with primary and metastatic CNS and PNS tumors and neurological complications of cancer.\u003cbr\u003e\u003cbr\u003eOur target audience will be the providers involved in the care of adult and pediatric neuro-oncology patients (oncologists, radiation oncologists, neurosurgeons, neurologists, neuroradiologists and neuropathologists). The course will also be of high relevance to nurse practitioners, physician assistants, psychologists, pharmacists and nurses.\u003cbr\u003e\u003ch3 class=\"variant-1\"\u003eWho Should Attend\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eSpecialty Physicians\u003c\/li\u003e\n\u003cli\u003eNurses, Pharmacists\u003c\/li\u003e\n\u003cli\u003ePhysician Assistants\u003c\/li\u003e\n\u003cli\u003ePsychologists\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 class=\"variant-1\"\u003eLearning Objectives\u003c\/h3\u003e\n\u003cbr\u003eUpon completion of this activity, participants will be able to:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eIdentify the role of biomarkers in the diagnosis of pediatric and adult CNS and PNS tumors.\u003c\/li\u003e\n\u003cli\u003eIdentify standard and novel treatment approaches to pediatric and adult CNS and PNS tumors.\u003c\/li\u003e\n\u003cli\u003eRecognize and address neurological complications associated with new cancer therapies.\u003c\/li\u003e\n\u003cli\u003eIdentify and manage long-term complications of CNS and PNS tumors and their treatment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e🧠 The \u003cstrong\u003eHarvard 3rd Annual Update in Neuro-Oncology 2023\u003c\/strong\u003e is best for \u003cstrong\u003eneurologists, oncologists, neurosurgeons, radiation oncologists, pathologists\u003c\/strong\u003e, and other healthcare professionals involved in the care of patients with \u003cstrong\u003ecentral and peripheral nervous system tumors\u003c\/strong\u003e. It’s ideal for:\u003cbr\u003e\u003ch3\u003e👩‍⚕️ Who Should Attend\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eClinicians treating \u003cstrong\u003eprimary and metastatic brain and spine tumors\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eSpecialists managing \u003cstrong\u003eneurological complications of cancer\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eResearchers and educators seeking updates on \u003cstrong\u003emolecular neuropathology and neuroradiology\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e📅 \u003cstrong\u003eDates\u003c\/strong\u003e: July 26–28, 2023\u003cbr\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"bundle--hms_program_details_list paragraph paragraph--type--hms-program-details-list paragraph--view-mode--default open\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12\"\u003e\n\u003cdiv class=\"hms-program-details-list--title field-wrapper field field--name-field-hms-pdl-title field--type-string field--label-hidden field__items\"\u003e\n\u003ch4 class=\"field__item\"\u003eWednesday, July 26, 2023\u003c\/h4\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--items field-wrapper field field--name-field-hms-pdl-item field--type-entity-reference-revisions field--label-hidden field__items\"\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e10:00-10:10 AM \u003cstrong\u003eWelcome: Pediatric Neuro-Oncology Session \u003c\/strong\u003eMariella Filbin, MD, PhD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e10:10-10:40 AM \u003cstrong\u003eKeynote: CAR T Cell Therapy for Diffuse Midline Gliomas \u003c\/strong\u003eMichelle Monje,  MD, PhD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e10:40-11:10 AM \u003cstrong\u003eWHO Classification, Pediatric CNS Tumors \u003c\/strong\u003eSanda Alexandrescu, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e11:10-11:40 AM \u003cstrong\u003eEmbryonal Tumors \u003c\/strong\u003eScott Pomeroy, MD, PhD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e11:40 AM-12:00 PM \u003cstrong\u003eBreak\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e12:00-12:30 PM \u003cstrong\u003ePediatric Low-Grade Gliomas \u003c\/strong\u003eSusan Chi, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e12:30-1:00 PM \u003cstrong\u003ePediatric High-Grade Gliomas \u003c\/strong\u003eMariella Filbin, MD, PhD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e1:00-1:30 PM \u003cstrong\u003eEpendymomas and Glioneuronal Tumors \u003c\/strong\u003ePratiti (Mimi) Bandopadhayay, MBBS, PhD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e1:30-1:45 PM \u003cstrong\u003eLive Question \u0026amp; Answer Session \u003c\/strong\u003eMariella Filbin, MD, PhD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e1:45-2:00 PM \u003cb\u003eBreak\u003c\/b\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e2:00-2:15 PM \u003cstrong\u003eChoroid Plexus Tumors \u003c\/strong\u003eViviana Benitez, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e2:15-2:30 PM \u003cstrong\u003ePineal Tumors \u003c\/strong\u003eShannon MacDonald, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e2:30-2:45 PM \u003cstrong\u003eGerm Cell Tumors \u003c\/strong\u003eAaron Yeo, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e2:45-3:15 PM \u003cstrong\u003eNeurofibromatosis \u003c\/strong\u003eScott Plotkin, MD, PhD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e3:15-3:30 PM \u003cstrong\u003eVon Hippel Lindau \u003c\/strong\u003eOthon Iliopoulos, MD, PhD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e3:30-3:45 PM \u003cstrong\u003eLive Question \u0026amp; Answer Session \u003c\/strong\u003eMariella Filbin, MD, PhD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e3:45-3:50 PM \u003cstrong\u003eAdjourn \u003c\/strong\u003eMariella Filbin, MD, PhD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"bundle--hms_program_details_list paragraph paragraph--type--hms-program-details-list paragraph--view-mode--default open\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12\"\u003e\n\u003cdiv class=\"hms-program-details-list--title field-wrapper field field--name-field-hms-pdl-title field--type-string field--label-hidden field__items\"\u003e\n\u003ch4 class=\"field__item\"\u003eThursday, July 27, 2023\u003c\/h4\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--items field-wrapper field field--name-field-hms-pdl-item field--type-entity-reference-revisions field--label-hidden field__items\"\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e10:00-10:05 AM \u003cstrong\u003eWelcome: Adult Neuro-Oncology \u003c\/strong\u003eTracy Batchelor, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e10:05-10:30 AM \u003cstrong\u003eKeynote: Surgical Immunotherapy Clinical Trials for Glioblastoma Multiforme (GBM) \u003c\/strong\u003eE. Antonio Chiocca, MD,PhD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e10:30-10:45 AM \u003cstrong\u003eAdvances in Surgery for Brain Tumors \u003c\/strong\u003eWilliam Curry, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e10:45-11:00 AM \u003cstrong\u003eAdvances in Imaging for Brain Tumors \u003c\/strong\u003eTina Young Poussaint, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e11:00-11:15 AM \u003cstrong\u003eAdvances in Radiation for Brain Tumors \u003c\/strong\u003eHelen Shih, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e11:15-11:25 AM \u003cstrong\u003eLive Question and Answer Session \u003c\/strong\u003eTracy Batchelor, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e11:25-11:30 AM \u003cb\u003eBreak\u003c\/b\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e11:30 AM-12:00 PM \u003cstrong\u003eWHO Classification for Adult Gliomas \u003c\/strong\u003eDavid Louis, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e12:00-12:30 PM \u003cstrong\u003eGliomas, IDH-Mutant \u003c\/strong\u003e​​​​​Nicolas Gonzalez Castro, MD, PhD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e12:30-12:45 PM \u003cstrong\u003eGliomas, IDH-Wildtype \u003c\/strong\u003eIsabel Arrillaga,  MD, PhD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e12:45-1:10 PM \u003cstrong\u003eAdvances in Experimental Therapies for Gliomas \u003c\/strong\u003eDavid Reardon, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e1:10-1:30 PM \u003cb\u003eBreak\u003c\/b\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e1:30-1:45 PM \u003cstrong\u003eMeningioma \u003c\/strong\u003eWenya Linda Bi, MD, PhD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e1:45-2:00 PM \u003cstrong\u003eCNS Lymphomas \u003c\/strong\u003eLakshmi Nayak, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e2:00-2:15 PM \u003cstrong\u003ePituitary Tumors \u003c\/strong\u003ePamela Jones, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e2:15-2:45 PM \u003cstrong\u003eLive Question \u0026amp; Answer Session \u003c\/strong\u003eTracy Batchelor, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e2:45-2:50 PM \u003cstrong\u003eAdjourn\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"bundle--hms_program_details_list paragraph paragraph--type--hms-program-details-list paragraph--view-mode--default open\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12\"\u003e\n\u003cdiv class=\"hms-program-details-list--title field-wrapper field field--name-field-hms-pdl-title field--type-string field--label-hidden field__items\"\u003e\n\u003ch4 class=\"field__item\"\u003eFriday, July 28, 2023\u003c\/h4\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--items field-wrapper field field--name-field-hms-pdl-item field--type-entity-reference-revisions field--label-hidden field__items\"\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e10:00-10:05 AM \u003cstrong\u003eWelcome: Neurological Complications of Cancer \u003c\/strong\u003ePatrick Wen, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e10:05-10:30 AM \u003cstrong\u003eKeynote: Neural Regulation of Cancer \u003c\/strong\u003eHumsa Venkatesh, PhD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e10:30-11:00 AM \u003cstrong\u003eMetastases to the Brain \u003c\/strong\u003ePriscilla Brastianos, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e11:00-11:15 AM \u003cstrong\u003eMetastases to the Leptomeninges \u003c\/strong\u003eRicky McFaline-Figueroa, MD, PhD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e11:15-11:30 AM \u003cstrong\u003eMetastases to the Epidural Space and Spinal Cord \u003c\/strong\u003eJohn Chi, MD, MPH\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e11:30-11:45 AM \u003cstrong\u003eLive Question and Answer Session \u003c\/strong\u003ePatrick Wen, MD\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e11:45 AM-12:15 PM \u003cb\u003eBreak\u003c\/b\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e12:15-12:30 PM \u003cstrong\u003eParaneoplastic Neurological Syndromes \u003c\/strong\u003eEudocia Lee, MD, MPH\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e12:30-1:00 PM \u003cstrong\u003eCommon Neurological Complications in Cancer Patients \u003c\/strong\u003eUgonma Chukwueke, MD, MPH\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e1:00-1:15 PM \u003cstrong\u003eNeurological Complications of Cancer Immunotherapies \u003c\/strong\u003eJorg Dietrich, MD, PhD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e1:15-1:30 PM \u003cstrong\u003eManaging Long-Term Survivors of CNS Tumors \u003c\/strong\u003eDeborah Forst, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e1:30 – 1:45 PM \u003cstrong\u003eLive Question and Answer Session \u003c\/strong\u003ePatrick Wen, MD\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"hms-program-details-list--item field__item\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"columns small-12 medium-12 large-4 hms-program-details-list--date\"\u003e1:45-2:00 PM \u003cstrong\u003eClosing \u0026amp; Adjourn \u003c\/strong\u003eTracy Batchelor, MD, MPH\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663495221577,"sku":"MED-AMB04902","price":30.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Harvard-3rd-Annual-Update-in-Neuro-Oncology-2023.jpg?v=1781875438"},{"product_id":"memorial-sloan-kettering-cancer-center-oncologic-toxicity-management-symposium-2025","title":"Memorial Sloan Kettering Cancer Center Oncologic Toxicity Management Symposium 2025","description":"\u003ch3\u003eMemorial Sloan Kettering Cancer Center Oncologic Toxicity Management Symposium 2025\u003c\/h3\u003e\n\u003cstrong\u003eInclude: 27 videos + 24 pdfs, size: 3.55 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eTarget Audience: oncologists, hematologists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eInformation:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003eDate \u0026amp; Location: Friday, June 20, 2025, 8:00 AM – 6:00 PM, Zuckerman Research Center, 417 East 68th Street, New York, NY\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cem\u003eSpecialties\u003c\/em\u003e – Allergy and Immunology, Cardiology, Dermatology, Dermatopathology, Emergency Medicine, Endocrinology, Diabetes and Metabolism, Gastroenterology, Gastrointestinal Oncology, Genitourinary Oncology, Geriatric Medicine, Gynecologic Oncology, Immunotherapy, Integrative Medicine, Medical Oncology, Neurology, Neuro-Oncology, Nurse Practitioner, Rheumatology, Solid Tumor Oncology\u003c\/div\u003e\n\u003ch3\u003eOverview\u003c\/h3\u003e\u003cbr\u003eThe \u003cstrong\u003e2025 Oncology Toxicity Management Symposium\u003c\/strong\u003e unites leading oncologists, researchers, and healthcare professionals to explore the latest breakthroughs in cancer treatment and toxicity management. With rapid advancements in oncology, this symposium serves as a critical platform for discussing emerging therapies, their clinical applications, and strategies to mitigate treatment-related adverse events, ultimately aiming to improve patient care and outcomes.\u003cbr\u003e\u003cbr\u003eAs oncology continues to evolve, new therapies are revolutionizing the landscape of cancer treatment. This symposium will provide a comprehensive, evidence-based approach to understanding next-generation treatments, their efficacy, and the challenges associated with their implementation in clinical practice.\u003cbr\u003e\u003cbr\u003eAttendees will gain deep insights into the mechanisms, benefits, and risks of cutting-edge therapies, including:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eRadioligand Therapy\u003c\/strong\u003e – A novel approach that delivers targeted radiation to cancer cells, offering precise treatment with minimal damage to surrounding tissues. The session will focus on clinical applications, effectiveness, and strategies to manage radiation-related toxicity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAntibody Drug Conjugates (ADCs)\u003c\/strong\u003e – A breakthrough class of targeted cancer therapies designed to deliver highly potent chemotherapy directly to cancer cells. Experts will discuss the latest ADC developments, clinical benefits, and effective management of associated toxicities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCAR-T Cell Therapy\u003c\/strong\u003e – A groundbreaking immunotherapy that harnesses the body’s own immune system to fight cancer. This session will address treatment protocols and management of adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBispecific Antibodies\u003c\/strong\u003e – A cutting-edge approach that redirects T-cells to attack tumor cells. Attendees will gain an understanding of the potential of Bispecific Antibodies, their clinical applications, and how to mitigate immune-related toxicities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSmall Molecule Inhibitors (SMIs)\u003c\/strong\u003e – Targeted agents that block key pathways involved in cancer growth. This session will explore the role of SMIs in oncology, their therapeutic potential, and management of associated risks such as cardiovascular toxicity and metabolic disturbances.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmune Checkpoint Inhibitors (ICIs)\u003c\/strong\u003e – A revolutionary class of immunotherapies that enhance the body’s natural ability to fight cancer. Experts will discuss how ICIs are reshaping oncology, the challenges of immune-related adverse events (irAEs), and best practices for toxicity management.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003eThrough expert-led presentations, panel discussions, and interactive Q\u0026amp;A sessions, attendees will deepen their understanding of novel therapies transforming oncology care, learn strategies to manage treatment-related toxicities, engage with thought leaders on cutting-edge research and clinical trials, and connect with peers to foster innovation in cancer treatment.\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eTarget Audience\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eThis symposium is an essential event for oncologists, hematologists, researchers, nurse practitioners, physician assistants, pharmacists, and all healthcare professionals involved in cancer care. Attendees will leave with actionable knowledge and practical tools to optimize patient outcomes and stay at the forefront of oncology advancements.\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eObjectives\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003eAt the conclusion of this symposium, attendees will be able to:\u003c\/div\u003e\n\u003col\u003e\n\u003cli\u003eDescribe the mechanism of action, indications, and clinical efficacy of Radioligand Therapy, Antibody Drug Conjugates (ADCs), Bispecific Antibodies, CAR-T Cell Therapy, Small Molecule Inhibitors (SMIs), and Immune Checkpoint Inhibitors (ICIs).\u003c\/li\u003e\n\u003cli\u003eDevelop evidence-based strategies to identify, prevent, and manage treatment-related toxicities, such as cytokine release syndrome (CRS), neurotoxicity, immune-related adverse events (irAEs), and organ-specific toxicities.\u003c\/li\u003e\n\u003cli\u003eRecognize the early signs of adverse reactions and implement effective interventions to reduce complications and improve patient safety.\u003c\/li\u003e\n\u003cli\u003eApply clinical case studies and expert insights to make informed, patient-centered decisions in oncology treatment planning.\u003c\/li\u003e\n\u003cli\u003eDiscuss how to balance treatment efficacy with toxicity management to optimize long-term patient outcomes.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cstrong\u003eTopics:\u003c\/strong\u003e\n\u003cbr\u003e\u003ch3 class=\"boxAgendaTitle\"\u003eFriday, June 20, 2025\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e8:10AM – 8:55AM Enhancing the Selectivity of RLT for Future Treatments and Trials Michael J. Morris , MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e9:00AM – 9:15AM HER2-ADCs Eleni Stavrou, MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e9:15AM – 9:30AM TROP-2 ADCs Jie Chi, MD, Assistant Attending\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e9:30AM – 9:45AM NECTIN-4 ADCs Gopakumar Iyer, MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e9:45AM – 10:00AM Hematologic Malignancies and ADCs Nisha Joseph, MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e10:00AM – 10:15AM Management of Dermatological Adverse Events with ADCs Allison Gordon, MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e10:15AM – 10:30AM Antibody Drug Conjugates (ADCs) Panel Discussion\/Q\u0026amp;A Neil Shah, MD (Moderator)\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e10:45AM – 11:00AM Bispecific Antibodies for Small Cell Cancers— DLL3 and Beyond Alissa Cooper, MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e11:15AM – 11:30AM Bispecific Antibodies for Leukemia and Lymphoma Suchita Sundaram, MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e11:30AM – 11:45AM Bispecific Antibodies for Multiple Myeloma Carlyn Tan, MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e11:45AM – 12:00PM Bispecific Antibodies Panel Discussion\/Q\u0026amp;A Urvi Shah , MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e1:00PM – 1:15PM Immune Effector Cell (IEC) Toxicities in Solid Tumor Geoffrey Ku, MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e1:15PM – 1:30PM CAR-T for Myeloma Doris Hansen, MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e1:30PM – 1:45PM CAR-T for Lymphoma Gunjan Shah , MD, MS\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e1:45PM – 2:00PM CAR-T for Leukemia Mark B Geyer , MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e2:00PM – 2:15PM Managent of Graft vs. Host Disease and Other CAR-T Adverse Events Gagan Raju , MD, MD\u003c\/li\u003e\n\u003cli\u003e2:15PM – 2:30PM Management of Neurotoxicity with Oncology Agents Bianca D. Santomasso, MD, PhD\u003c\/li\u003e\n\u003cli\u003e2:30PM – 2:45PM CAR-T Cell Therapies Panel Discussion\/Q\u0026amp;A David Faleck, MD (Moderator)\u003c\/li\u003e\n\u003cli\u003e3:00PM – 3:15PM VEGF Tyrosine Kinase Inhibitors and HIF-2 Alpha Inhibitors Martin H Voss, MD\u003c\/li\u003e\n\u003cli\u003e3:15PM – 3:30PM EGFR and ALK Inhibitors Isabel Preeshagul, MD\u003c\/li\u003e\n\u003cli\u003e3:30PM – 4:00PM CDK4\/6 and PI3K Inhibitors Serena Wong, MD\u003c\/li\u003e\n\u003cli\u003e4:00PM – 4:30PM Management of Endocrine Adverse Events James Flory , MD\u003c\/li\u003e\n\u003cli\u003e4:40PM – 4:55PM LAG-3 Inhibitors Michael Postow, MD\u003c\/li\u003e\n\u003cli\u003e4:55PM – 5:10PM Management of Infusion Reactions from ICIs and Other Oncology Agents Autumn C Guyer, MD\u003c\/li\u003e\n\u003cli\u003e5:10PM – 5:25PM Management of Gastrointestinal Immune-Related Adverse Events David Faleck, MD\u003c\/li\u003e\n\u003cli\u003e5:25PM – 5:40PM Management of Cutaneous Immune-Related Adverse Events Alina Markova , MD\u003c\/li\u003e\n\u003cli\u003e5:40PM – 5:55PM Novel Immune Checkpoint Inhibitors (ICIs) Panel Discussion\/Q\u0026amp;A Steven Maron, MD,MSc (Moderator)\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663495287113,"sku":"MED-AMB04886","price":40.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Memorial-Sloan-Kettering-Cancer-Center-Oncologic-Toxicity-Management-Symposium-2025.jpg?v=1781875438"},{"product_id":"harvard-early-detection-and-interception","title":"Harvard Early Detection and Interception of Cancer Current Practice Recommendations and Novel Emerging Approaches 2025 (Videos)","description":"\u003cdiv class=\"prod-edition\"\u003e\n\u003cdiv class=\"prod-edition\"\u003e\n\u003cdiv class=\"prod-edition\"\u003e\n\u003cdiv class=\"prod-edition\"\u003e\n\u003cdiv class=\"prod-edition\"\u003e\n\u003cdiv class=\"wysiwyg\"\u003e\n\u003ch3\u003eHarvard Early Detection and Interception of Cancer Current Practice Recommendations and Novel Emerging Approaches 2025 (Videos)\u003c\/h3\u003e\n\u003cbr\u003eThrough this course we will provide a comprehensive review of current cancer screening guidelines, provide guidance regarding high-risk populations and their management, educate regarding emerging technologies for early cancer detection, and provide referral pathways for complex patients.\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"program-overview__learning-objectives\"\u003e\n\u003ch3\u003eLearning Objectives\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e Identify and implement current cancer screening guidelines, with a focus on early detection and intervention for high-risk populations, and provide recommendations for managing these patients.\u003c\/li\u003e\n\u003cli\u003e Identify and establish appropriate referral pathways for patients with pre-malignant conditions requiring specialized care.\u003c\/li\u003e\n\u003cli\u003e Evaluate emerging technologies in cancer detection and assess their application for early detection of cancer.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663495352649,"sku":"MED-AMB04852","price":40.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Harvard-Early-Detection-and-Interception-of-Cancer-Current-Practice-Recommendations-and-Novel-Emerging-Approaches-2025-Videos.png?v=1781875438"},{"product_id":"memorial-sloan-kettering-cancer-center-9th-annual-msk-symposium-on-lymphoma-2025","title":"Memorial Sloan Kettering Cancer Center 9th Annual MSK Symposium on Lymphoma 2025","description":"\u003cdiv\u003e\n\u003ch3\u003eMemorial Sloan Kettering Cancer Center 9th Annual MSK Symposium on Lymphoma 2025\u003c\/h3\u003e\n\u003cstrong\u003eInclude: 37 videos + 30 pdfs, size: 6.71 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eTarget Audience: internists, oncologists, hematologists as well as medical and radiation oncologists, hematopathologists, scientists, and medical trainees\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eInformation:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003e\n\u003cbr\u003e\u003cbr\u003eDate \u0026amp; Location: Friday, April 25, 2025, 8:00 AM – Saturday, April 26, 2025, 12:55 PM, Zuckerman Research Center, 417 East 68th Street, New York, NY\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eSpecialties\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cem\u003eSpecialties\u003c\/em\u003e – Anatomic Pathology, Bone Marrow Transplant, Cellular Therapeutics, Clinical Pathology, Geriatric Medicine, Hematology, Hematopathology, Immunotherapy, Internal Medicine, Laboratory Medicine, Leukemia, Lymphoma, Medical Oncology, Molecular Pathology, Nuclear Medicine, Oncology and Hematology, Radiation Oncology\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003eOverview\u003c\/strong\u003e\u003c\/div\u003e\n\u003cbr\u003eThis annual symposium provides a comprehensive overview of the latest advancements in the evolving field of lymphoma. Renowned national and international experts present cutting-edge discoveries in lymphoma biology, state-of-the-art diagnostic techniques, and innovative treatment strategies. The program highlights the clinical management of common lymphoma subtypes while also examining groundbreaking drug developments that are redefining patient care. Attendees will gain valuable insights into the latest findings in lymphoma biology and pathology, exploring how these breakthroughs are being translated into practical, impactful solutions for clinical practice.\u003cbr\u003e\u003cbr\u003eThe target audience for this symposium includes internists, oncologists, hematologists as well as medical and radiation oncologists, hematopathologists, scientists, and medical trainees involved in the diagnosis, treatment, and biomedical research of lymphoma. Participants have the choice of attending either in-person or virtually.\u003cbr\u003e\u003cbr\u003eWe look forward to welcoming colleagues and esteemed faculty from around the world to exchange insights and advance the future of lymphoma care.\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eObjectives\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003eAt the conclusion of this symposium, attendees will be able to:\u003c\/div\u003e\n\u003col\u003e\n\u003cli\u003eDescribe recent advances in lymphoma classification\u003c\/li\u003e\n\u003cli\u003eDiscuss first line treatment options in most frequent lymphoma entities\u003c\/li\u003e\n\u003cli\u003eDescribe new agents mode of actions, efficacy, side effects\u003c\/li\u003e\n\u003cli\u003eDiscuss options and recommendations for patients in the relapse refractory setting\u003c\/li\u003e\n\u003cli\u003eProvide adequate information to help shared decision with patients regarding their treatment\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eTopics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eAdvances in Biology.mp4\u003cbr\u003eAdvances in Biology.pdf\u003cbr\u003eAdvancing Therapeutic Options in the Relapse Setting.mp4\u003cbr\u003eAdvancing Therapeutic Options in the Relapse Setting.pdf\u003cbr\u003eB-Cell Dynamics in the Germinal Center.mp4\u003cbr\u003eB-Cell Dynamics in the Germinal Center.pdf\u003cbr\u003eBiology of Hodgkin Lymphoma.mp4\u003cbr\u003eBiology of Hodgkin Lymphoma.pdf\u003cbr\u003eCAR T-Cell Therapy for B Cell Lymphoma- Approach to Management and Care in the Outpatient Setting.mp4\u003cbr\u003eCAR T-Cell Therapy for B Cell Lymphoma- Approach to Management and Care in the Outpatient Setting.pdf\u003cbr\u003eCellular Therapies for Treating Mantle Cell Lymphoma.mp4\u003cbr\u003eCellular Therapies for Treating Mantle Cell Lymphoma.pdf\u003cbr\u003eCurrent Dilemma in the First Line Therapy Setting.mp4\u003cbr\u003eCurrent Dilemma in the First Line Therapy Setting.pdf\u003cbr\u003eEpidemiology and Outcomes of Lymphoma.mp4\u003cbr\u003eEpidemiology and Outcomes of Lymphoma.pdf\u003cbr\u003eGerminal Center Biology.pdf\u003cbr\u003eHistologic Transformation of Follicular Lymphoma.mp4\u003cbr\u003eHistologic Transformation of Follicular Lymphoma.pdf\u003cbr\u003eLessons and Challenges.mp4\u003cbr\u003eLessons and Challenges.pdf\u003cbr\u003eLymphoma Survivorship- Optimizing Quality of Life and Monitoring Long Term Side Effects of Treatment.mp4\u003cbr\u003eLymphoma Survivorship- Optimizing Quality of Life and Monitoring Long Term Side Effects of Treatment.pdf\u003cbr\u003eLymphoma2025_Brochure.pdf\u003cbr\u003eManagement of Fertility in Patients with Hodgkin’s and Non-Hodgkin Lymphoma.mp4\u003cbr\u003eManagement of Fertility in Patients with Hodgkin’s and Non-Hodgkin Lymphoma.pdf\u003cbr\u003eManagement of Older Patients.mp4\u003cbr\u003eManagement of Older Patients.pdf\u003cbr\u003eMantle Cell Lymphoma in Ambulatory Setting- Focus on Supportive Care and Adverse Event Management.mp4\u003cbr\u003eMantle Cell Lymphoma in Ambulatory Setting- Focus on Supportive Care and Adverse Event Management.pdf\u003cbr\u003eNew Antibodies Engaging Immune Cells.mp4\u003cbr\u003eNew Antibodies Engaging Immune Cells.pdf\u003cbr\u003eNew Drugs on the Horizon for Follicular Lymphoma.mp4\u003cbr\u003eNew Drugs on the Horizon for Follicular Lymphoma.pdf\u003cbr\u003eNotch and Marginal Zone Biology.mp4\u003cbr\u003eNotch and Marginal Zone Biology.pdf\u003cbr\u003eOptimizing First Line Therapy.mp4\u003cbr\u003eOptimizing First Line Therapy.pdf\u003cbr\u003eOptimizing Patient Selection in 2025.mp4\u003cbr\u003eOptimizing Patient Selection in 2025.pdf\u003cbr\u003eOptions After First Line Treatment Failure.mp4\u003cbr\u003eOptions After First Line Treatment Failure.pdf\u003cbr\u003ePanel Discussion- Advances in Therapeutic Strategies for Mantle Cell Lymphoma.mp4\u003cbr\u003ePanel Discussion- Aggressive B-Cell Lymphoma \u0026amp; Car T-Cell Therapies in Large B-Cell Lymphoma.mp4\u003cbr\u003ePanel Discussion- Aggressive B-Cell Lymphoma- Addressing Remaining Gaps on the Path to a Definitive Cure.mp4\u003cbr\u003ePanel Discussion- Current Challenges in the Management of Patients with Follicular Lymphoma.mp4\u003cbr\u003ePanel Discussion- Empowering APPs and Nurses.mp4\u003cbr\u003ePanel Discussion- Hodgkin Lymphoma.mp4\u003cbr\u003ePanel Discussion- Improving Outcomes of Patients with T-Cell Lymphoma.mp4\u003cbr\u003ePanel Discussion- The Dark Side of B-Cells.mp4\u003cbr\u003eProgress in Large B-Cell Lymphoma Management.mp4\u003cbr\u003eProgress in Large B-Cell Lymphoma Management.pdf\u003cbr\u003eRadiation Therapy and CAR T.mp4\u003cbr\u003eRecent Insights Into Mantle Cell Lymphoma Biology.mp4\u003cbr\u003eRecent Insights Into Mantle Cell Lymphoma Biology.pdf\u003cbr\u003eResearch Spotlight- Updates of Active Hodgkin’s Lymphoma Protocols at Memorial Sloan Kettering.mp4\u003cbr\u003eResearch Spotlight- Updates of Active Hodgkin’s Lymphoma Protocols at Memorial Sloan Kettering.pdf\u003cbr\u003eSingle Cell Analysis of B-Cell Lymphoma.mp4\u003cbr\u003eSingle Cell Analysis of B-Cell Lymphoma.pdf\u003cbr\u003eThe Evolving Standard of Care in First Line.mp4\u003cbr\u003eThe Evolving Standard of Care in First Line.pdf\u003cbr\u003eTreatment Initiation Versus Active Surveillance.mp4\u003cbr\u003eTreatment Initiation Versus Active Surveillance.pdf\u003cbr\u003eUpdate on Burkitt Lymphoma.mp4\u003cbr\u003eUpdate on Burkitt Lymphoma.pdf\u003cbr\u003eUpdate on Primary Mediastinal B-Cell Lymphoma.mp4\u003cbr\u003eUpdate on Primary Mediastinal B-Cell Lymphoma.pdf\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663495418185,"sku":"MED-AMB04813","price":45.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/Memorial-Sloan-Kettering-Cancer-Center-9th-Annual-MSK-Symposium-on-Lymphoma-2025-3.jpg?v=1781875438"},{"product_id":"rna-therapeutics-institute-rna","title":"RNA Therapeutics Institute RNA Therapeutics From Concept to Clinic 2024","description":"\u003ch3\u003eRNA Therapeutics Institute RNA Therapeutics From Concept to Clinic 2024\u003c\/h3\u003e\n\u003cstrong\u003e+ Target Audience: R\u0026amp;D scientists, CMC\/quality leaders, translational and clinical teams, regulatory\/strategy professionals,\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e manufacturing\/operations managers\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cp data-end=\"384\" data-start=\"80\"\u003eA translational, bench-to-bedside program covering the full lifecycle of RNA medicines. Faculty connect platform science (siRNA, ASO, mRNA, saRNA) with delivery, CMC, regulatory strategy, and clinical development to help teams move candidates efficiently and safely toward approval.\u003c\/p\u003e\n\u003cp data-end=\"411\" data-start=\"386\"\u003e\u003cstrong data-end=\"409\" data-start=\"386\"\u003eWhat You Will Learn\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"1426\" data-start=\"412\"\u003e\n\u003cli data-end=\"515\" data-start=\"412\"\u003e\n\u003cp data-end=\"515\" data-start=\"414\"\u003eModality selection and design: siRNA vs. ASO vs. (sa)mRNA—chemistries, modifications, and stability\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"615\" data-start=\"516\"\u003e\n\u003cp data-end=\"615\" data-start=\"518\"\u003eDelivery systems: LNPs, GALNAc conjugates, polymers\/peptides, local vs. systemic administration\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"728\" data-start=\"616\"\u003e\n\u003cp data-end=\"728\" data-start=\"618\"\u003ePreclinical translation: in vitro\/in vivo models, PK\/PD, biodistribution, immunogenicity and off-target risk\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"836\" data-start=\"729\"\u003e\n\u003cp data-end=\"836\" data-start=\"731\"\u003eCMC fundamentals: process development, analytics, release\/stability testing, scale-up and tech transfer\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"954\" data-start=\"837\"\u003e\n\u003cp data-end=\"954\" data-start=\"839\"\u003eClinical development: FIH design, dose selection, biomarkers, patient selection, endpoints, and safety monitoring\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1074\" data-start=\"955\"\u003e\n\u003cp data-end=\"1074\" data-start=\"957\"\u003eRegulatory \u0026amp; quality: IND\/IMPD packages, comparability, potency assays, pharm tox expectations, and risk management\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1194\" data-start=\"1075\"\u003e\n\u003cp data-end=\"1194\" data-start=\"1077\"\u003eManufacturing operations: raw materials (lipids, nucleotides, enzymes), single-use workflows, contamination control\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1322\" data-start=\"1195\"\u003e\n\u003cp data-end=\"1322\" data-start=\"1197\"\u003eData \u0026amp; tools: sequence optimization, secondary structure prediction, bioinformatics\/AI for target and off-target assessment\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1426\" data-start=\"1323\"\u003e\n\u003cp data-end=\"1426\" data-start=\"1325\"\u003eAccess \u0026amp; value: manufacturing cost drivers, IP strategy, partnerships, and commercialization pathways\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"1447\" data-start=\"1428\"\u003e\u003cstrong data-end=\"1445\" data-start=\"1428\"\u003eEvent Details\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"1723\" data-start=\"1448\"\u003e\n\u003cli data-end=\"1521\" data-start=\"1448\"\u003e\n\u003cp data-end=\"1521\" data-start=\"1450\"\u003eFormat: Case-based lectures, panel Q\u0026amp;A, and short technical workshops\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1629\" data-start=\"1522\"\u003e\n\u003cp data-end=\"1629\" data-start=\"1524\"\u003eStructure: Concept\/design → delivery\/PKPD → CMC\/manufacturing → clinical\/regulatory → commercialization\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1723\" data-start=\"1630\"\u003e\n\u003cp data-end=\"1723\" data-start=\"1632\"\u003eTakeaways: Checklists, study-design templates, and CMC\/quality worksheets for immediate use\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"1968\" data-start=\"1725\"\u003e\u003cstrong data-end=\"1746\" data-start=\"1725\"\u003eWho Should Attend\u003c\/strong\u003e\u003cbr\u003eR\u0026amp;D scientists, CMC\/quality leaders, translational and clinical teams, regulatory\/strategy professionals, manufacturing\/operations managers, platform and biotech founders, investors, and trainees entering the RNA space.\u003c\/p\u003e\n\u003cp data-end=\"1986\" data-start=\"1970\"\u003e\u003cstrong data-end=\"1984\" data-start=\"1970\"\u003eWhy Attend\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"2236\" data-start=\"1987\"\u003e\n\u003cli data-end=\"2062\" data-start=\"1987\"\u003e\n\u003cp data-end=\"2062\" data-start=\"1989\"\u003eReplace trial-and-error with validated design and development playbooks\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2142\" data-start=\"2063\"\u003e\n\u003cp data-end=\"2142\" data-start=\"2065\"\u003eAnticipate regulatory and manufacturing pitfalls early to de-risk timelines\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2236\" data-start=\"2143\"\u003e\n\u003cp data-end=\"2236\" data-start=\"2145\"\u003eBring back practical tools to align discovery, CMC, and clinical teams around the same plan\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003e* Detail:\u003cbr\u003e\u003cbr\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/screenshot-2024-05-24-at-11.46.35am.png?v=1770208101\"\u003e\u003cimg alt=\"Day 3- RNATx Program\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/screenshot-2024-05-24-at-11.46.53am.png?v=1770208104\"\u003e","brand":"Medical Education Hub","offers":[{"title":"Default Title","offer_id":54663495450953,"sku":"MED-AMB04792","price":30.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1019\/0382\/7273\/files\/RNA-Therapeutics-Institute-RNA-Therapeutics-From-Concept-to-Clinic-2024-1.webp?v=1781875439"}],"url":"https:\/\/medicalducation.com\/collections\/hematology-oncology.oembed","provider":"Medical Education Hub","version":"1.0","type":"link"}